<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE svg PUBLIC "-//W3C//DTD SVG 1.1//EN"
 "http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd">
<!-- Generated by graphviz version 2.49.0 (20210828.1703)
 -->
<!-- Pages: 1 -->
<svg width="4191pt" height="2185pt"
 viewBox="0.00 0.00 4190.55 2184.80" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g id="graph0" class="graph" transform="scale(1 1) rotate(0) translate(50.4 2134.4)">
<polygon fill="white" stroke="transparent" points="-50.4,50.4 -50.4,-2134.4 4140.15,-2134.4 4140.15,50.4 -50.4,50.4"/>
<!-- 17577005&#45;&gt;25910928 -->
<g id="edge1" class="edge">
<title>17577005:n&#45;&gt;25910928:s</title>
<path fill="none" stroke="black" d="M2639.75,-281C2639.75,-684.29 831.75,-34.71 831.75,-438"/>
</g>
<!-- 17577005&#45;&gt;27312796 -->
<g id="edge2" class="edge">
<title>17577005:n&#45;&gt;27312796:s</title>
<path fill="none" stroke="black" d="M2639.75,-281C2639.75,-485.28 2662.19,-541.07 2615.75,-740 2599.13,-811.15 2550.75,-817.94 2550.75,-891"/>
</g>
<!-- 17577005&#45;&gt;27412905 -->
<g id="edge3" class="edge">
<title>17577005:n&#45;&gt;27412905:s</title>
<path fill="none" stroke="black" d="M2639.75,-281C2639.75,-585.98 2161.13,-198.95 1971.75,-438 1952.98,-461.69 1971.12,-475.78 1971.75,-506 1975.3,-677.22 1987.75,-719.74 1987.75,-891"/>
</g>
<!-- 17577005&#45;&gt;27680880 -->
<g id="edge4" class="edge">
<title>17577005:n&#45;&gt;27680880:s</title>
<path fill="none" stroke="black" d="M2639.75,-281C2639.75,-429.52 2423.36,-311.99 2344.75,-438 2185.03,-693.99 2321.75,-814.77 2321.75,-1116.5"/>
</g>
<!-- 17577005&#45;&gt;27933569 -->
<g id="edge5" class="edge">
<title>17577005:n&#45;&gt;27933569:s</title>
<path fill="none" stroke="black" d="M2639.75,-281C2639.75,-479.86 1942.64,-362.31 1758.75,-438 1600.39,-503.18 1560.62,-533.74 1441.75,-657 1411.36,-688.5 1418.69,-708.07 1388.75,-740 1311.1,-822.81 1242.71,-794.61 1182.75,-891 1166.54,-917.06 1179.32,-929.53 1170.75,-959 1149.6,-1031.71 1105.75,-1040.77 1105.75,-1116.5"/>
</g>
<!-- 17577005&#45;&gt;28188243 -->
<g id="edge6" class="edge">
<title>17577005:n&#45;&gt;28188243:s</title>
<path fill="none" stroke="black" d="M2639.75,-281C2639.75,-448.68 2663.85,-489.46 2670.75,-657 2676.27,-791.11 2696.49,-827.27 2670.75,-959 2656.26,-1033.16 2606.75,-1040.94 2606.75,-1116.5"/>
</g>
<!-- 17577005&#45;&gt;28300870 -->
<g id="edge7" class="edge">
<title>17577005:n&#45;&gt;28300870:s</title>
<path fill="none" stroke="black" d="M2639.75,-281C2639.75,-557.5 3070.12,-221.21 3241.75,-438 3265.15,-467.56 3257.75,-1078.8 3257.75,-1116.5"/>
</g>
<!-- 17577005&#45;&gt;28408716 -->
<g id="edge8" class="edge">
<title>17577005:n&#45;&gt;28408716:s</title>
<path fill="none" stroke="black" d="M2639.75,-281C2639.75,-599.41 2180.39,-228.35 1940.75,-438 1930.98,-446.54 1862.83,-644.4 1859.75,-657 1835.66,-755.56 1802.75,-1008.54 1802.75,-1110"/>
</g>
<!-- 17577005&#45;&gt;28614582 -->
<g id="edge9" class="edge">
<title>17577005:n&#45;&gt;28614582:s</title>
<path fill="none" stroke="black" d="M2639.75,-281C2639.75,-429.13 2853.71,-313.35 2933.75,-438 2965.08,-486.8 2957.48,-901.59 2965.75,-959 2975.98,-1030.07 3001.75,-1044.69 3001.75,-1116.5"/>
</g>
<!-- 17577005&#45;&gt;28956288 -->
<g id="edge10" class="edge">
<title>17577005:n&#45;&gt;28956288:s</title>
<path fill="none" stroke="black" d="M2639.75,-281C2639.75,-617.21 2197.5,-281.87 1899.75,-438 1860.76,-458.44 1860.7,-476.82 1827.75,-506 1749.06,-575.68 1691.49,-562.37 1645.75,-657 1632.78,-683.82 1652.29,-1169.69 1633.75,-1193 1464.45,-1405.85 1040.75,-1072.03 1040.75,-1344"/>
</g>
<!-- 17577005&#45;&gt;29371284 -->
<g id="edge11" class="edge">
<title>17577005:n&#45;&gt;29371284:s</title>
<path fill="none" stroke="black" d="M2639.75,-281C2639.75,-433.07 2853.32,-315.74 2943.75,-438 2955.03,-453.25 3064.05,-1091.1 3065.75,-1110 3069.05,-1146.74 3090.24,-1165.42 3065.75,-1193 2877.02,-1405.5 1795.75,-1059.79 1795.75,-1344"/>
</g>
<!-- 17577005&#45;&gt;29973392 -->
<g id="edge12" class="edge">
<title>17577005:n&#45;&gt;29973392:s</title>
<path fill="none" stroke="black" d="M2639.75,-281C2639.75,-611.13 2152.46,-209.97 1913.75,-438 1891.14,-459.59 1904.84,-476.09 1895.75,-506 1875.1,-573.91 1865.46,-589.42 1843.75,-657 1805.72,-775.35 1765.64,-1099.49 1683.75,-1193 1575.88,-1316.17 1347.75,-1180.28 1347.75,-1344"/>
</g>
<!-- 17577005&#45;&gt;30383768 -->
<g id="edge13" class="edge">
<title>17577005:n&#45;&gt;30383768:s</title>
<path fill="none" stroke="black" d="M2639.75,-281C2639.75,-450.84 2044.91,-364.59 1891.75,-438 1753.34,-504.33 1696.5,-521.33 1624.75,-657 1616.87,-671.89 1599.92,-942.3 1597.75,-959 1588.58,-1029.43 1570.75,-1045.48 1570.75,-1116.5"/>
</g>
<!-- 17577005&#45;&gt;30571400 -->
<g id="edge14" class="edge">
<title>17577005:n&#45;&gt;30571400:s</title>
<path fill="none" stroke="black" d="M2639.75,-281C2639.75,-560.52 3066,-226.5 3248.75,-438 3303.84,-501.76 3363.15,-1120.17 3320.75,-1193 3252.35,-1310.48 3054.75,-1208.06 3054.75,-1344"/>
</g>
<!-- 17577005&#45;&gt;31022899 -->
<g id="edge15" class="edge">
<title>17577005:n&#45;&gt;31022899:s</title>
<path fill="none" stroke="black" d="M2639.75,-281C2639.75,-437.82 2859.82,-313.94 2955.75,-438 3007.82,-505.34 3140.59,-1127.9 3085.75,-1193 2820.73,-1507.53 2173.75,-938.7 2173.75,-1350"/>
</g>
<!-- 17577005&#45;&gt;31195999 -->
<g id="edge16" class="edge">
<title>17577005:n&#45;&gt;31195999:s</title>
<path fill="none" stroke="black" d="M2639.75,-281C2639.75,-494.54 3449.64,-275.14 3587.75,-438 3609.45,-463.59 3587.89,-706.44 3587.75,-740 3586.64,-1008.45 3582.75,-1075.55 3582.75,-1344"/>
</g>
<!-- 17577005&#45;&gt;33950207 -->
<g id="edge17" class="edge">
<title>17577005:n&#45;&gt;33950207:s</title>
<path fill="none" stroke="black" d="M2639.75,-281C2639.75,-496.07 3445.06,-283.56 3594.75,-438 3670.54,-516.2 3752.53,-1314.64 3703.75,-1412 3630.92,-1557.35 3560.34,-1567.32 3410.75,-1631 3220.52,-1711.97 2492.75,-1575.26 2492.75,-1782"/>
</g>
<!-- 17577005&#45;&gt;34379219 -->
<g id="edge18" class="edge">
<title>17577005:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M2639.75,-281C2639.75,-505.51 3454.32,-308.55 3637.75,-438 3767.23,-529.38 3952.75,-1042.26 3952.75,-1150.5 3952.75,-1150.5 3952.75,-1150.5 3952.75,-1598 3952.75,-2238.4 2492.75,-1914.45 2492.75,-2016"/>
</g>
<!-- 17577005&#45;&gt;34722686 -->
<g id="edge19" class="edge">
<title>17577005:n&#45;&gt;34722686:s</title>
<path fill="none" stroke="black" d="M2639.75,-281C2639.75,-500.02 3438.87,-304.83 3612.75,-438 3677.77,-487.8 3898.53,-1029.92 3915.75,-1110 3923.5,-1146.06 3915.91,-1156.11 3915.75,-1193 3915.64,-1217.33 3926.13,-1611.37 3911.75,-1631 3772.5,-1821.09 3407.75,-1559.87 3407.75,-1795.5"/>
</g>
<!-- 19717844&#45;&gt;25365537 -->
<g id="edge20" class="edge">
<title>19717844:n&#45;&gt;25365537:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-477.05 434.75,184.05 434.75,-225"/>
</g>
<!-- 19717844&#45;&gt;25587093 -->
<g id="edge21" class="edge">
<title>19717844:n&#45;&gt;25587093:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-297.8 3104.79,-85.39 3291.75,-219 3380.86,-282.68 3378.91,-331.57 3404.75,-438 3417.16,-489.12 3385.75,-646.74 3385.75,-663.5"/>
</g>
<!-- 19717844&#45;&gt;25862791 -->
<g id="edge22" class="edge">
<title>19717844:n&#45;&gt;25862791:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-298.9 1425.37,-80.34 1240.75,-219 1067.38,-349.2 1039.75,-446.69 1039.75,-663.5"/>
</g>
<!-- 19717844&#45;&gt;25910928 -->
<g id="edge23" class="edge">
<title>19717844:n&#45;&gt;25910928:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-389.53 1044.91,19.93 829.75,-219 809.52,-241.46 829.55,-256.78 829.75,-287 830.19,-354.12 831.75,-370.88 831.75,-438"/>
</g>
<!-- 19717844&#45;&gt;26199338 -->
<g id="edge24" class="edge">
<title>19717844:n&#45;&gt;26199338:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-278.89 519.81,-64.06 376.75,-219 356.24,-241.2 376.42,-256.78 376.75,-287 378.52,-451.47 384.75,-492.52 384.75,-657"/>
</g>
<!-- 19717844&#45;&gt;26848150 -->
<g id="edge25" class="edge">
<title>19717844:n&#45;&gt;26848150:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-265.76 1530.58,-78.17 1391.75,-219 1321.55,-290.21 1321.75,-563.5 1321.75,-663.5"/>
</g>
<!-- 19717844&#45;&gt;27312796 -->
<g id="edge26" class="edge">
<title>19717844:n&#45;&gt;27312796:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-268.99 2449.48,-253.31 2528.75,-438 2582.24,-562.64 2582.55,-604.72 2572.75,-740 2567.84,-807.64 2550.75,-823.18 2550.75,-891"/>
</g>
<!-- 19717844&#45;&gt;27412905 -->
<g id="edge27" class="edge">
<title>19717844:n&#45;&gt;27412905:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-277.7 1944.02,-48.64 1821.75,-219 1804.12,-243.55 1820.92,-256.79 1821.75,-287 1827.31,-490.38 1807.42,-553.07 1887.75,-740 1919.53,-813.95 1987.75,-810.51 1987.75,-891"/>
</g>
<!-- 19717844&#45;&gt;27550177 -->
<g id="edge28" class="edge">
<title>19717844:n&#45;&gt;27550177:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-391.52 1075.48,-19.56 820.75,-219 581.02,-406.69 722.75,-592.54 722.75,-897"/>
</g>
<!-- 19717844&#45;&gt;27680880 -->
<g id="edge29" class="edge">
<title>19717844:n&#45;&gt;27680880:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-366.67 2246.76,-442.07 2267.75,-740 2274.65,-838.06 2284.76,-861.7 2298.75,-959 2308.82,-1029.02 2321.75,-1045.76 2321.75,-1116.5"/>
</g>
<!-- 19717844&#45;&gt;27889397 -->
<g id="edge30" class="edge">
<title>19717844:n&#45;&gt;27889397:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-301.84 1953.06,-80.37 1764.75,-219 1498.35,-415.11 1444.75,-560.2 1444.75,-891"/>
</g>
<!-- 19717844&#45;&gt;27933569 -->
<g id="edge31" class="edge">
<title>19717844:n&#45;&gt;27933569:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-273.21 1509.94,-81.35 1357.75,-219 1128.26,-426.56 1255.78,-592.1 1175.75,-891 1167.66,-921.2 1166.65,-929.03 1157.75,-959 1136.75,-1029.66 1105.75,-1042.78 1105.75,-1116.5"/>
</g>
<!-- 19717844&#45;&gt;28188243 -->
<g id="edge32" class="edge">
<title>19717844:n&#45;&gt;28188243:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-264.69 2571.86,-57.93 2684.75,-219 2686.32,-221.24 2692.99,-889.87 2677.75,-959 2661.22,-1033.98 2606.75,-1039.72 2606.75,-1116.5"/>
</g>
<!-- 19717844&#45;&gt;28300870 -->
<g id="edge33" class="edge">
<title>19717844:n&#45;&gt;28300870:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-296.04 3132.79,-48.08 3283.75,-219 3302.29,-239.99 3289.75,-442.99 3289.75,-471 3289.75,-471 3289.75,-471 3289.75,-699.5 3289.75,-815.05 3283.14,-843.83 3273.75,-959 3268.02,-1029.13 3257.75,-1046.14 3257.75,-1116.5"/>
</g>
<!-- 19717844&#45;&gt;28408716 -->
<g id="edge34" class="edge">
<title>19717844:n&#45;&gt;28408716:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-280.65 1941.18,-48.03 1814.75,-219 1748.13,-309.08 1808.75,-358.97 1808.75,-471 1808.75,-471 1808.75,-471 1808.75,-699.5 1808.75,-881.96 1802.75,-927.54 1802.75,-1110"/>
</g>
<!-- 19717844&#45;&gt;28614582 -->
<g id="edge35" class="edge">
<title>19717844:n&#45;&gt;28614582:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-278.54 2537.93,-109.49 2717.75,-219 2852.49,-301.06 2967.75,-313.24 2967.75,-471 2967.75,-471 2967.75,-471 2967.75,-699.5 2967.75,-885.45 3001.75,-930.55 3001.75,-1116.5"/>
</g>
<!-- 19717844&#45;&gt;28860793 -->
<g id="edge36" class="edge">
<title>19717844:n&#45;&gt;28860793:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-442.94 2852.06,63.37 3098.75,-219 3109.25,-231.02 3110.96,-490.06 3111.75,-506 3119.24,-658.52 3198.43,-1079.97 3095.75,-1193 2937.55,-1367.14 2048.75,-1114.73 2048.75,-1350"/>
</g>
<!-- 19717844&#45;&gt;28874129 -->
<g id="edge37" class="edge">
<title>19717844:n&#45;&gt;28874129:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-460.01 1656.96,76.83 1399.75,-219 1361.74,-262.71 1388.43,-682.36 1382.75,-740 1376.07,-807.7 1367.94,-823.74 1357.75,-891 1342.59,-991.02 1326.75,-1015.34 1326.75,-1116.5"/>
</g>
<!-- 19717844&#45;&gt;28956288 -->
<g id="edge38" class="edge">
<title>19717844:n&#45;&gt;28956288:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-285.43 470.46,-64.23 317.75,-219 165.24,-373.56 244.34,-1037.35 395.75,-1193 601.03,-1404.04 1040.75,-1049.58 1040.75,-1344"/>
</g>
<!-- 19717844&#45;&gt;29171208 -->
<g id="edge39" class="edge">
<title>19717844:n&#45;&gt;29171208:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-257.44 2951.03,-112.57 3107.75,-219 3202.53,-283.37 3212.32,-327.82 3243.75,-438 3252.04,-467.06 3245.69,-475.84 3243.75,-506 3241.27,-544.41 3181.11,-1164.96 3154.75,-1193 2889.02,-1475.56 2297.75,-970.12 2297.75,-1358"/>
</g>
<!-- 19717844&#45;&gt;29371284 -->
<g id="edge40" class="edge">
<title>19717844:n&#45;&gt;29371284:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-292.91 1925.68,-42.92 1785.75,-219 1715.86,-306.93 1766.75,-358.68 1766.75,-471 1766.75,-471 1766.75,-471 1766.75,-699.5 1766.75,-919.14 1702.58,-976.7 1740.75,-1193 1753.16,-1263.34 1795.75,-1272.58 1795.75,-1344"/>
</g>
<!-- 19717844&#45;&gt;29373602 -->
<g id="edge41" class="edge">
<title>19717844:n&#45;&gt;29373602:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-312.1 3172.66,-58.71 3356.75,-219 3519.99,-361.14 3509.81,-1047.29 3349.75,-1193 3114.39,-1407.25 2649.75,-1025.73 2649.75,-1344"/>
</g>
<!-- 19717844&#45;&gt;29525786 -->
<g id="edge42" class="edge">
<title>19717844:n&#45;&gt;29525786:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-406.11 1018.88,-7.92 754.75,-219 625.07,-322.63 593.21,-804.05 652.75,-959 686.55,-1046.98 794.75,-1022.25 794.75,-1116.5"/>
</g>
<!-- 19717844&#45;&gt;29622587 -->
<g id="edge43" class="edge">
<title>19717844:n&#45;&gt;29622587:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-265.95 2549.04,-77.78 2687.75,-219 2831.83,-365.7 2803.19,-454.14 2836.75,-657 2842.77,-693.39 2837.17,-703.11 2836.75,-740 2835.64,-837.35 2842.19,-862.2 2831.75,-959 2823.76,-1033.05 2799.75,-1049.02 2799.75,-1123.5"/>
</g>
<!-- 19717844&#45;&gt;29909576 -->
<g id="edge44" class="edge">
<title>19717844:n&#45;&gt;29909576:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-305.71 3142.77,-69.7 3327.75,-219 3408.5,-284.18 3382.88,-337.5 3408.75,-438 3433.28,-533.33 3434.39,-558.84 3441.75,-657 3450.86,-778.67 3412.19,-1110.01 3322.75,-1193 3051.1,-1445.06 2502.75,-973.43 2502.75,-1344"/>
</g>
<!-- 19717844&#45;&gt;29973392 -->
<g id="edge45" class="edge">
<title>19717844:n&#45;&gt;29973392:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-279.89 518.12,-69.72 367.75,-219 229.08,-356.66 338.2,-461.78 329.75,-657 328.15,-693.85 324.65,-703.47 329.75,-740 336.98,-791.83 419.78,-1158.07 458.75,-1193 607.96,-1326.75 1347.75,-1143.61 1347.75,-1344"/>
</g>
<!-- 19717844&#45;&gt;30423205 -->
<g id="edge46" class="edge">
<title>19717844:n&#45;&gt;30423205:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-297.5 375,-60.78 208.75,-219 137.71,-286.61 189.54,-340.24 181.75,-438 147.31,-869.7 94.12,-994.65 209.75,-1412 229.6,-1483.65 281.75,-1488.65 281.75,-1563"/>
</g>
<!-- 19717844&#45;&gt;30571400 -->
<g id="edge47" class="edge">
<title>19717844:n&#45;&gt;30571400:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-325.09 3195.83,-85.85 3415.75,-219 3517.53,-280.63 3533.85,-324.55 3569.75,-438 3672.58,-763 3691.9,-969.23 3434.75,-1193 3297.65,-1312.3 3054.75,-1162.27 3054.75,-1344"/>
</g>
<!-- 19717844&#45;&gt;30924051 -->
<g id="edge48" class="edge">
<title>19717844:n&#45;&gt;30924051:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-317.82 3199.46,-49.25 3382.75,-219 3700.35,-513.14 3685.19,-886.24 3379.75,-1193 3233.57,-1339.81 2938.75,-1136.83 2938.75,-1344"/>
</g>
<!-- 19717844&#45;&gt;31022899 -->
<g id="edge49" class="edge">
<title>19717844:n&#45;&gt;31022899:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-440.32 2848.46,61.97 3092.75,-219 3103.22,-231.04 3103.62,-490.08 3104.75,-506 3109.49,-573.27 3116.41,-589.64 3119.75,-657 3121.6,-694.38 3122.13,-837.7 3118.75,-959 3115.84,-1063.1 3176.01,-1115.24 3106.75,-1193 2966.91,-1350 2173.75,-1139.75 2173.75,-1350"/>
</g>
<!-- 19717844&#45;&gt;31195999 -->
<g id="edge50" class="edge">
<title>19717844:n&#45;&gt;31195999:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-344.71 3267.81,-76.07 3504.75,-219 3606.2,-280.2 3618.53,-325.85 3656.75,-438 3765.01,-755.67 3714.9,-865.23 3642.75,-1193 3627.22,-1263.53 3582.75,-1271.78 3582.75,-1344"/>
</g>
<!-- 19717844&#45;&gt;32341789 -->
<g id="edge51" class="edge">
<title>19717844:n&#45;&gt;32341789:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-335.01 3239.52,-69.5 3460.75,-219 3740.6,-408.11 3672.82,-623.51 3633.75,-959 3621.41,-1064.92 3625.94,-1096.42 3580.75,-1193 3543.52,-1272.55 3460.75,-1262.17 3460.75,-1350"/>
</g>
<!-- 19717844&#45;&gt;32415705 -->
<g id="edge52" class="edge">
<title>19717844:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-294.51 393.43,-56.39 235.75,-219 143.47,-314.16 164.3,-1296.73 229.75,-1412 291.04,-1519.96 464.75,-1438.85 464.75,-1563"/>
</g>
<!-- 19717844&#45;&gt;33093817 -->
<g id="edge53" class="edge">
<title>19717844:n&#45;&gt;33093817:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-336.52 1898.91,-58.36 1683.75,-219 1501.8,-354.84 1500.56,-444.43 1420.75,-657 1349.74,-846.11 1380.4,-908.02 1383.75,-1110 1384.36,-1146.88 1399.2,-1159.5 1383.75,-1193 1338.72,-1290.62 1199.75,-1242.5 1199.75,-1350"/>
</g>
<!-- 19717844&#45;&gt;33253294 -->
<g id="edge54" class="edge">
<title>19717844:n&#45;&gt;33253294:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-406.11 3555.84,31.67 3782.75,-219 3804.15,-242.64 3783.16,-474.11 3782.75,-506 3778.82,-812.02 3794.52,-892.65 3735.75,-1193 3716.25,-1292.64 3741.74,-1339.42 3670.75,-1412 3511.14,-1575.18 3181.75,-1340.74 3181.75,-1569"/>
</g>
<!-- 19717844&#45;&gt;33587284 -->
<g id="edge55" class="edge">
<title>19717844:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-289.97 441.72,-70.5 276.75,-219 203.21,-285.2 245.67,-339.46 236.75,-438 217.13,-654.54 167.98,-1266.72 329.75,-1412 611.34,-1664.9 1166.75,-1190.51 1166.75,-1569"/>
</g>
<!-- 19717844&#45;&gt;33657116 -->
<g id="edge56" class="edge">
<title>19717844:n&#45;&gt;33657116:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-404.57 3549.93,30.57 3775.75,-219 3820.34,-268.29 3733.47,-1365.74 3685.75,-1412 3460.11,-1630.71 2279.75,-1248.76 2279.75,-1563"/>
</g>
<!-- 19717844&#45;&gt;33950207 -->
<g id="edge57" class="edge">
<title>19717844:n&#45;&gt;33950207:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-409.21 3564.65,31.11 3796.75,-219 3872.95,-301.12 3802.75,-358.97 3802.75,-471 3802.75,-471 3802.75,-471 3802.75,-699.5 3802.75,-779.24 3754.1,-1341.55 3716.75,-1412 3651.37,-1535.29 3616.73,-1568.93 3491.75,-1631 3290.66,-1730.87 2492.75,-1557.48 2492.75,-1782"/>
</g>
<!-- 19717844&#45;&gt;34173286 -->
<g id="edge58" class="edge">
<title>19717844:n&#45;&gt;34173286:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-304.82 317.01,-58.65 142.75,-219 70.26,-285.7 118.7,-340.01 108.75,-438 64.98,-868.68 78.33,-980.72 115.75,-1412 124.21,-1509.55 78.84,-1554.33 139.75,-1631 271.28,-1796.59 588.75,-1577.02 588.75,-1788.5"/>
</g>
<!-- 19717844&#45;&gt;34280330 -->
<g id="edge59" class="edge">
<title>19717844:n&#45;&gt;34280330:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-354.42 3311.03,-59.24 3548.75,-219 3641.04,-281.03 3638.8,-331.19 3669.75,-438 3696.88,-531.65 3678.4,-559.59 3682.75,-657 3687.39,-760.94 3688.19,-786.97 3689.75,-891 3690.61,-948.93 3709.47,-1369.84 3669.75,-1412 3438.39,-1657.54 2159.75,-1231.64 2159.75,-1569"/>
</g>
<!-- 19717844&#45;&gt;34379219 -->
<g id="edge60" class="edge">
<title>19717844:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-422.7 3570.86,-10.42 3857.75,-219 3956.45,-290.76 3966.75,-348.97 3966.75,-471 3966.75,-471 3966.75,-471 3966.75,-1598 3966.75,-1689.52 4008.9,-1770.43 3898.75,-1865 3660.31,-2069.69 2492.75,-1701.76 2492.75,-2016"/>
</g>
<!-- 19717844&#45;&gt;34398204 -->
<g id="edge61" class="edge">
<title>19717844:n&#45;&gt;34398204:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-407.66 3561.74,32.76 3789.75,-219 3817.35,-249.48 3781.19,-918.03 3777.75,-959 3768.95,-1063.6 3764.56,-1089.73 3745.75,-1193 3727.85,-1291.22 3761.11,-1336.53 3695.75,-1412 3573.51,-1553.13 3303.75,-1376.3 3303.75,-1563"/>
</g>
<!-- 19717844&#45;&gt;34643934 -->
<g id="edge62" class="edge">
<title>19717844:n&#45;&gt;34643934:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-301.6 337.25,-54.14 171.75,-219 60.59,-329.73 75.62,-1524.39 190.75,-1631 352.51,-1780.8 2168.75,-1568.03 2168.75,-1788.5"/>
</g>
<!-- 19717844&#45;&gt;34722686 -->
<g id="edge63" class="edge">
<title>19717844:n&#45;&gt;34722686:s</title>
<path fill="none" stroke="black" d="M2268.75,-68C2268.75,-413.63 3530.99,-24.57 3816.75,-219 3920.77,-289.78 3945.75,-345.18 3945.75,-471 3945.75,-471 3945.75,-471 3945.75,-1152.5 3945.75,-1205.7 3960.06,-1588.73 3927.75,-1631 3780.52,-1823.57 3407.75,-1553.1 3407.75,-1795.5"/>
</g>
<!-- 19757444&#45;&gt;25862791 -->
<g id="edge64" class="edge">
<title>19757444:n&#45;&gt;25862791:s</title>
<path fill="none" stroke="black" d="M3350.75,-492C3350.75,-749.48 1039.75,-406.02 1039.75,-663.5"/>
</g>
<!-- 19757444&#45;&gt;27412905 -->
<g id="edge65" class="edge">
<title>19757444:n&#45;&gt;27412905:s</title>
<path fill="none" stroke="black" d="M3350.75,-492C3350.75,-643.83 2833.52,-614.57 2687.75,-657 2677.9,-659.87 1987.75,-880.75 1987.75,-891"/>
</g>
<!-- 19757444&#45;&gt;28300870 -->
<g id="edge66" class="edge">
<title>19757444:n&#45;&gt;28300870:s</title>
<path fill="none" stroke="black" d="M3350.75,-492C3350.75,-567.46 3322.05,-582.39 3310.75,-657 3290.6,-789.97 3310.21,-825.79 3291.75,-959 3281.92,-1029.93 3257.75,-1044.89 3257.75,-1116.5"/>
</g>
<!-- 19757444&#45;&gt;28408716 -->
<g id="edge67" class="edge">
<title>19757444:n&#45;&gt;28408716:s</title>
<path fill="none" stroke="black" d="M3350.75,-492C3350.75,-698.18 2634.86,-596.54 2437.75,-657 2191.96,-732.39 2083.39,-702.33 1908.75,-891 1886.98,-914.52 1897.77,-929.72 1884.75,-959 1853.72,-1028.78 1802.75,-1033.63 1802.75,-1110"/>
</g>
<!-- 19757444&#45;&gt;29373602 -->
<g id="edge68" class="edge">
<title>19757444:n&#45;&gt;29373602:s</title>
<path fill="none" stroke="black" d="M3350.75,-492C3350.75,-565.92 3334.9,-583.26 3329.75,-657 3328.71,-671.85 3332.13,-1181.44 3322.75,-1193 3129.62,-1431.06 2649.75,-1037.45 2649.75,-1344"/>
</g>
<!-- 19757444&#45;&gt;29525786 -->
<g id="edge69" class="edge">
<title>19757444:n&#45;&gt;29525786:s</title>
<path fill="none" stroke="black" d="M3350.75,-492C3350.75,-699.04 1676.43,-557.74 1494.75,-657 1453.87,-679.33 1468.95,-713.35 1430.75,-740 1246.97,-868.19 1124.38,-750.61 949.75,-891 922.59,-912.83 929.77,-929.82 910.75,-959 863.27,-1031.83 794.75,-1029.56 794.75,-1116.5"/>
</g>
<!-- 19757444&#45;&gt;30423205 -->
<g id="edge70" class="edge">
<title>19757444:n&#45;&gt;30423205:s</title>
<path fill="none" stroke="black" d="M3350.75,-492C3350.75,-602.17 3483.07,-560.23 3535.75,-657 3554.21,-690.93 3639.77,-1305.49 3642.75,-1344 3645.08,-1374.13 3663.63,-1390.16 3642.75,-1412 3384.41,-1682.2 281.75,-1189.18 281.75,-1563"/>
</g>
<!-- 19757444&#45;&gt;30571400 -->
<g id="edge71" class="edge">
<title>19757444:n&#45;&gt;30571400:s</title>
<path fill="none" stroke="black" d="M3350.75,-492C3350.75,-565.82 3335.98,-583.3 3331.75,-657 3329.63,-693.83 3329.56,-703.18 3331.75,-740 3335.75,-807.47 3344.66,-823.61 3349.75,-891 3357.07,-988.11 3355.19,-1012.63 3356.75,-1110 3357.34,-1146.88 3376.14,-1161.62 3356.75,-1193 3277.85,-1320.65 3054.75,-1193.93 3054.75,-1344"/>
</g>
<!-- 19757444&#45;&gt;30924051 -->
<g id="edge72" class="edge">
<title>19757444:n&#45;&gt;30924051:s</title>
<path fill="none" stroke="black" d="M3350.75,-492C3350.75,-565.87 3335.2,-583.26 3330.75,-657 3328.52,-693.82 3329.77,-703.12 3330.75,-740 3332.52,-807.18 3336.35,-823.84 3338.75,-891 3342.21,-988.29 3341.86,-1012.65 3342.75,-1110 3343.08,-1146.89 3363.77,-1162.69 3342.75,-1193 3233.48,-1350.49 2938.75,-1152.31 2938.75,-1344"/>
</g>
<!-- 19757444&#45;&gt;31112292 -->
<g id="edge73" class="edge">
<title>19757444:n&#45;&gt;31112292:s</title>
<path fill="none" stroke="black" d="M3350.75,-492C3350.75,-610.35 3501.24,-554.13 3559.75,-657 3578.78,-690.47 3648.21,-1305.58 3650.75,-1344 3652.74,-1374.16 3669.96,-1388.67 3650.75,-1412 3427.9,-1682.52 2876.75,-1212.51 2876.75,-1563"/>
</g>
<!-- 19757444&#45;&gt;31195999 -->
<g id="edge74" class="edge">
<title>19757444:n&#45;&gt;31195999:s</title>
<path fill="none" stroke="black" d="M3350.75,-492C3350.75,-599.22 3480.16,-560.43 3526.75,-657 3543.39,-691.49 3582.75,-1305.71 3582.75,-1344"/>
</g>
<!-- 19757444&#45;&gt;31390972 -->
<g id="edge75" class="edge">
<title>19757444:n&#45;&gt;31390972:s</title>
<path fill="none" stroke="black" d="M3350.75,-492C3350.75,-620.35 3517.82,-549.38 3587.75,-657 3615.67,-699.98 3666.76,-1059.37 3674.75,-1110 3691.08,-1213.51 3697.29,-1239.4 3703.75,-1344 3705.61,-1374.16 3717.22,-1384.95 3703.75,-1412 3631.75,-1556.58 3560.25,-1563 3413.75,-1631 3137.66,-1759.15 2745.75,-1477.62 2745.75,-1782"/>
</g>
<!-- 19757444&#45;&gt;32341789 -->
<g id="edge76" class="edge">
<title>19757444:n&#45;&gt;32341789:s</title>
<path fill="none" stroke="black" d="M3350.75,-492C3350.75,-596.34 3474.87,-561.88 3517.75,-657 3542.24,-711.33 3551.22,-1134.95 3537.75,-1193 3520.18,-1268.71 3460.75,-1272.28 3460.75,-1350"/>
</g>
<!-- 19757444&#45;&gt;34398204 -->
<g id="edge77" class="edge">
<title>19757444:n&#45;&gt;34398204:s</title>
<path fill="none" stroke="black" d="M3350.75,-492C3350.75,-615.29 3510.27,-551.31 3573.75,-657 3608.68,-715.17 3607.34,-892.11 3618.75,-959 3635.89,-1059.55 3750.36,-1327.83 3692.75,-1412 3587.99,-1565.04 3303.75,-1377.54 3303.75,-1563"/>
</g>
<!-- 19757444&#45;&gt;34722686 -->
<g id="edge78" class="edge">
<title>19757444:n&#45;&gt;34722686:s</title>
<path fill="none" stroke="black" d="M3350.75,-492C3350.75,-628.11 3523.94,-550.54 3608.75,-657 3697.56,-768.5 3633.03,-843.62 3716.75,-959 3781.12,-1047.72 3863.48,-1011.58 3911.75,-1110 3915.24,-1117.13 3922.58,-1606.72 3904.75,-1631 3767,-1818.52 3407.75,-1562.83 3407.75,-1795.5"/>
</g>
<!-- 20299623&#45;&gt;25862791 -->
<g id="edge79" class="edge">
<title>20299623:n&#45;&gt;25862791:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-597.89 1457.57,-265.78 1198.75,-438 1173.22,-454.98 1039.75,-632.84 1039.75,-663.5"/>
</g>
<!-- 20299623&#45;&gt;25910928 -->
<g id="edge80" class="edge">
<title>20299623:n&#45;&gt;25910928:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-522.73 831.75,-202.27 831.75,-438"/>
</g>
<!-- 20299623&#45;&gt;27312796 -->
<g id="edge81" class="edge">
<title>20299623:n&#45;&gt;27312796:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-571.47 2316.59,-223.76 2503.75,-438 2636.91,-590.44 2550.75,-688.59 2550.75,-891"/>
</g>
<!-- 20299623&#45;&gt;27412905 -->
<g id="edge82" class="edge">
<title>20299623:n&#45;&gt;27412905:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-357.03 1846.85,-368.71 1836.75,-438 1832.39,-467.91 1832.29,-476.11 1836.75,-506 1847.08,-575.39 1862.41,-589.86 1882.75,-657 1893.92,-693.87 1893.1,-704.37 1907.75,-740 1936.61,-810.25 1987.75,-815.05 1987.75,-891"/>
</g>
<!-- 20299623&#45;&gt;27680880 -->
<g id="edge83" class="edge">
<title>20299623:n&#45;&gt;27680880:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-384.35 1870.24,-409.89 1885.75,-506 1896.95,-575.39 1912.17,-589.79 1932.75,-657 1944.03,-693.84 1939.75,-705.94 1957.75,-740 1998.05,-816.29 2040.74,-814.04 2079.75,-891 2093.88,-918.88 2079.88,-933.35 2097.75,-959 2167.3,-1058.87 2321.75,-994.8 2321.75,-1116.5"/>
</g>
<!-- 20299623&#45;&gt;28188243 -->
<g id="edge84" class="edge">
<title>20299623:n&#45;&gt;28188243:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-613.53 2364.43,-212.67 2600.75,-438 2685.09,-518.42 2679.91,-844.04 2660.75,-959 2648.58,-1031.99 2606.75,-1042.5 2606.75,-1116.5"/>
</g>
<!-- 20299623&#45;&gt;28408716 -->
<g id="edge85" class="edge">
<title>20299623:n&#45;&gt;28408716:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-357.42 1846.61,-368.76 1833.75,-438 1779.14,-731.96 1802.75,-811.02 1802.75,-1110"/>
</g>
<!-- 20299623&#45;&gt;28614582 -->
<g id="edge86" class="edge">
<title>20299623:n&#45;&gt;28614582:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-466.83 2517.98,-353.55 2676.75,-438 2797.72,-502.35 2827.73,-536.93 2893.75,-657 2960.08,-777.65 2930.87,-825.06 2962.75,-959 2979.45,-1029.15 3001.75,-1044.39 3001.75,-1116.5"/>
</g>
<!-- 20299623&#45;&gt;28860793 -->
<g id="edge87" class="edge">
<title>20299623:n&#45;&gt;28860793:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-384.34 1864.41,-409.72 1878.75,-506 1889.08,-575.39 1909.46,-588.53 1924.75,-657 1932.87,-693.38 1920.99,-706.22 1936.75,-740 1974.81,-821.58 2039.63,-806.9 2071.75,-891 2119.63,-1016.39 2081.5,-1059.13 2071.75,-1193 2066.62,-1263.34 2048.75,-1279.48 2048.75,-1350"/>
</g>
<!-- 20299623&#45;&gt;28956288 -->
<g id="edge88" class="edge">
<title>20299623:n&#45;&gt;28956288:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-412.27 1741.87,-360.12 1643.75,-438 1534.94,-524.36 1501.66,-544.08 1420.75,-657 1396.89,-690.29 1407.07,-708.63 1380.75,-740 1306.84,-828.05 1247.22,-805.17 1170.75,-891 1096.63,-974.19 1078.6,-1002.66 1048.75,-1110 1020.87,-1210.26 1040.75,-1239.94 1040.75,-1344"/>
</g>
<!-- 20299623&#45;&gt;29371284 -->
<g id="edge89" class="edge">
<title>20299623:n&#45;&gt;29371284:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-359.05 1839.93,-368.03 1822.75,-438 1799.39,-533.09 1808.92,-559.61 1798.75,-657 1784.73,-791.15 1786.44,-825.28 1768.75,-959 1759.82,-1026.44 1749.32,-1042.2 1743.75,-1110 1740.72,-1146.76 1737.66,-1156.62 1743.75,-1193 1755.46,-1263.01 1795.75,-1273.02 1795.75,-1344"/>
</g>
<!-- 20299623&#45;&gt;29373602 -->
<g id="edge90" class="edge">
<title>20299623:n&#45;&gt;29373602:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-562.41 2310.27,-223.28 2482.75,-438 2500.88,-460.58 2496.65,-930.06 2497.75,-959 2499.72,-1011.02 2488.52,-1145.03 2508.75,-1193 2544.42,-1277.61 2649.75,-1252.18 2649.75,-1344"/>
</g>
<!-- 20299623&#45;&gt;29622587 -->
<g id="edge91" class="edge">
<title>20299623:n&#45;&gt;29622587:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-454.83 2475.66,-355.37 2621.75,-438 2736.74,-503.04 2774.81,-533.89 2822.75,-657 2898.06,-850.44 2799.75,-915.91 2799.75,-1123.5"/>
</g>
<!-- 20299623&#45;&gt;29973392 -->
<g id="edge92" class="edge">
<title>20299623:n&#45;&gt;29973392:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-302.46 1474.33,-644.14 1465.75,-657 1404.65,-748.54 1403,-782.47 1384.75,-891 1362.48,-1023.4 1410.72,-1060.09 1391.75,-1193 1381.87,-1262.2 1347.75,-1274.1 1347.75,-1344"/>
</g>
<!-- 20299623&#45;&gt;30383768 -->
<g id="edge93" class="edge">
<title>20299623:n&#45;&gt;30383768:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-370.03 1820.07,-370.48 1771.75,-438 1702.49,-534.76 1658.29,-545.13 1617.75,-657 1606.27,-688.66 1596.47,-925.54 1592.75,-959 1584.94,-1029.25 1570.75,-1045.82 1570.75,-1116.5"/>
</g>
<!-- 20299623&#45;&gt;31112292 -->
<g id="edge94" class="edge">
<title>20299623:n&#45;&gt;31112292:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-558.97 2306.57,-224.27 2474.75,-438 2500.69,-470.97 2472.97,-1152.46 2483.75,-1193 2503.47,-1267.22 2539.52,-1272.58 2567.75,-1344 2579.2,-1372.97 2565.42,-1387.57 2584.75,-1412 2675.39,-1526.59 2876.75,-1416.9 2876.75,-1563"/>
</g>
<!-- 20299623&#45;&gt;31195999 -->
<g id="edge95" class="edge">
<title>20299623:n&#45;&gt;31195999:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-634.84 3157.32,-234.95 3439.75,-438 3605.24,-556.98 3582.75,-1140.17 3582.75,-1344"/>
</g>
<!-- 20299623&#45;&gt;32341789 -->
<g id="edge96" class="edge">
<title>20299623:n&#45;&gt;32341789:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-626.22 3115.87,-253.84 3400.75,-438 3495.05,-498.96 3493.62,-549.7 3526.75,-657 3561.9,-770.86 3571.64,-1077.39 3542.75,-1193 3523.66,-1269.37 3460.75,-1271.28 3460.75,-1350"/>
</g>
<!-- 20299623&#45;&gt;32415705 -->
<g id="edge97" class="edge">
<title>20299623:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-623.1 1424.96,-258.59 1140.75,-438 1037.69,-503.05 1044.08,-556.09 975.75,-657 953.75,-689.49 818.97,-929.82 792.75,-959 718.78,-1041.32 666.33,-1025.59 594.75,-1110 567.74,-1141.84 573.54,-1158.02 550.75,-1193 504.1,-1264.59 459.74,-1263.27 431.75,-1344 399.5,-1437 464.75,-1464.57 464.75,-1563"/>
</g>
<!-- 20299623&#45;&gt;33657116 -->
<g id="edge98" class="edge">
<title>20299623:n&#45;&gt;33657116:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-384.4 1861.17,-409.42 1873.75,-506 1882.71,-574.84 1898.28,-589.32 1913.75,-657 1922.12,-693.62 1913.98,-705.9 1929.75,-740 1965.83,-818.06 2021.14,-810.26 2050.75,-891 2096.97,-1017.04 2085.3,-1061.82 2056.75,-1193 2041.05,-1265.1 2003.44,-1271.9 1987.75,-1344 1981.32,-1373.53 1972.03,-1386.18 1987.75,-1412 2063.71,-1536.8 2279.75,-1416.9 2279.75,-1563"/>
</g>
<!-- 20299623&#45;&gt;34280330 -->
<g id="edge99" class="edge">
<title>20299623:n&#45;&gt;34280330:s</title>
<path fill="none" stroke="black" d="M1881.75,-287C1881.75,-384.97 1843.32,-408.96 1856.75,-506 1857.67,-512.69 1919.63,-734.01 1922.75,-740 1962.66,-816.81 2016.74,-809.45 2045.75,-891 2055.88,-919.47 2047.1,-928.81 2045.75,-959 2041.08,-1063.31 2044.42,-1090.45 2024.75,-1193 2011.55,-1261.77 1989.85,-1274.71 1979.75,-1344 1975.39,-1373.91 1967.24,-1384.49 1979.75,-1412 2023.69,-1508.63 2159.75,-1462.84 2159.75,-1569"/>
</g>
<!-- 21387461&#45;&gt;27412905 -->
<g id="edge100" class="edge">
<title>21387461:n&#45;&gt;27412905:s</title>
<path fill="none" stroke="black" d="M2751.75,-733.5C2751.75,-1080.2 1987.75,-544.3 1987.75,-891"/>
</g>
<!-- 21387461&#45;&gt;27550177 -->
<g id="edge101" class="edge">
<title>21387461:n&#45;&gt;27550177:s</title>
<path fill="none" stroke="black" d="M2751.75,-733.5C2751.75,-1185.85 722.75,-444.65 722.75,-897"/>
</g>
<!-- 21387461&#45;&gt;27889397 -->
<g id="edge102" class="edge">
<title>21387461:n&#45;&gt;27889397:s</title>
<path fill="none" stroke="black" d="M2751.75,-733.5C2751.75,-1026.05 1444.75,-598.45 1444.75,-891"/>
</g>
<!-- 21387461&#45;&gt;28300870 -->
<g id="edge103" class="edge">
<title>21387461:n&#45;&gt;28300870:s</title>
<path fill="none" stroke="black" d="M2751.75,-733.5C2751.75,-804.01 3257.75,-1045.99 3257.75,-1116.5"/>
</g>
<!-- 21387461&#45;&gt;28874129 -->
<g id="edge104" class="edge">
<title>21387461:n&#45;&gt;28874129:s</title>
<path fill="none" stroke="black" d="M2751.75,-733.5C2751.75,-972.96 1910.38,-808.04 1685.75,-891 1597.37,-923.64 1326.75,-1022.29 1326.75,-1116.5"/>
</g>
<!-- 21387461&#45;&gt;29360144 -->
<g id="edge105" class="edge">
<title>21387461:n&#45;&gt;29360144:s</title>
<path fill="none" stroke="black" d="M2751.75,-733.5C2751.75,-1105.48 2188.14,-623.42 1929.75,-891 1882.57,-939.86 1925.76,-1140.43 1882.75,-1193 1760.04,-1342.97 1473.75,-1150.23 1473.75,-1344"/>
</g>
<!-- 21387461&#45;&gt;29373602 -->
<g id="edge106" class="edge">
<title>21387461:n&#45;&gt;29373602:s</title>
<path fill="none" stroke="black" d="M2751.75,-733.5C2751.75,-806.18 2722.33,-819.8 2707.75,-891 2697.56,-940.71 2649.75,-1293.26 2649.75,-1344"/>
</g>
<!-- 21387461&#45;&gt;29654196 -->
<g id="edge107" class="edge">
<title>21387461:n&#45;&gt;29654196:s</title>
<path fill="none" stroke="black" d="M2751.75,-733.5C2751.75,-779.18 2058.73,-1084.62 2020.75,-1110 1973.29,-1141.72 1968.9,-1159.42 1922.75,-1193 1815.74,-1270.86 1669.75,-1217.66 1669.75,-1350"/>
</g>
<!-- 21387461&#45;&gt;30299591 -->
<g id="edge108" class="edge">
<title>21387461:n&#45;&gt;30299591:s</title>
<path fill="none" stroke="black" d="M2751.75,-733.5C2751.75,-831.71 2864.93,-802.14 2906.75,-891 2921.11,-921.52 2919.79,-1164.44 2937.75,-1193 3006.03,-1301.6 3183.75,-1215.71 3183.75,-1344"/>
</g>
<!-- 21387461&#45;&gt;30383768 -->
<g id="edge109" class="edge">
<title>21387461:n&#45;&gt;30383768:s</title>
<path fill="none" stroke="black" d="M2751.75,-733.5C2751.75,-923.86 2086.1,-819.34 1909.75,-891 1742.1,-959.12 1570.75,-935.54 1570.75,-1116.5"/>
</g>
<!-- 21387461&#45;&gt;30571400 -->
<g id="edge110" class="edge">
<title>21387461:n&#45;&gt;30571400:s</title>
<path fill="none" stroke="black" d="M2751.75,-733.5C2751.75,-823.4 2876.72,-1023.1 2899.75,-1110 2909.29,-1146.03 2895.5,-1159.45 2911.75,-1193 2952.02,-1276.19 3054.75,-1251.57 3054.75,-1344"/>
</g>
<!-- 21387461&#45;&gt;30924051 -->
<g id="edge111" class="edge">
<title>21387461:n&#45;&gt;30924051:s</title>
<path fill="none" stroke="black" d="M2751.75,-733.5C2751.75,-909.13 2832.38,-938.84 2871.75,-1110 2880.1,-1146.32 2874.65,-1156.85 2883.75,-1193 2901.17,-1262.27 2938.75,-1272.58 2938.75,-1344"/>
</g>
<!-- 21387461&#45;&gt;31112292 -->
<g id="edge112" class="edge">
<title>21387461:n&#45;&gt;31112292:s</title>
<path fill="none" stroke="black" d="M2751.75,-733.5C2751.75,-835.68 2705.51,-1095.09 2734.75,-1193 2757.71,-1269.89 2804.17,-1269.4 2833.75,-1344 2845.06,-1372.53 2839.99,-1381.85 2845.75,-1412 2858.59,-1479.3 2876.75,-1494.49 2876.75,-1563"/>
</g>
<!-- 21387461&#45;&gt;31195999 -->
<g id="edge113" class="edge">
<title>21387461:n&#45;&gt;31195999:s</title>
<path fill="none" stroke="black" d="M2751.75,-733.5C2751.75,-866.71 2895.3,-818.04 3006.75,-891 3142.99,-980.2 3582.75,-1181.16 3582.75,-1344"/>
</g>
<!-- 21387461&#45;&gt;33657116 -->
<g id="edge114" class="edge">
<title>21387461:n&#45;&gt;33657116:s</title>
<path fill="none" stroke="black" d="M2751.75,-733.5C2751.75,-803.96 2738.72,-820.72 2733.75,-891 2726.88,-988.13 2729.08,-1012.64 2727.75,-1110 2727.24,-1146.89 2719.61,-1157.02 2727.75,-1193 2750.35,-1292.93 2861.27,-1330.07 2799.75,-1412 2655.24,-1604.44 2279.75,-1322.34 2279.75,-1563"/>
</g>
<!-- 21387461&#45;&gt;34280330 -->
<g id="edge115" class="edge">
<title>21387461:n&#45;&gt;34280330:s</title>
<path fill="none" stroke="black" d="M2751.75,-733.5C2751.75,-804.12 2736.39,-820.61 2730.75,-891 2722.97,-988.06 2726.08,-1012.64 2724.75,-1110 2724.24,-1146.89 2720.79,-1156.32 2724.75,-1193 2735.32,-1290.86 2817.87,-1334.06 2757.75,-1412 2589.92,-1629.58 2159.75,-1294.22 2159.75,-1569"/>
</g>
<!-- 21387461&#45;&gt;34398204 -->
<g id="edge116" class="edge">
<title>21387461:n&#45;&gt;34398204:s</title>
<path fill="none" stroke="black" d="M2751.75,-733.5C2751.75,-809.75 2790.42,-820.62 2819.75,-891 2860.09,-987.83 2876.97,-1009.72 2907.75,-1110 2918.82,-1146.08 2906.15,-1160.74 2925.75,-1193 2980.31,-1282.83 3054.94,-1253.13 3107.75,-1344 3123.17,-1370.53 3104.26,-1385.51 3119.75,-1412 3173.15,-1503.32 3303.75,-1457.21 3303.75,-1563"/>
</g>
<!-- 21830957&#45;&gt;25587093 -->
<g id="edge117" class="edge">
<title>21830957:n&#45;&gt;25587093:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-456.78 3302.23,-291.09 3398.75,-438 3415.34,-463.26 3399.99,-475.8 3398.75,-506 3395.86,-576.18 3385.75,-593.26 3385.75,-663.5"/>
</g>
<!-- 21830957&#45;&gt;25862791 -->
<g id="edge118" class="edge">
<title>21830957:n&#45;&gt;25862791:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-461.84 1587.5,-381.38 1415.75,-438 1323.21,-468.5 1039.75,-566.07 1039.75,-663.5"/>
</g>
<!-- 21830957&#45;&gt;25910928 -->
<g id="edge119" class="edge">
<title>21830957:n&#45;&gt;25910928:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-526.51 831.75,-192.49 831.75,-438"/>
</g>
<!-- 21830957&#45;&gt;26199338 -->
<g id="edge120" class="edge">
<title>21830957:n&#45;&gt;26199338:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-533.16 1013.23,-365.39 771.75,-438 677.12,-466.46 384.75,-558.18 384.75,-657"/>
</g>
<!-- 21830957&#45;&gt;26848150 -->
<g id="edge121" class="edge">
<title>21830957:n&#45;&gt;26848150:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-548.4 2100.48,-366.76 1842.75,-438 1599.55,-505.22 1321.75,-411.19 1321.75,-663.5"/>
</g>
<!-- 21830957&#45;&gt;27312796 -->
<g id="edge122" class="edge">
<title>21830957:n&#45;&gt;27312796:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-399.95 2718.34,-556.47 2654.75,-657 2633.86,-690.02 2640.91,-703.99 2625.75,-740 2596.67,-809.06 2550.75,-816.07 2550.75,-891"/>
</g>
<!-- 21830957&#45;&gt;27412905 -->
<g id="edge123" class="edge">
<title>21830957:n&#45;&gt;27412905:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-595.94 2633.9,-313.19 2344.75,-438 2184.49,-507.17 2110.8,-508.7 2018.75,-657 1963.42,-746.13 1987.75,-786.09 1987.75,-891"/>
</g>
<!-- 21830957&#45;&gt;27550177 -->
<g id="edge124" class="edge">
<title>21830957:n&#45;&gt;27550177:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-546.63 2104.66,-359.97 1850.75,-438 1746.92,-469.91 1486.33,-576.19 1413.75,-657 1387.43,-686.29 1412.26,-713.93 1382.75,-740 1156.75,-939.6 722.75,-595.48 722.75,-897"/>
</g>
<!-- 21830957&#45;&gt;27680880 -->
<g id="edge125" class="edge">
<title>21830957:n&#45;&gt;27680880:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-395.41 2916.55,-361.2 2831.75,-438 2691.94,-564.62 2321.75,-927.88 2321.75,-1116.5"/>
</g>
<!-- 21830957&#45;&gt;27889397 -->
<g id="edge126" class="edge">
<title>21830957:n&#45;&gt;27889397:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-528.14 2119.43,-273.77 1934.75,-438 1911.38,-458.77 1938.04,-483.11 1916.75,-506 1775.89,-657.35 1608.04,-497.29 1476.75,-657 1475.7,-658.27 1444.75,-889.36 1444.75,-891"/>
</g>
<!-- 21830957&#45;&gt;27933569 -->
<g id="edge127" class="edge">
<title>21830957:n&#45;&gt;27933569:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-542.01 2067.45,-265.3 1871.75,-438 1848.31,-458.69 1874.74,-482.84 1853.75,-506 1724.73,-648.34 1584.62,-521.2 1448.75,-657 1420.89,-684.84 1442.25,-709.17 1417.75,-740 1342.11,-835.14 1256.38,-789.35 1189.75,-891 1172.92,-916.67 1186.87,-929.7 1177.75,-959 1154.87,-1032.49 1105.75,-1039.53 1105.75,-1116.5"/>
</g>
<!-- 21830957&#45;&gt;28188243 -->
<g id="edge128" class="edge">
<title>21830957:n&#45;&gt;28188243:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-507.22 2919.58,-539.01 2815.75,-740 2804.77,-761.25 2606.75,-1092.58 2606.75,-1116.5"/>
</g>
<!-- 21830957&#45;&gt;28300870 -->
<g id="edge129" class="edge">
<title>21830957:n&#45;&gt;28300870:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-406.24 3210.56,-327.63 3269.75,-438 3311.35,-515.58 3257.75,-1082.61 3257.75,-1116.5"/>
</g>
<!-- 21830957&#45;&gt;28408716 -->
<g id="edge130" class="edge">
<title>21830957:n&#45;&gt;28408716:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-525.06 2124,-268.14 1948.75,-438 1926.71,-459.36 1945.94,-476.72 1936.75,-506 1914.58,-576.57 1887.7,-586.06 1866.75,-657 1863.15,-669.19 1802.75,-1097.29 1802.75,-1110"/>
</g>
<!-- 21830957&#45;&gt;28614582 -->
<g id="edge131" class="edge">
<title>21830957:n&#45;&gt;28614582:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-652.64 3001.75,-744.86 3001.75,-1116.5"/>
</g>
<!-- 21830957&#45;&gt;28860793 -->
<g id="edge132" class="edge">
<title>21830957:n&#45;&gt;28860793:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-351.1 3045.64,-368.09 3050.75,-438 3056.86,-521.75 3139.5,-1129.33 3084.75,-1193 2932.93,-1369.56 2048.75,-1117.15 2048.75,-1350"/>
</g>
<!-- 21830957&#45;&gt;28874129 -->
<g id="edge133" class="edge">
<title>21830957:n&#45;&gt;28874129:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-531.22 2137.36,-312.73 1920.75,-438 1887.58,-457.18 1898.62,-483.3 1867.75,-506 1713.98,-619.06 1592.97,-514.73 1465.75,-657 1440.38,-685.36 1456.77,-703.9 1444.75,-740 1421.77,-808.99 1404.43,-821.91 1381.75,-891 1349.57,-989.01 1326.75,-1013.34 1326.75,-1116.5"/>
</g>
<!-- 21830957&#45;&gt;28956288 -->
<g id="edge134" class="edge">
<title>21830957:n&#45;&gt;28956288:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-505.07 2227.86,-316.27 2039.75,-438 1942.15,-501.15 1933.52,-546.72 1896.75,-657 1892.03,-671.15 1871.66,-1181.85 1861.75,-1193 1615.15,-1470.19 1040.75,-972.99 1040.75,-1344"/>
</g>
<!-- 21830957&#45;&gt;29171208 -->
<g id="edge135" class="edge">
<title>21830957:n&#45;&gt;29171208:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-354.23 3072.68,-365.94 3085.75,-438 3100.73,-520.63 3172.96,-1128.04 3119.75,-1193 2883.61,-1481.25 2297.75,-985.38 2297.75,-1358"/>
</g>
<!-- 21830957&#45;&gt;29371284 -->
<g id="edge136" class="edge">
<title>21830957:n&#45;&gt;29371284:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-331.71 3107.43,-1155.1 3073.75,-1193 2883.77,-1406.75 1795.75,-1058.02 1795.75,-1344"/>
</g>
<!-- 21830957&#45;&gt;29373602 -->
<g id="edge137" class="edge">
<title>21830957:n&#45;&gt;29373602:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-401.48 3201.48,-330.94 3256.75,-438 3269.89,-463.45 3288.41,-469.09 3223.75,-959 3214.8,-1026.75 3206.08,-1042.61 3194.75,-1110 3191.65,-1128.38 3195.02,-1178.98 3182.75,-1193 3020.55,-1378.24 2649.75,-1097.79 2649.75,-1344"/>
</g>
<!-- 21830957&#45;&gt;29525786 -->
<g id="edge138" class="edge">
<title>21830957:n&#45;&gt;29525786:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-545.09 2102.81,-339.57 1857.75,-438 1810.23,-457.08 1809.12,-480.45 1764.75,-506 1620.05,-589.32 1527.9,-528.95 1420.75,-657 1396.39,-686.1 1426.69,-712.31 1400.75,-740 1246.07,-905.03 1078.71,-735.2 914.75,-891 891.4,-913.18 903.68,-929.97 889.75,-959 854.37,-1032.7 794.75,-1034.75 794.75,-1116.5"/>
</g>
<!-- 21830957&#45;&gt;29622587 -->
<g id="edge139" class="edge">
<title>21830957:n&#45;&gt;29622587:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-590.21 2982.69,-667.43 2879.75,-959 2852.68,-1035.66 2799.75,-1042.2 2799.75,-1123.5"/>
</g>
<!-- 21830957&#45;&gt;29909576 -->
<g id="edge140" class="edge">
<title>21830957:n&#45;&gt;29909576:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-396.82 3192.11,-334.33 3243.75,-438 3257.22,-465.05 3245.52,-475.83 3243.75,-506 3241.49,-544.36 3188.42,-1164.4 3162.75,-1193 2961.71,-1416.91 2502.75,-1043.09 2502.75,-1344"/>
</g>
<!-- 21830957&#45;&gt;29973392 -->
<g id="edge141" class="edge">
<title>21830957:n&#45;&gt;29973392:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-473.74 2358.37,-358.59 2182.75,-438 2039.43,-502.8 1978.12,-517.87 1904.75,-657 1890.82,-683.4 1887.46,-1169.75 1868.75,-1193 1717.55,-1380.78 1347.75,-1102.92 1347.75,-1344"/>
</g>
<!-- 21830957&#45;&gt;30299591 -->
<g id="edge142" class="edge">
<title>21830957:n&#45;&gt;30299591:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-468.68 3308.33,-293.22 3427.75,-438 3490.81,-514.46 3453.69,-559.2 3469.75,-657 3508.42,-892.58 3579.99,-1003.54 3434.75,-1193 3355.54,-1296.32 3183.75,-1213.81 3183.75,-1344"/>
</g>
<!-- 21830957&#45;&gt;30383768 -->
<g id="edge143" class="edge">
<title>21830957:n&#45;&gt;30383768:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-526.6 2120.59,-269.67 1941.75,-438 1919.28,-459.15 1946.33,-481.36 1927.75,-506 1840.48,-621.7 1721.05,-537.72 1638.75,-657 1619.55,-684.81 1608.12,-925.64 1602.75,-959 1591.4,-1029.52 1570.75,-1045.07 1570.75,-1116.5"/>
</g>
<!-- 21830957&#45;&gt;30571400 -->
<g id="edge144" class="edge">
<title>21830957:n&#45;&gt;30571400:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-459.23 3288.36,-303.02 3404.75,-438 3470.43,-514.17 3448.98,-557.24 3461.75,-657 3492.16,-894.63 3554,-1005.61 3404.75,-1193 3299.2,-1325.52 3054.75,-1174.59 3054.75,-1344"/>
</g>
<!-- 21830957&#45;&gt;30924051 -->
<g id="edge145" class="edge">
<title>21830957:n&#45;&gt;30924051:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-409.58 3213.6,-327.14 3278.75,-438 3321.32,-510.45 3370.06,-1123.55 3322.75,-1193 3219.49,-1344.56 2938.75,-1160.61 2938.75,-1344"/>
</g>
<!-- 21830957&#45;&gt;31022899 -->
<g id="edge146" class="edge">
<title>21830957:n&#45;&gt;31022899:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-353.35 3068.25,-366.42 3078.75,-438 3090.92,-521.02 3148.86,-1128.88 3094.75,-1193 2960.84,-1351.67 2173.75,-1142.38 2173.75,-1350"/>
</g>
<!-- 21830957&#45;&gt;31195999 -->
<g id="edge147" class="edge">
<title>21830957:n&#45;&gt;31195999:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-489.89 3316.25,-306.74 3478.75,-438 3567.69,-509.85 3577.9,-548.42 3613.75,-657 3651.12,-770.2 3655.77,-1075.48 3635.75,-1193 3623.8,-1263.11 3582.75,-1272.88 3582.75,-1344"/>
</g>
<!-- 21830957&#45;&gt;31390972 -->
<g id="edge148" class="edge">
<title>21830957:n&#45;&gt;31390972:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-599.41 3526.86,-196.82 3734.75,-438 3766.61,-474.96 3748.45,-608.26 3750.75,-657 3758.66,-824.8 3792.09,-1263.93 3712.75,-1412 3647.44,-1533.88 3613.74,-1565.89 3491.75,-1631 3342.53,-1710.64 2745.75,-1612.86 2745.75,-1782"/>
</g>
<!-- 21830957&#45;&gt;32341789 -->
<g id="edge149" class="edge">
<title>21830957:n&#45;&gt;32341789:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-476.96 3315.76,-293.16 3447.75,-438 3676.55,-689.08 3670.98,-869.69 3566.75,-1193 3540.91,-1273.13 3460.75,-1265.81 3460.75,-1350"/>
</g>
<!-- 21830957&#45;&gt;32415705 -->
<g id="edge150" class="edge">
<title>21830957:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-505.46 3345.9,-291.26 3515.75,-438 3598.02,-509.08 3595.82,-552.2 3624.75,-657 3635.91,-697.45 3678.71,-1381.63 3649.75,-1412 3405.23,-1668.38 464.75,-1208.71 464.75,-1563"/>
</g>
<!-- 21830957&#45;&gt;32676543 -->
<g id="edge151" class="edge">
<title>21830957:n&#45;&gt;32676543:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-592.91 3521,-197.61 3719.75,-438 3734.65,-456.02 3769.21,-1341.93 3727.75,-1412 3656.74,-1532 3566.01,-1481.68 3452.75,-1563 3416.46,-1589.05 3419.8,-1613.41 3378.75,-1631 3136.36,-1734.85 1010.75,-1524.81 1010.75,-1788.5"/>
</g>
<!-- 21830957&#45;&gt;33093817 -->
<g id="edge152" class="edge">
<title>21830957:n&#45;&gt;33093817:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-306.35 3080.9,-1174.34 3063.75,-1193 2923.08,-1346.01 1199.75,-1142.16 1199.75,-1350"/>
</g>
<!-- 21830957&#45;&gt;33253294 -->
<g id="edge153" class="edge">
<title>21830957:n&#45;&gt;33253294:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-577.76 3493.87,-210.76 3684.75,-438 3716.11,-475.34 3697.19,-608.26 3698.75,-657 3701.43,-740.97 3711.2,-1347.19 3657.75,-1412 3516,-1583.85 3181.75,-1346.23 3181.75,-1569"/>
</g>
<!-- 21830957&#45;&gt;33587284 -->
<g id="edge154" class="edge">
<title>21830957:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-565.68 3481.85,-213.38 3656.75,-438 3673.37,-459.35 3675.27,-1392.28 3656.75,-1412 3466.99,-1614.09 1166.75,-1291.78 1166.75,-1569"/>
</g>
<!-- 21830957&#45;&gt;33657116 -->
<g id="edge155" class="edge">
<title>21830957:n&#45;&gt;33657116:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-572.15 3488.59,-211.68 3671.75,-438 3702.38,-475.85 3677.24,-608.33 3678.75,-657 3681.96,-761 3684.19,-786.97 3685.75,-891 3686.61,-948.91 3710.13,-1369.54 3670.75,-1412 3459.29,-1639.95 2279.75,-1252.07 2279.75,-1563"/>
</g>
<!-- 21830957&#45;&gt;34173286 -->
<g id="edge156" class="edge">
<title>21830957:n&#45;&gt;34173286:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-586.84 3510.86,-202.29 3705.75,-438 3740.19,-479.65 3725.75,-869.95 3725.75,-924 3725.75,-924 3725.75,-924 3725.75,-1152.5 3725.75,-1269.41 3752.28,-1318.02 3682.75,-1412 3593.02,-1533.27 3471.65,-1444.14 3378.75,-1563 3359.69,-1587.38 3387.31,-1610.94 3363.75,-1631 3128.58,-1831.18 588.75,-1479.67 588.75,-1788.5"/>
</g>
<!-- 21830957&#45;&gt;34280330 -->
<g id="edge157" class="edge">
<title>21830957:n&#45;&gt;34280330:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-568.7 3483.09,-214.09 3663.75,-438 3680.74,-459.06 3682.03,-1392.06 3663.75,-1412 3436.61,-1659.65 2159.75,-1232.96 2159.75,-1569"/>
</g>
<!-- 21830957&#45;&gt;34379219 -->
<g id="edge158" class="edge">
<title>21830957:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-609.82 3516.46,-215.69 3758.75,-438 4001.18,-660.45 3959.75,-821.47 3959.75,-1150.5 3959.75,-1150.5 3959.75,-1150.5 3959.75,-1598 3959.75,-1699.42 3947.19,-1800.69 3863.75,-1865 3620.98,-2052.12 2492.75,-1709.49 2492.75,-2016"/>
</g>
<!-- 21830957&#45;&gt;34398204 -->
<g id="edge159" class="edge">
<title>21830957:n&#45;&gt;34398204:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-582.52 3505.61,-203.99 3695.75,-438 3726.45,-475.78 3700.87,-608.32 3701.75,-657 3703.26,-740.95 3721.66,-1345.24 3670.75,-1412 3563.79,-1552.24 3303.75,-1386.62 3303.75,-1563"/>
</g>
<!-- 21830957&#45;&gt;34643934 -->
<g id="edge160" class="edge">
<title>21830957:n&#45;&gt;34643934:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-595.94 3522.51,-198.26 3726.75,-438 3738.66,-451.98 3753.75,-984.96 3753.75,-1150.5 3753.75,-1150.5 3753.75,-1150.5 3753.75,-1379 3753.75,-1556.1 3455.04,-1630.08 3452.75,-1631 3185.82,-1737.72 2168.75,-1501.03 2168.75,-1788.5"/>
</g>
<!-- 21830957&#45;&gt;34722686 -->
<g id="edge161" class="edge">
<title>21830957:n&#45;&gt;34722686:s</title>
<path fill="none" stroke="black" d="M3035.75,-281C3035.75,-604.61 3513.05,-214.14 3746.75,-438 3750.23,-441.34 3925.12,-1105.21 3925.75,-1110 3931.03,-1150.33 3945.48,-1596.2 3919.75,-1631 3777.62,-1823.16 3407.75,-1556.49 3407.75,-1795.5"/>
</g>
<!-- 21870978&#45;&gt;25587093 -->
<g id="edge162" class="edge">
<title>21870978:n&#45;&gt;25587093:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-944.95 3385.75,-224.55 3385.75,-663.5"/>
</g>
<!-- 21870978&#45;&gt;26848150 -->
<g id="edge163" class="edge">
<title>21870978:n&#45;&gt;26848150:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-750.52 1321.75,-418.98 1321.75,-663.5"/>
</g>
<!-- 21870978&#45;&gt;27312796 -->
<g id="edge164" class="edge">
<title>21870978:n&#45;&gt;27312796:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-581.54 2461.58,-586.52 2488.75,-657 2527.44,-757.39 2550.75,-783.41 2550.75,-891"/>
</g>
<!-- 21870978&#45;&gt;27412905 -->
<g id="edge165" class="edge">
<title>21870978:n&#45;&gt;27412905:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-666.48 2193.6,-540.95 2082.75,-657 2005.22,-738.16 1987.75,-778.76 1987.75,-891"/>
</g>
<!-- 21870978&#45;&gt;27550177 -->
<g id="edge166" class="edge">
<title>21870978:n&#45;&gt;27550177:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-666.32 1121.35,-589.88 975.75,-657 834.99,-721.88 722.75,-742.01 722.75,-897"/>
</g>
<!-- 21870978&#45;&gt;27680880 -->
<g id="edge167" class="edge">
<title>21870978:n&#45;&gt;27680880:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-574.55 2321.75,-1047.95 2321.75,-1116.5"/>
</g>
<!-- 21870978&#45;&gt;27889397 -->
<g id="edge168" class="edge">
<title>21870978:n&#45;&gt;27889397:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-713.4 1638.4,-512.38 1489.75,-657 1485,-661.62 1444.75,-884.38 1444.75,-891"/>
</g>
<!-- 21870978&#45;&gt;28188243 -->
<g id="edge169" class="edge">
<title>21870978:n&#45;&gt;28188243:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-624.23 2571.24,-554.27 2629.75,-657 2663.01,-715.4 2653.88,-892.29 2645.75,-959 2637.02,-1030.58 2606.75,-1044.39 2606.75,-1116.5"/>
</g>
<!-- 21870978&#45;&gt;28300870 -->
<g id="edge170" class="edge">
<title>21870978:n&#45;&gt;28300870:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-718.65 2722.68,-498.77 2864.75,-657 2889.96,-685.09 2865.46,-706.44 2882.75,-740 2912.85,-798.46 3035.07,-912.68 3081.75,-959 3156.25,-1032.94 3257.75,-1011.53 3257.75,-1116.5"/>
</g>
<!-- 21870978&#45;&gt;28860793 -->
<g id="edge171" class="edge">
<title>21870978:n&#45;&gt;28860793:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-588.25 2346.4,-586.67 2303.75,-657 2188.38,-847.23 2150.64,-895.74 2090.75,-1110 2080.71,-1145.9 2084.91,-1156.24 2078.75,-1193 2066.99,-1263.06 2048.75,-1278.96 2048.75,-1350"/>
</g>
<!-- 21870978&#45;&gt;28956288 -->
<g id="edge172" class="edge">
<title>21870978:n&#45;&gt;28956288:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-849.51 1873.59,-393.89 1652.75,-657 1633.6,-679.81 1659.32,-1169.72 1640.75,-1193 1469.27,-1407.97 1040.75,-1069.02 1040.75,-1344"/>
</g>
<!-- 21870978&#45;&gt;29171208 -->
<g id="edge173" class="edge">
<title>21870978:n&#45;&gt;29171208:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-575.29 2264.43,-1041.26 2255.75,-1110 2251.13,-1146.6 2251.16,-1156.4 2255.75,-1193 2265.15,-1268.08 2297.75,-1282.33 2297.75,-1358"/>
</g>
<!-- 21870978&#45;&gt;29371284 -->
<g id="edge174" class="edge">
<title>21870978:n&#45;&gt;29371284:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-727.52 2076.12,-485.63 1935.75,-657 1859.81,-749.7 1912.27,-1078.56 1876.75,-1193 1854.17,-1265.73 1795.75,-1267.84 1795.75,-1344"/>
</g>
<!-- 21870978&#45;&gt;29373602 -->
<g id="edge175" class="edge">
<title>21870978:n&#45;&gt;29373602:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-576.03 2442.94,-588.15 2455.75,-657 2466.67,-715.73 2472.66,-1138.79 2497.75,-1193 2537.74,-1279.42 2649.75,-1248.78 2649.75,-1344"/>
</g>
<!-- 21870978&#45;&gt;29525786 -->
<g id="edge176" class="edge">
<title>21870978:n&#45;&gt;29525786:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-722.61 1620.39,-526.17 1447.75,-657 1415.41,-681.5 1440.32,-713.33 1409.75,-740 1234.82,-892.61 1074.4,-727.37 909.75,-891 887.31,-913.3 901.61,-930.1 888.75,-959 855.6,-1033.47 794.75,-1034.98 794.75,-1116.5"/>
</g>
<!-- 21870978&#45;&gt;29622587 -->
<g id="edge177" class="edge">
<title>21870978:n&#45;&gt;29622587:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-698.1 2706.18,-499.21 2815.75,-657 2836.79,-687.3 2816.52,-703.12 2815.75,-740 2812.19,-910.56 2799.75,-952.91 2799.75,-1123.5"/>
</g>
<!-- 21870978&#45;&gt;29909576 -->
<g id="edge178" class="edge">
<title>21870978:n&#45;&gt;29909576:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-575.1 2437.61,-588.65 2447.75,-657 2482.73,-892.99 2450.02,-955.93 2476.75,-1193 2484.38,-1260.67 2502.75,-1275.9 2502.75,-1344"/>
</g>
<!-- 21870978&#45;&gt;30383768 -->
<g id="edge179" class="edge">
<title>21870978:n&#45;&gt;30383768:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-852.56 1874.1,-396.31 1645.75,-657 1634.67,-669.65 1630.12,-942.53 1626.75,-959 1611.82,-1031.78 1570.75,-1042.21 1570.75,-1116.5"/>
</g>
<!-- 21870978&#45;&gt;30571400 -->
<g id="edge180" class="edge">
<title>21870978:n&#45;&gt;30571400:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-709.81 2709.86,-503.34 2843.75,-657 2861.17,-676.99 2886.1,-864.89 2890.75,-891 2914.57,-1024.73 2884,-1068.25 2937.75,-1193 2971.34,-1270.97 3054.75,-1259.1 3054.75,-1344"/>
</g>
<!-- 21870978&#45;&gt;30924051 -->
<g id="edge181" class="edge">
<title>21870978:n&#45;&gt;30924051:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-701.02 2698.44,-506.73 2822.75,-657 2899.68,-750.01 2889.96,-1074.1 2910.75,-1193 2922.5,-1260.24 2938.75,-1275.74 2938.75,-1344"/>
</g>
<!-- 21870978&#45;&gt;31022899 -->
<g id="edge182" class="edge">
<title>21870978:n&#45;&gt;31022899:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-581.23 2122.22,-1036.83 2104.75,-1110 2096.18,-1145.88 2097.16,-1156.9 2104.75,-1193 2120.41,-1267.59 2173.75,-1273.78 2173.75,-1350"/>
</g>
<!-- 21870978&#45;&gt;31195999 -->
<g id="edge183" class="edge">
<title>21870978:n&#45;&gt;31195999:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-738.43 3277.18,-496.97 3445.75,-657 3473.97,-683.8 3582.75,-1305.08 3582.75,-1344"/>
</g>
<!-- 21870978&#45;&gt;32341789 -->
<g id="edge184" class="edge">
<title>21870978:n&#45;&gt;32341789:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-737.12 3286.02,-484.42 3439.75,-657 3452.56,-671.38 3460.75,-1330.74 3460.75,-1350"/>
</g>
<!-- 21870978&#45;&gt;32415705 -->
<g id="edge185" class="edge">
<title>21870978:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-716.12 2098.64,-496.75 1962.75,-657 1947.47,-675.02 1890.94,-1150.6 1884.75,-1193 1884.3,-1196.05 1851.98,-1409.88 1849.75,-1412 1625.43,-1625.39 464.75,-1253.4 464.75,-1563"/>
</g>
<!-- 21870978&#45;&gt;32539675 -->
<g id="edge186" class="edge">
<title>21870978:n&#45;&gt;32539675:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-585.77 2470.64,-586.39 2507.75,-657 2560.19,-756.81 2583.53,-780.46 2605.75,-891 2625.5,-989.28 2568.88,-1011.23 2551.75,-1110 2545.44,-1146.35 2536.68,-1159.33 2551.75,-1193 2601.97,-1305.22 2797.77,-1316.17 2720.75,-1412 2517.47,-1664.91 2007.75,-1244.52 2007.75,-1569"/>
</g>
<!-- 21870978&#45;&gt;32676543 -->
<g id="edge187" class="edge">
<title>21870978:n&#45;&gt;32676543:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-573.44 2421.59,-589.69 2425.75,-657 2440.43,-894.82 2448.4,-955.01 2436.75,-1193 2435.55,-1217.42 2410.9,-1613.58 2393.75,-1631 2176.73,-1851.41 1010.75,-1479.18 1010.75,-1788.5"/>
</g>
<!-- 21870978&#45;&gt;33253294 -->
<g id="edge188" class="edge">
<title>21870978:n&#45;&gt;33253294:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-723.29 2700.61,-528.39 2875.75,-657 2912.23,-683.79 2905.12,-705.78 2934.75,-740 2954.24,-762.52 3311.02,-1082.62 3322.75,-1110 3347.83,-1168.59 3324.39,-1341.81 3296.75,-1412 3265.05,-1492.48 3181.75,-1482.51 3181.75,-1569"/>
</g>
<!-- 21870978&#45;&gt;33587284 -->
<g id="edge189" class="edge">
<title>21870978:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-692.7 2149.99,-524.21 2018.75,-657 1940.75,-735.92 1953.73,-782.25 1931.75,-891 1905.12,-1022.68 1938.1,-1060.05 1918.75,-1193 1917.84,-1199.21 1868.24,-1407.62 1863.75,-1412 1636.48,-1633.77 1166.75,-1251.46 1166.75,-1569"/>
</g>
<!-- 21870978&#45;&gt;33657116 -->
<g id="edge190" class="edge">
<title>21870978:n&#45;&gt;33657116:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-707.59 2429.43,-1221.07 2364.75,-1412 2340.03,-1484.94 2279.75,-1485.99 2279.75,-1563"/>
</g>
<!-- 21870978&#45;&gt;34173286 -->
<g id="edge191" class="edge">
<title>21870978:n&#45;&gt;34173286:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-573.13 2413.86,-589.87 2414.75,-657 2417.9,-895.23 2427.54,-955.66 2406.75,-1193 2398.17,-1290.93 2391.9,-1315.03 2375.75,-1412 2359.46,-1509.76 2407.22,-1564.49 2333.75,-1631 2045.09,-1892.29 588.75,-1399.15 588.75,-1788.5"/>
</g>
<!-- 21870978&#45;&gt;34280330 -->
<g id="edge192" class="edge">
<title>21870978:n&#45;&gt;34280330:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-811.5 2417.7,-888.97 2387.75,-1193 2385.33,-1217.54 2364.09,-1390.65 2351.75,-1412 2296.58,-1507.43 2159.75,-1458.77 2159.75,-1569"/>
</g>
<!-- 21870978&#45;&gt;34379219 -->
<g id="edge193" class="edge">
<title>21870978:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-574.26 2431.05,-589.18 2438.75,-657 2465.62,-893.74 2454.56,-954.84 2447.75,-1193 2444.96,-1290.36 2425.36,-1315.67 2439.75,-1412 2465.14,-1582.06 2527.36,-1611.94 2552.75,-1782 2558.19,-1818.48 2559.68,-1828.77 2552.75,-1865 2539.17,-1935.93 2492.75,-1943.78 2492.75,-2016"/>
</g>
<!-- 21870978&#45;&gt;34398204 -->
<g id="edge194" class="edge">
<title>21870978:n&#45;&gt;34398204:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-736.86 2710.4,-537.2 2907.75,-657 3032.14,-732.51 3045.88,-777.35 3136.75,-891 3159.23,-919.12 3158.16,-930.97 3180.75,-959 3240.09,-1032.66 3294.69,-1022.54 3330.75,-1110 3344.81,-1144.1 3331.08,-1156.11 3330.75,-1193 3329.86,-1290.35 3334.98,-1315 3326.75,-1412 3321,-1479.64 3303.75,-1495.11 3303.75,-1563"/>
</g>
<!-- 21870978&#45;&gt;34643934 -->
<g id="edge195" class="edge">
<title>21870978:n&#45;&gt;34643934:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-573.82 2427.02,-589.42 2432.75,-657 2452.85,-894.42 2453.51,-954.93 2443.75,-1193 2443.68,-1194.52 2408.52,-1629.69 2407.75,-1631 2342.88,-1740.43 2168.75,-1661.29 2168.75,-1788.5"/>
</g>
<!-- 21870978&#45;&gt;34722686 -->
<g id="edge196" class="edge">
<title>21870978:n&#45;&gt;34722686:s</title>
<path fill="none" stroke="black" d="M2410.75,-506C2410.75,-761.2 2749.86,-519.32 2964.75,-657 3184.1,-797.55 3237.68,-869.05 3336.75,-1110 3394.98,-1251.64 3407.75,-1642.35 3407.75,-1795.5"/>
</g>
<!-- 23562920&#45;&gt;25365537 -->
<g id="edge197" class="edge">
<title>23562920:n&#45;&gt;25365537:s</title>
<path fill="none" stroke="black" d="M183.75,-68C183.75,-199.58 434.75,-93.42 434.75,-225"/>
</g>
<!-- 23562920&#45;&gt;26199338 -->
<g id="edge198" class="edge">
<title>23562920:n&#45;&gt;26199338:s</title>
<path fill="none" stroke="black" d="M183.75,-68C183.75,-268.29 211.84,-321.49 289.75,-506 320.59,-579.04 384.75,-577.71 384.75,-657"/>
</g>
<!-- 23562920&#45;&gt;26848150 -->
<g id="edge199" class="edge">
<title>23562920:n&#45;&gt;26848150:s</title>
<path fill="none" stroke="black" d="M183.75,-68C183.75,-312.32 1102.42,-43.84 1272.75,-219 1342.03,-290.25 1321.75,-564.12 1321.75,-663.5"/>
</g>
<!-- 23562920&#45;&gt;27412905 -->
<g id="edge200" class="edge">
<title>23562920:n&#45;&gt;27412905:s</title>
<path fill="none" stroke="black" d="M183.75,-68C183.75,-245.42 806.71,-144.53 967.75,-219 1108.93,-284.29 1168.4,-300.3 1240.75,-438 1256.39,-467.78 1240.58,-714.69 1262.75,-740 1479.55,-987.64 1987.75,-561.86 1987.75,-891"/>
</g>
<!-- 23562920&#45;&gt;27550177 -->
<g id="edge201" class="edge">
<title>23562920:n&#45;&gt;27550177:s</title>
<path fill="none" stroke="black" d="M183.75,-68C183.75,-286.14 517.05,-46.63 650.75,-219 686.29,-264.83 673.77,-682.7 682.75,-740 693.89,-811.14 722.75,-824.99 722.75,-897"/>
</g>
<!-- 23562920&#45;&gt;28188243 -->
<g id="edge202" class="edge">
<title>23562920:n&#45;&gt;28188243:s</title>
<path fill="none" stroke="black" d="M183.75,-68C183.75,-276.85 500.46,-54.19 628.75,-219 663.25,-263.33 648.75,-414.82 648.75,-471 648.75,-471 648.75,-471 648.75,-699.5 648.75,-728.34 634.95,-938.03 654.75,-959 804.13,-1117.21 2606.75,-898.91 2606.75,-1116.5"/>
</g>
<!-- 23562920&#45;&gt;28408716 -->
<g id="edge203" class="edge">
<title>23562920:n&#45;&gt;28408716:s</title>
<path fill="none" stroke="black" d="M183.75,-68C183.75,-273.91 499.28,-53.47 621.75,-219 646.21,-252.07 620.07,-928.57 647.75,-959 821.9,-1150.51 1802.75,-851.15 1802.75,-1110"/>
</g>
<!-- 23562920&#45;&gt;28860793 -->
<g id="edge204" class="edge">
<title>23562920:n&#45;&gt;28860793:s</title>
<path fill="none" stroke="black" d="M183.75,-68C183.75,-589.57 99.34,-881.6 517.75,-1193 792.11,-1397.19 2048.75,-1007.99 2048.75,-1350"/>
</g>
<!-- 23562920&#45;&gt;28956288 -->
<g id="edge205" class="edge">
<title>23562920:n&#45;&gt;28956288:s</title>
<path fill="none" stroke="black" d="M183.75,-68C183.75,-141.79 130.44,-146.9 114.75,-219 90.11,-332.17 97.66,-628.43 128.75,-740 189.79,-959.08 186.21,-1054.69 366.75,-1193 610.44,-1379.69 1040.75,-1037.02 1040.75,-1344"/>
</g>
<!-- 23562920&#45;&gt;32415705 -->
<g id="edge206" class="edge">
<title>23562920:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M183.75,-68C183.75,-147.53 109.96,-142.64 87.75,-219 50.55,-346.83 123.14,-1302.43 198.75,-1412 275.96,-1523.89 464.75,-1427.06 464.75,-1563"/>
</g>
<!-- 23562920&#45;&gt;32676543 -->
<g id="edge207" class="edge">
<title>23562920:n&#45;&gt;32676543:s</title>
<path fill="none" stroke="black" d="M183.75,-68C183.75,-149.24 104.7,-141.37 80.75,-219 57.58,-294.07 102.62,-1575.03 157.75,-1631 428.27,-1905.67 1010.75,-1402.98 1010.75,-1788.5"/>
</g>
<!-- 23562920&#45;&gt;33093817 -->
<g id="edge208" class="edge">
<title>23562920:n&#45;&gt;33093817:s</title>
<path fill="none" stroke="black" d="M183.75,-68C183.75,-138.42 146.54,-149.41 135.75,-219 100.1,-448.83 110.93,-519.45 184.75,-740 257.46,-957.26 246.62,-1056.67 430.75,-1193 711.09,-1400.58 1199.75,-1001.17 1199.75,-1350"/>
</g>
<!-- 23562920&#45;&gt;33587284 -->
<g id="edge209" class="edge">
<title>23562920:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M183.75,-68C183.75,-143.54 124.42,-145.81 105.75,-219 81.68,-313.34 101.86,-340.65 100.75,-438 98.23,-658.18 117.3,-1266.7 282.75,-1412 432.66,-1543.66 1166.75,-1369.48 1166.75,-1569"/>
</g>
<!-- 23562920&#45;&gt;34173286 -->
<g id="edge210" class="edge">
<title>23562920:n&#45;&gt;34173286:s</title>
<path fill="none" stroke="black" d="M183.75,-68C183.75,-151.03 100.39,-140.36 73.75,-219 37.79,-325.11 67.75,-358.97 67.75,-471 67.75,-471 67.75,-471 67.75,-926 67.75,-1239.56 -101.04,-1386.07 94.75,-1631 238.63,-1811 588.75,-1558.06 588.75,-1788.5"/>
</g>
<!-- 24251359&#45;&gt;26848150 -->
<g id="edge211" class="edge">
<title>24251359:n&#45;&gt;26848150:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-919.71 1321.75,-249.79 1321.75,-663.5"/>
</g>
<!-- 24251359&#45;&gt;27312796 -->
<g id="edge212" class="edge">
<title>24251359:n&#45;&gt;27312796:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-733.46 2857.93,-506.08 2687.75,-657 2657.53,-683.8 2670.19,-704.6 2650.75,-740 2612,-810.56 2550.75,-810.51 2550.75,-891"/>
</g>
<!-- 24251359&#45;&gt;27412905 -->
<g id="edge213" class="edge">
<title>24251359:n&#45;&gt;27412905:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-762.92 2863.44,-578.7 2618.75,-657 2476.31,-702.58 1987.75,-741.45 1987.75,-891"/>
</g>
<!-- 24251359&#45;&gt;27889397 -->
<g id="edge214" class="edge">
<title>24251359:n&#45;&gt;27889397:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-880.62 1769.68,-399.34 1497.75,-657 1484.22,-669.82 1489.53,-721.75 1485.75,-740 1471.63,-808.09 1444.75,-821.46 1444.75,-891"/>
</g>
<!-- 24251359&#45;&gt;27933569 -->
<g id="edge215" class="edge">
<title>24251359:n&#45;&gt;27933569:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-694.08 1648.38,-554.39 1490.75,-657 1455.4,-680.01 1473.95,-709.57 1444.75,-740 1355.38,-833.09 1269.53,-784.44 1196.75,-891 1179.44,-916.34 1194.39,-929.87 1184.75,-959 1160.13,-1033.34 1105.75,-1038.19 1105.75,-1116.5"/>
</g>
<!-- 24251359&#45;&gt;28300870 -->
<g id="edge216" class="edge">
<title>24251359:n&#45;&gt;28300870:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-642.86 3257.75,-979.64 3257.75,-1116.5"/>
</g>
<!-- 24251359&#45;&gt;28614582 -->
<g id="edge217" class="edge">
<title>24251359:n&#45;&gt;28614582:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-578.22 3138.9,-588.27 3116.75,-657 3108.68,-682.05 3001.75,-1090.18 3001.75,-1116.5"/>
</g>
<!-- 24251359&#45;&gt;28860793 -->
<g id="edge218" class="edge">
<title>24251359:n&#45;&gt;28860793:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-544.37 3132.27,-1165.27 3105.75,-1193 2941.61,-1364.61 2048.75,-1112.53 2048.75,-1350"/>
</g>
<!-- 24251359&#45;&gt;28956288 -->
<g id="edge219" class="edge">
<title>24251359:n&#45;&gt;28956288:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-741.73 2337.99,-552.37 2126.75,-657 1993.82,-722.84 1988.19,-780.93 1888.75,-891 1831.09,-954.81 1719.16,-1146.61 1646.75,-1193 1413.02,-1342.72 1040.75,-1066.43 1040.75,-1344"/>
</g>
<!-- 24251359&#45;&gt;29171208 -->
<g id="edge220" class="edge">
<title>24251359:n&#45;&gt;29171208:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-525.1 3160.21,-1178.52 3147.75,-1193 2896.72,-1484.68 2297.75,-973.17 2297.75,-1358"/>
</g>
<!-- 24251359&#45;&gt;29371284 -->
<g id="edge221" class="edge">
<title>24251359:n&#45;&gt;29371284:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-525.25 3099.46,-1179.49 3085.75,-1193 2880.12,-1395.53 1795.75,-1055.38 1795.75,-1344"/>
</g>
<!-- 24251359&#45;&gt;29373602 -->
<g id="edge222" class="edge">
<title>24251359:n&#45;&gt;29373602:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-582.35 3209.1,-1132.33 3162.75,-1193 3018.45,-1381.85 2649.75,-1106.33 2649.75,-1344"/>
</g>
<!-- 24251359&#45;&gt;29622587 -->
<g id="edge223" class="edge">
<title>24251359:n&#45;&gt;29622587:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-535.47 2916.12,-933.86 2900.75,-959 2855.98,-1032.19 2799.75,-1037.71 2799.75,-1123.5"/>
</g>
<!-- 24251359&#45;&gt;29909576 -->
<g id="edge224" class="edge">
<title>24251359:n&#45;&gt;29909576:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-544.19 3178.98,-1163.49 3154.75,-1193 2965.96,-1422.86 2502.75,-1046.55 2502.75,-1344"/>
</g>
<!-- 24251359&#45;&gt;31022899 -->
<g id="edge225" class="edge">
<title>24251359:n&#45;&gt;31022899:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-525.11 3153.51,-1178.77 3140.75,-1193 2995.39,-1355.07 2173.75,-1132.3 2173.75,-1350"/>
</g>
<!-- 24251359&#45;&gt;31195999 -->
<g id="edge226" class="edge">
<title>24251359:n&#45;&gt;31195999:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-669.32 3416.17,-524.57 3511.75,-657 3517.36,-664.78 3582.75,-1334.41 3582.75,-1344"/>
</g>
<!-- 24251359&#45;&gt;32341789 -->
<g id="edge227" class="edge">
<title>24251359:n&#45;&gt;32341789:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-666.08 3411.82,-525.95 3503.75,-657 3520.87,-681.41 3536.95,-1163.84 3530.75,-1193 3514.84,-1267.73 3460.75,-1273.6 3460.75,-1350"/>
</g>
<!-- 24251359&#45;&gt;32676543 -->
<g id="edge228" class="edge">
<title>24251359:n&#45;&gt;32676543:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-654.48 3393.02,-533.04 3474.75,-657 3491.15,-681.88 3504.47,-1164.5 3495.75,-1193 3472.04,-1270.44 3421.32,-1267.85 3393.75,-1344 3371.92,-1404.27 3410.84,-1586.45 3364.75,-1631 3176.27,-1813.19 1010.75,-1526.36 1010.75,-1788.5"/>
</g>
<!-- 24251359&#45;&gt;33093817 -->
<g id="edge229" class="edge">
<title>24251359:n&#45;&gt;33093817:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-718.23 2429.8,-575.75 2233.75,-657 2069.98,-724.87 2001.79,-738.9 1910.75,-891 1893.35,-920.06 1892.52,-1167.94 1869.75,-1193 1664.02,-1419.31 1199.75,-1044.16 1199.75,-1350"/>
</g>
<!-- 24251359&#45;&gt;33253294 -->
<g id="edge230" class="edge">
<title>24251359:n&#45;&gt;33253294:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-648.95 3387.12,-534.46 3460.75,-657 3491.45,-708.1 3453.38,-1135.48 3437.75,-1193 3409.29,-1297.73 3391.65,-1322.86 3329.75,-1412 3275.05,-1490.76 3181.75,-1473.11 3181.75,-1569"/>
</g>
<!-- 24251359&#45;&gt;33657116 -->
<g id="edge231" class="edge">
<title>24251359:n&#45;&gt;33657116:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-641.56 3373.64,-539.8 3441.75,-657 3451.82,-674.34 3456.24,-1020.78 3411.75,-1193 3393.2,-1264.8 3369.79,-1275.76 3340.75,-1344 3328.08,-1373.77 3340,-1391.77 3314.75,-1412 3133.32,-1557.29 2279.75,-1330.57 2279.75,-1563"/>
</g>
<!-- 24251359&#45;&gt;33950207 -->
<g id="edge232" class="edge">
<title>24251359:n&#45;&gt;33950207:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-662.86 3407.65,-527.22 3495.75,-657 3510.38,-678.56 3509.91,-864.96 3510.75,-891 3515.04,-1025.15 3551.47,-1065.1 3510.75,-1193 3485.79,-1271.38 3430.2,-1266.12 3403.75,-1344 3362.7,-1464.87 3477.05,-1535.15 3392.75,-1631 3258.81,-1783.27 2492.75,-1579.2 2492.75,-1782"/>
</g>
<!-- 24251359&#45;&gt;34173286 -->
<g id="edge233" class="edge">
<title>24251359:n&#45;&gt;34173286:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-651.71 3391.81,-532.64 3467.75,-657 3498.81,-707.87 3460.68,-1135.05 3446.75,-1193 3429.86,-1263.21 3404,-1273.88 3386.75,-1344 3382.92,-1359.57 3368.35,-1619.94 3356.75,-1631 3133.83,-1843.61 588.75,-1480.45 588.75,-1788.5"/>
</g>
<!-- 24251359&#45;&gt;34280330 -->
<g id="edge234" class="edge">
<title>24251359:n&#45;&gt;34280330:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-644.46 3312.61,-972.6 3329.75,-1110 3334.31,-1146.61 3334.59,-1156.43 3329.75,-1193 3326.44,-1217.98 3289.63,-1395.31 3270.75,-1412 3083.95,-1577.16 2159.75,-1319.66 2159.75,-1569"/>
</g>
<!-- 24251359&#45;&gt;34379219 -->
<g id="edge235" class="edge">
<title>24251359:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-679.5 3397.53,-553.45 3536.75,-657 3746,-812.66 3816.83,-866.31 3909.75,-1110 3930.38,-1164.12 3955.57,-1580.19 3927.75,-1631 3685.92,-2072.63 2492.75,-1924.15 2492.75,-2016"/>
</g>
<!-- 24251359&#45;&gt;34643934 -->
<g id="edge236" class="edge">
<title>24251359:n&#45;&gt;34643934:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-657.66 3397.26,-531.73 3482.75,-657 3497.46,-678.55 3501.63,-864.93 3502.75,-891 3505.61,-958.05 3522.97,-1129.01 3502.75,-1193 3478.04,-1271.19 3423.08,-1266.35 3396.75,-1344 3386.5,-1374.23 3406.31,-1607.47 3384.75,-1631 3200.64,-1831.87 2168.75,-1516.02 2168.75,-1788.5"/>
</g>
<!-- 24251359&#45;&gt;34722686 -->
<g id="edge237" class="edge">
<title>24251359:n&#45;&gt;34722686:s</title>
<path fill="none" stroke="black" d="M3176.75,-506C3176.75,-672.56 3406.68,-534.69 3519.75,-657 3546.27,-685.69 3532.07,-704.66 3548.75,-740 3597.35,-842.98 3603.24,-876.51 3681.75,-959 3764.27,-1045.7 3848.65,-1004.26 3904.75,-1110 3932.32,-1161.96 3849.11,-1586.4 3810.75,-1631 3684.59,-1777.67 3407.75,-1602.04 3407.75,-1795.5"/>
</g>
<!-- 24315724&#45;&gt;25910928 -->
<g id="edge238" class="edge">
<title>24315724:n&#45;&gt;25910928:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-360.24 831.75,-364.76 831.75,-438"/>
</g>
<!-- 24315724&#45;&gt;26199338 -->
<g id="edge239" class="edge">
<title>24315724:n&#45;&gt;26199338:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-441.85 692.12,-327.38 583.75,-438 560.5,-461.73 572.4,-479.22 552.75,-506 493.34,-586.93 384.75,-556.61 384.75,-657"/>
</g>
<!-- 24315724&#45;&gt;26848150 -->
<g id="edge240" class="edge">
<title>24315724:n&#45;&gt;26848150:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-460.5 1142.68,-308.14 1257.75,-438 1326.84,-515.97 1321.75,-559.32 1321.75,-663.5"/>
</g>
<!-- 24315724&#45;&gt;27312796 -->
<g id="edge241" class="edge">
<title>24315724:n&#45;&gt;27312796:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-311.44 2550.75,-866.56 2550.75,-891"/>
</g>
<!-- 24315724&#45;&gt;27550177 -->
<g id="edge242" class="edge">
<title>24315724:n&#45;&gt;27550177:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-375.85 801.76,-356.34 766.75,-438 685.98,-626.35 722.75,-692.06 722.75,-897"/>
</g>
<!-- 24315724&#45;&gt;27933569 -->
<g id="edge243" class="edge">
<title>24315724:n&#45;&gt;27933569:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-420.63 1091.08,-322.19 1157.75,-438 1215.51,-538.35 1168.64,-844.6 1150.75,-959 1139.5,-1030.93 1105.75,-1043.7 1105.75,-1116.5"/>
</g>
<!-- 24315724&#45;&gt;28188243 -->
<g id="edge244" class="edge">
<title>24315724:n&#45;&gt;28188243:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-463.24 2322.95,-351.93 2476.75,-438 2583.09,-497.52 2600.87,-542.19 2641.75,-657 2686.79,-783.5 2668.98,-825.96 2650.75,-959 2640.88,-1031.01 2606.75,-1043.82 2606.75,-1116.5"/>
</g>
<!-- 24315724&#45;&gt;28614582 -->
<g id="edge245" class="edge">
<title>24315724:n&#45;&gt;28614582:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-468.55 2353.41,-377.94 2524.75,-438 2608.33,-467.3 2804.58,-586.17 2857.75,-657 2899.9,-713.16 2929.6,-892.04 2950.75,-959 2972.91,-1029.16 3001.75,-1042.92 3001.75,-1116.5"/>
</g>
<!-- 24315724&#45;&gt;28860793 -->
<g id="edge246" class="edge">
<title>24315724:n&#45;&gt;28860793:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-474.57 1054.18,-475.3 1100.75,-657 1114.63,-711.16 1112.4,-881.25 1090.75,-959 1070.26,-1032.57 1027.55,-1035.98 1008.75,-1110 999.66,-1145.75 984.69,-1165.04 1008.75,-1193 1161.19,-1370.18 2048.75,-1116.27 2048.75,-1350"/>
</g>
<!-- 24315724&#45;&gt;28956288 -->
<g id="edge247" class="edge">
<title>24315724:n&#45;&gt;28956288:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-422.56 722.47,-336.39 632.75,-438 597.86,-477.5 558.64,-607.08 541.75,-657 533.12,-682.48 483.65,-864.39 479.75,-891 465.63,-987.35 474.3,-1012.63 472.75,-1110 472.16,-1146.88 450.26,-1163.76 472.75,-1193 631.97,-1400.08 1040.75,-1082.79 1040.75,-1344"/>
</g>
<!-- 24315724&#45;&gt;29360144 -->
<g id="edge248" class="edge">
<title>24315724:n&#45;&gt;29360144:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-401.6 751.46,-342.09 688.75,-438 642.33,-508.98 521.98,-1128.25 576.75,-1193 707.28,-1347.34 1473.75,-1141.86 1473.75,-1344"/>
</g>
<!-- 24315724&#45;&gt;29371284 -->
<g id="edge249" class="edge">
<title>24315724:n&#45;&gt;29371284:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-373.56 803.76,-356.45 774.75,-438 697.09,-656.29 870.4,-740.71 792.75,-959 753.37,-1069.7 592.38,-1104.57 669.75,-1193 835.98,-1383.01 1795.75,-1091.54 1795.75,-1344"/>
</g>
<!-- 24315724&#45;&gt;29525786 -->
<g id="edge250" class="edge">
<title>24315724:n&#45;&gt;29525786:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-419.82 879.73,-914.45 868.75,-959 850.24,-1034.09 794.75,-1039.16 794.75,-1116.5"/>
</g>
<!-- 24315724&#45;&gt;29654196 -->
<g id="edge251" class="edge">
<title>24315724:n&#45;&gt;29654196:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-383.49 787.82,-353.22 741.75,-438 660.61,-587.29 509.84,-1064.26 620.75,-1193 774.59,-1371.58 1669.75,-1114.29 1669.75,-1350"/>
</g>
<!-- 24315724&#45;&gt;29909576 -->
<g id="edge252" class="edge">
<title>24315724:n&#45;&gt;29909576:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-370.03 964.91,-366.87 1007.75,-438 1063.63,-530.8 1090.34,-551.46 1114.75,-657 1126.84,-709.29 1129.15,-876.67 1107.75,-959 1088.74,-1032.11 1047.58,-1036.6 1029.75,-1110 1021.04,-1145.85 1005.03,-1165.62 1029.75,-1193 1250.24,-1437.25 2502.75,-1014.95 2502.75,-1344"/>
</g>
<!-- 24315724&#45;&gt;29973392 -->
<g id="edge253" class="edge">
<title>24315724:n&#45;&gt;29973392:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-411.52 737.82,-339.42 661.75,-438 642.34,-463.15 650.68,-476.17 639.75,-506 614.78,-574.12 594.06,-586.31 577.75,-657 532.42,-853.41 558.97,-908.46 555.75,-1110 555.16,-1146.88 532.23,-1164.58 555.75,-1193 784.18,-1469.09 1347.75,-985.66 1347.75,-1344"/>
</g>
<!-- 24315724&#45;&gt;30299591 -->
<g id="edge254" class="edge">
<title>24315724:n&#45;&gt;30299591:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-435.48 1111.66,-315.63 1195.75,-438 1233.95,-493.6 1189.25,-683.91 1226.75,-740 1305.32,-857.54 1434.28,-769.59 1506.75,-891 1541.15,-948.64 1455.45,-1143.46 1500.75,-1193 1754.13,-1470.13 3183.75,-968.5 3183.75,-1344"/>
</g>
<!-- 24315724&#45;&gt;30383768 -->
<g id="edge255" class="edge">
<title>24315724:n&#45;&gt;30383768:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-449.51 1137.36,-305.01 1230.75,-438 1269.43,-493.1 1216.68,-684.47 1254.75,-740 1342.3,-867.73 1485.74,-760.27 1568.75,-891 1622.47,-975.61 1570.75,-1016.27 1570.75,-1116.5"/>
</g>
<!-- 24315724&#45;&gt;30423205 -->
<g id="edge256" class="edge">
<title>24315724:n&#45;&gt;30423205:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-477.44 656.19,-333.87 496.75,-438 382.81,-512.41 343.3,-535.13 282.75,-657 193.16,-837.3 281.75,-1361.67 281.75,-1563"/>
</g>
<!-- 24315724&#45;&gt;30571400 -->
<g id="edge257" class="edge">
<title>24315724:n&#45;&gt;30571400:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-383.81 1003.05,-356.15 1054.75,-438 1109.53,-524.75 1111.31,-555.73 1127.75,-657 1136.92,-713.53 1139.45,-888.04 1122.75,-959 1105.75,-1031.19 1067.91,-1037.62 1051.75,-1110 1047.73,-1128 1039.2,-1179.48 1051.75,-1193 1203.52,-1356.64 3054.75,-1120.81 3054.75,-1344"/>
</g>
<!-- 24315724&#45;&gt;30924051 -->
<g id="edge258" class="edge">
<title>24315724:n&#45;&gt;30924051:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-376.73 984.25,-361.88 1031.75,-438 1087.45,-527.28 1101.36,-553.76 1121.75,-657 1132.34,-710.62 1134.69,-880.3 1115.75,-959 1098.35,-1031.29 1060.15,-1037.48 1043.75,-1110 1035.61,-1145.98 1018.72,-1165.9 1043.75,-1193 1187.05,-1348.18 2938.75,-1132.78 2938.75,-1344"/>
</g>
<!-- 24315724&#45;&gt;31022899 -->
<g id="edge259" class="edge">
<title>24315724:n&#45;&gt;31022899:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-364.23 945.61,-370.84 983.75,-438 1038.98,-535.26 1079.25,-548.84 1107.75,-657 1121.23,-708.18 1123.33,-873.63 1099.75,-959 1079.35,-1032.82 1035.79,-1035.82 1016.75,-1110 1012.16,-1127.87 1004.61,-1179.11 1016.75,-1193 1187.44,-1388.42 2173.75,-1090.53 2173.75,-1350"/>
</g>
<!-- 24315724&#45;&gt;31112292 -->
<g id="edge260" class="edge">
<title>24315724:n&#45;&gt;31112292:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-435.87 696.98,-326.14 598.75,-438 590.24,-447.69 525.21,-644.58 521.75,-657 467.15,-852.56 467.38,-907.02 462.75,-1110 461.9,-1146.88 441.35,-1162.95 462.75,-1193 581.68,-1360.06 728.89,-1229.09 898.75,-1344 931.89,-1366.42 922.02,-1393.97 957.75,-1412 1148.69,-1508.36 2876.75,-1349.12 2876.75,-1563"/>
</g>
<!-- 24315724&#45;&gt;31390972 -->
<g id="edge261" class="edge">
<title>24315724:n&#45;&gt;31390972:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-425.66 1092.61,-323.45 1170.75,-438 1208.89,-493.93 1185.87,-677.04 1210.75,-740 1241.07,-816.74 1293.54,-812.43 1318.75,-891 1327.98,-919.78 1325.25,-929.49 1318.75,-959 1295.37,-1065.01 1190.85,-1101.17 1248.75,-1193 1331.76,-1324.67 1444.82,-1244.77 1564.75,-1344 1593.65,-1367.92 1588.53,-1385.17 1614.75,-1412 1726.16,-1525.99 1752.99,-1566.49 1898.75,-1631 2073.58,-1708.38 2745.75,-1590.81 2745.75,-1782"/>
</g>
<!-- 24315724&#45;&gt;32341789 -->
<g id="edge262" class="edge">
<title>24315724:n&#45;&gt;32341789:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-439.45 1117.76,-313.49 1205.75,-438 1244.74,-493.17 1203.13,-683.88 1240.75,-740 1317.94,-855.18 1443.32,-771.56 1513.75,-891 1530.79,-919.91 1484.99,-1168.34 1507.75,-1193 1655.39,-1352.99 3460.75,-1132.3 3460.75,-1350"/>
</g>
<!-- 24315724&#45;&gt;32415705 -->
<g id="edge263" class="edge">
<title>24315724:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-468.32 639.02,-302.31 518.75,-438 498.01,-461.4 517.17,-479.4 500.75,-506 447.48,-592.27 371.43,-564.58 329.75,-657 314.81,-690.12 251.76,-1083.53 361.75,-1412 387.54,-1489.03 464.75,-1481.76 464.75,-1563"/>
</g>
<!-- 24315724&#45;&gt;32539675 -->
<g id="edge264" class="edge">
<title>24315724:n&#45;&gt;32539675:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-689.71 883.18,-791.24 910.75,-1193 917.46,-1290.84 869.2,-1341.86 937.75,-1412 1105.71,-1583.88 2007.75,-1328.68 2007.75,-1569"/>
</g>
<!-- 24315724&#45;&gt;32676543 -->
<g id="edge265" class="edge">
<title>24315724:n&#45;&gt;32676543:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-518.71 583.72,-298.45 398.75,-438 306.33,-507.72 293.94,-547.04 257.75,-657 223.87,-759.9 144.97,-1547.3 213.75,-1631 442.98,-1909.97 1010.75,-1427.43 1010.75,-1788.5"/>
</g>
<!-- 24315724&#45;&gt;33093817 -->
<g id="edge266" class="edge">
<title>24315724:n&#45;&gt;33093817:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-414.53 735.07,-339.76 653.75,-438 619.54,-479.32 495.84,-838.13 486.75,-891 481.62,-920.78 484.57,-928.86 486.75,-959 494.32,-1063.82 449.58,-1115.67 520.75,-1193 730.5,-1420.91 1199.75,-1040.26 1199.75,-1350"/>
</g>
<!-- 24315724&#45;&gt;33253294 -->
<g id="edge267" class="edge">
<title>24315724:n&#45;&gt;33253294:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-488.48 907.61,-992.98 931.75,-1193 937.7,-1242.33 939.38,-1379.25 976.75,-1412 1161.47,-1573.89 3181.75,-1323.38 3181.75,-1569"/>
</g>
<!-- 24315724&#45;&gt;33587284 -->
<g id="edge268" class="edge">
<title>24315724:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-452.75 681.67,-329.06 556.75,-438 529.97,-461.35 538.06,-479.2 514.75,-506 445.78,-585.31 377.43,-561.87 332.75,-657 314.85,-695.09 366.1,-1381.17 394.75,-1412 633.07,-1668.51 1166.75,-1218.87 1166.75,-1569"/>
</g>
<!-- 24315724&#45;&gt;33950207 -->
<g id="edge269" class="edge">
<title>24315724:n&#45;&gt;33950207:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-474.12 656.08,-327.95 504.75,-438 473.31,-460.86 474.93,-476.39 449.75,-506 391.42,-574.57 349.71,-574.05 314.75,-657 274.26,-753.06 302.3,-786.82 298.75,-891 297.72,-921.2 298.42,-928.78 298.75,-959 299.86,-1063.02 293.6,-1089.47 303.75,-1193 306.16,-1217.59 362.4,-1614.45 380.75,-1631 555.42,-1788.6 2492.75,-1546.73 2492.75,-1782"/>
</g>
<!-- 24315724&#45;&gt;34173286 -->
<g id="edge270" class="edge">
<title>24315724:n&#45;&gt;34173286:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-549.5 522.44,-263.03 326.75,-438 248.91,-507.59 266.82,-555.65 241.75,-657 215.68,-762.33 109.01,-1541.76 170.75,-1631 283.7,-1794.26 588.75,-1589.97 588.75,-1788.5"/>
</g>
<!-- 24315724&#45;&gt;34379219 -->
<g id="edge271" class="edge">
<title>24315724:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M897.75,-287C897.75,-518.71 583.72,-298.45 398.75,-438 306.33,-507.72 301.24,-549.72 257.75,-657 206.99,-782.21 26.29,-1766.48 118.75,-1865 299.61,-2057.74 2492.75,-1751.69 2492.75,-2016"/>
</g>
<!-- 25359164&#45;&gt;25862791 -->
<g id="edge272" class="edge">
<title>25359164:n&#45;&gt;25862791:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-458.46 784.98,-323.66 912.75,-438 998.46,-514.71 1039.75,-548.48 1039.75,-663.5"/>
</g>
<!-- 25359164&#45;&gt;25910928 -->
<g id="edge273" class="edge">
<title>25359164:n&#45;&gt;25910928:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-426.05 831.75,-298.95 831.75,-438"/>
</g>
<!-- 25359164&#45;&gt;26848150 -->
<g id="edge274" class="edge">
<title>25359164:n&#45;&gt;26848150:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-596.58 1011.57,-226.61 1237.75,-438 1260.76,-459.51 1247.36,-476.26 1257.75,-506 1282.66,-577.33 1321.75,-587.94 1321.75,-663.5"/>
</g>
<!-- 25359164&#45;&gt;27412905 -->
<g id="edge275" class="edge">
<title>25359164:n&#45;&gt;27412905:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-575.36 989.16,-229.87 1188.75,-438 1212.41,-462.68 1223.67,-715.72 1247.75,-740 1484.1,-978.34 1987.75,-555.33 1987.75,-891"/>
</g>
<!-- 25359164&#45;&gt;27550177 -->
<g id="edge276" class="edge">
<title>25359164:n&#45;&gt;27550177:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-360.06 601.96,-367.95 622.75,-438 661.5,-568.57 643.22,-607.5 674.75,-740 691.64,-810.98 722.75,-824.03 722.75,-897"/>
</g>
<!-- 25359164&#45;&gt;27680880 -->
<g id="edge277" class="edge">
<title>25359164:n&#45;&gt;27680880:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-580.12 996.13,-227.15 1199.75,-438 1211.63,-450.3 1247.61,-727.94 1259.75,-740 1512.07,-990.74 1762.23,-676.15 2045.75,-891 2072.68,-911.41 2057.24,-933.79 2079.75,-959 2165.2,-1054.73 2321.75,-988.17 2321.75,-1116.5"/>
</g>
<!-- 25359164&#45;&gt;27889397 -->
<g id="edge278" class="edge">
<title>25359164:n&#45;&gt;27889397:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-531.93 909.73,-269.77 1087.75,-438 1162.63,-508.77 1135.32,-557.97 1163.75,-657 1174.19,-693.37 1160.25,-709.57 1182.75,-740 1262.63,-848.08 1444.75,-756.6 1444.75,-891"/>
</g>
<!-- 25359164&#45;&gt;27933569 -->
<g id="edge279" class="edge">
<title>25359164:n&#45;&gt;27933569:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-358.27 597.69,-368.13 611.75,-438 623.18,-494.83 604.7,-912.82 639.75,-959 771.93,-1133.14 1105.75,-897.88 1105.75,-1116.5"/>
</g>
<!-- 25359164&#45;&gt;28408716 -->
<g id="edge280" class="edge">
<title>25359164:n&#45;&gt;28408716:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-553.37 946.13,-252.97 1137.75,-438 1238.5,-535.29 1136.74,-633.54 1227.75,-740 1328.89,-858.31 1413.02,-806.5 1543.75,-891 1670.35,-972.83 1802.75,-959.25 1802.75,-1110"/>
</g>
<!-- 25359164&#45;&gt;28860793 -->
<g id="edge281" class="edge">
<title>25359164:n&#45;&gt;28860793:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-354.89 539.87,-370.31 534.75,-438 517.26,-668.89 492.95,-731.43 535.75,-959 546.04,-1013.75 581.62,-1158.98 625.75,-1193 877.71,-1387.24 2048.75,-1031.86 2048.75,-1350"/>
</g>
<!-- 25359164&#45;&gt;28956288 -->
<g id="edge282" class="edge">
<title>25359164:n&#45;&gt;28956288:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-363.37 496.01,-364.37 475.75,-438 464.61,-478.45 432.07,-1159.82 457.75,-1193 621.57,-1404.67 1040.75,-1076.34 1040.75,-1344"/>
</g>
<!-- 25359164&#45;&gt;29171208 -->
<g id="edge283" class="edge">
<title>25359164:n&#45;&gt;29171208:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-436.36 535.89,-813.53 569.75,-959 576.22,-986.8 652.53,-1176.39 675.75,-1193 970.41,-1403.81 2297.75,-995.7 2297.75,-1358"/>
</g>
<!-- 25359164&#45;&gt;29371284 -->
<g id="edge284" class="edge">
<title>25359164:n&#45;&gt;29371284:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-355.6 535.69,-370.12 525.75,-438 492.19,-667.11 483.82,-731.65 527.75,-959 548.34,-1065.58 514.91,-1122.84 597.75,-1193 802.5,-1366.43 1795.75,-1075.67 1795.75,-1344"/>
</g>
<!-- 25359164&#45;&gt;29525786 -->
<g id="edge285" class="edge">
<title>25359164:n&#45;&gt;29525786:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-357.69 595.29,-368.41 607.75,-438 617.95,-495.02 601.73,-906.29 625.75,-959 668.32,-1052.43 794.75,-1013.83 794.75,-1116.5"/>
</g>
<!-- 25359164&#45;&gt;29909576 -->
<g id="edge286" class="edge">
<title>25359164:n&#45;&gt;29909576:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-361.7 559.03,-886.68 577.75,-959 596.67,-1032.13 622.35,-1042.25 655.75,-1110 673.77,-1146.56 661.28,-1169.74 694.75,-1193 860.27,-1308.06 2502.75,-1142.41 2502.75,-1344"/>
</g>
<!-- 25359164&#45;&gt;29973392 -->
<g id="edge287" class="edge">
<title>25359164:n&#45;&gt;29973392:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-356.43 529.52,-369.58 517.75,-438 489.26,-603.46 432.17,-1069.35 545.75,-1193 791.1,-1460.13 1347.75,-981.29 1347.75,-1344"/>
</g>
<!-- 25359164&#45;&gt;30383768 -->
<g id="edge288" class="edge">
<title>25359164:n&#45;&gt;30383768:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-543.06 931.72,-257.91 1113.75,-438 1185.66,-509.15 1152.95,-558.44 1175.75,-657 1184.2,-693.52 1167.74,-710.4 1190.75,-740 1289.99,-867.66 1420.28,-765.11 1521.75,-891 1586.11,-970.85 1570.75,-1013.94 1570.75,-1116.5"/>
</g>
<!-- 25359164&#45;&gt;30423205 -->
<g id="edge289" class="edge">
<title>25359164:n&#45;&gt;30423205:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-442.66 328.63,-308.85 241.75,-438 228.14,-458.23 229.49,-632.64 228.75,-657 218.56,-992.4 170.41,-1081.38 227.75,-1412 239.93,-1482.23 281.75,-1491.73 281.75,-1563"/>
</g>
<!-- 25359164&#45;&gt;30571400 -->
<g id="edge290" class="edge">
<title>25359164:n&#45;&gt;30571400:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-324.48 605.58,-923.23 616.75,-959 639.77,-1032.72 670.77,-1039.7 702.75,-1110 718.93,-1145.57 700.63,-1169.36 731.75,-1193 937.69,-1349.49 3054.75,-1085.34 3054.75,-1344"/>
</g>
<!-- 25359164&#45;&gt;30924051 -->
<g id="edge291" class="edge">
<title>25359164:n&#45;&gt;30924051:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-305.68 579.3,-941.13 584.75,-959 607.74,-1034.39 637.97,-1041.96 677.75,-1110 699.03,-1146.41 688.16,-1170.37 723.75,-1193 931.91,-1325.37 2938.75,-1097.32 2938.75,-1344"/>
</g>
<!-- 25359164&#45;&gt;31022899 -->
<g id="edge292" class="edge">
<title>25359164:n&#45;&gt;31022899:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-585.67 492.24,-667.16 555.75,-959 561.74,-986.54 631.11,-1176.2 653.75,-1193 926.41,-1395.4 2173.75,-1010.43 2173.75,-1350"/>
</g>
<!-- 25359164&#45;&gt;31112292 -->
<g id="edge293" class="edge">
<title>25359164:n&#45;&gt;31112292:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-368.24 497.8,-369.11 454.75,-438 395.34,-533.03 358.49,-548.68 329.75,-657 318.74,-698.47 357.05,-1148.9 394.75,-1193 542.8,-1366.23 726.88,-1179.66 884.75,-1344 906.4,-1366.55 878.72,-1392 902.75,-1412 1071.81,-1552.73 2876.75,-1343.03 2876.75,-1563"/>
</g>
<!-- 25359164&#45;&gt;32415705 -->
<g id="edge294" class="edge">
<title>25359164:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-434.68 342.73,-314.5 261.75,-438 206.44,-522.34 236.86,-790.19 233.75,-891 226.51,-1125.43 209.92,-1203.71 317.75,-1412 360.8,-1495.18 464.75,-1469.34 464.75,-1563"/>
</g>
<!-- 25359164&#45;&gt;33093817 -->
<g id="edge295" class="edge">
<title>25359164:n&#45;&gt;33093817:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-360.6 507.1,-366.47 489.75,-438 469.97,-519.53 426.07,-1129.37 480.75,-1193 693.93,-1441.07 1199.75,-1022.91 1199.75,-1350"/>
</g>
<!-- 25359164&#45;&gt;33253294 -->
<g id="edge296" class="edge">
<title>25359164:n&#45;&gt;33253294:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-364.68 492.22,-363.65 469.75,-438 457.61,-478.17 425.29,-1158.9 449.75,-1193 571.71,-1363.06 725.13,-1222.81 895.75,-1344 926.99,-1366.19 914.93,-1393.98 948.75,-1412 1168.27,-1528.94 3181.75,-1320.28 3181.75,-1569"/>
</g>
<!-- 25359164&#45;&gt;33587284 -->
<g id="edge297" class="edge">
<title>25359164:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-429.17 350.67,-317.17 275.75,-438 245.23,-487.22 256.61,-901.32 261.75,-959 271.12,-1064.25 277.22,-1090.72 303.75,-1193 329.58,-1292.59 301.31,-1344.26 378.75,-1412 647.51,-1647.14 1166.75,-1211.89 1166.75,-1569"/>
</g>
<!-- 25359164&#45;&gt;33657116 -->
<g id="edge298" class="edge">
<title>25359164:n&#45;&gt;33657116:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-417.95 369.4,-324.12 304.75,-438 263.16,-511.26 318.51,-1129.4 373.75,-1193 526.8,-1369.22 721.63,-1169.59 876.75,-1344 897.14,-1366.93 866.34,-1391.03 888.75,-1412 1115.8,-1624.42 2279.75,-1252.07 2279.75,-1563"/>
</g>
<!-- 25359164&#45;&gt;34173286 -->
<g id="edge299" class="edge">
<title>25359164:n&#45;&gt;34173286:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-448.7 325.32,-309.83 226.75,-438 164.5,-518.94 158.33,-789.25 149.75,-891 138.46,-1024.75 149.44,-1058.78 149.75,-1193 149.97,-1290.33 147.86,-1314.71 150.75,-1412 153.64,-1509.44 104.87,-1552.56 162.75,-1631 282.6,-1793.43 588.75,-1586.64 588.75,-1788.5"/>
</g>
<!-- 25359164&#45;&gt;34280330 -->
<g id="edge300" class="edge">
<title>25359164:n&#45;&gt;34280330:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-421.01 364.6,-322.43 296.75,-438 254.24,-510.41 272.64,-1130.54 328.75,-1193 495.57,-1378.71 702.04,-1159.09 869.75,-1344 890.36,-1366.73 859.48,-1390.88 881.75,-1412 1089.31,-1608.95 2159.75,-1282.87 2159.75,-1569"/>
</g>
<!-- 25359164&#45;&gt;34379219 -->
<g id="edge301" class="edge">
<title>25359164:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-459.69 307.51,-303.07 199.75,-438 150.14,-500.11 41.34,-1807.05 95.75,-1865 278.42,-2059.54 2492.75,-1749.14 2492.75,-2016"/>
</g>
<!-- 25359164&#45;&gt;34643934 -->
<g id="edge302" class="edge">
<title>25359164:n&#45;&gt;34643934:s</title>
<path fill="none" stroke="black" d="M557.75,-287C557.75,-445.47 325.34,-307.98 234.75,-438 205.87,-479.44 198.86,-840.53 196.75,-891 195.48,-921.2 196.49,-928.78 196.75,-959 197.64,-1063.01 197.84,-1089.03 200.75,-1193 203.47,-1290.37 150.32,-1560.7 217.75,-1631 368.29,-1787.96 2168.75,-1571.02 2168.75,-1788.5"/>
</g>
<!-- 25365537&#45;&gt;25862791 -->
<g id="edge303" class="edge">
<title>25365537:n&#45;&gt;25862791:s</title>
<path fill="none" stroke="black" d="M434.75,-281C434.75,-495.34 736.66,-289.01 890.75,-438 914.01,-460.49 900.84,-477.83 916.75,-506 960.42,-583.34 1039.75,-574.68 1039.75,-663.5"/>
</g>
<!-- 25365537&#45;&gt;25910928 -->
<g id="edge304" class="edge">
<title>25365537:n&#45;&gt;25910928:s</title>
<path fill="none" stroke="black" d="M434.75,-281C434.75,-470.74 831.75,-248.26 831.75,-438"/>
</g>
<!-- 25365537&#45;&gt;26199338 -->
<g id="edge305" class="edge">
<title>25365537:n&#45;&gt;26199338:s</title>
<path fill="none" stroke="black" d="M434.75,-281C434.75,-449.58 384.75,-488.42 384.75,-657"/>
</g>
<!-- 25365537&#45;&gt;26848150 -->
<g id="edge306" class="edge">
<title>25365537:n&#45;&gt;26848150:s</title>
<path fill="none" stroke="black" d="M434.75,-281C434.75,-594.64 853.1,-277.81 1122.75,-438 1180.21,-472.13 1321.75,-596.67 1321.75,-663.5"/>
</g>
<!-- 25365537&#45;&gt;27412905 -->
<g id="edge307" class="edge">
<title>25365537:n&#45;&gt;27412905:s</title>
<path fill="none" stroke="black" d="M434.75,-281C434.75,-524.12 753.69,-307.4 958.75,-438 959.34,-438.38 1227.14,-739.65 1227.75,-740 1377.21,-825.5 1987.75,-718.81 1987.75,-891"/>
</g>
<!-- 25365537&#45;&gt;27889397 -->
<g id="edge308" class="edge">
<title>25365537:n&#45;&gt;27889397:s</title>
<path fill="none" stroke="black" d="M434.75,-281C434.75,-501.66 716.89,-323.89 905.75,-438 1026.01,-510.66 1054.14,-541.22 1133.75,-657 1156.43,-689.99 1141.91,-710.29 1168.75,-740 1262.47,-843.76 1444.75,-751.18 1444.75,-891"/>
</g>
<!-- 25365537&#45;&gt;27933569 -->
<g id="edge309" class="edge">
<title>25365537:n&#45;&gt;27933569:s</title>
<path fill="none" stroke="black" d="M434.75,-281C434.75,-320.03 591.6,-930.95 618.75,-959 776.95,-1122.46 1105.75,-889.02 1105.75,-1116.5"/>
</g>
<!-- 25365537&#45;&gt;28860793 -->
<g id="edge310" class="edge">
<title>25365537:n&#45;&gt;28860793:s</title>
<path fill="none" stroke="black" d="M434.75,-281C434.75,-432.22 458.17,-811.79 492.75,-959 518.08,-1066.87 491.38,-1124.85 578.75,-1193 837.77,-1395.07 2048.75,-1021.48 2048.75,-1350"/>
</g>
<!-- 25365537&#45;&gt;28956288 -->
<g id="edge311" class="edge">
<title>25365537:n&#45;&gt;28956288:s</title>
<path fill="none" stroke="black" d="M434.75,-281C434.75,-371.88 334.71,-352.56 303.75,-438 274.76,-517.98 371.3,-1132.15 430.75,-1193 625.92,-1392.78 1040.75,-1064.71 1040.75,-1344"/>
</g>
<!-- 25365537&#45;&gt;29525786 -->
<g id="edge312" class="edge">
<title>25365537:n&#45;&gt;29525786:s</title>
<path fill="none" stroke="black" d="M434.75,-281C434.75,-358.48 553.81,-895.18 597.75,-959 661.31,-1051.34 794.75,-1004.4 794.75,-1116.5"/>
</g>
<!-- 25365537&#45;&gt;29973392 -->
<g id="edge313" class="edge">
<title>25365537:n&#45;&gt;29973392:s</title>
<path fill="none" stroke="black" d="M434.75,-281C434.75,-356.35 441.34,-884.24 450.75,-959 464.07,-1064.9 427.43,-1119.42 504.75,-1193 780.48,-1455.4 1347.75,-963.37 1347.75,-1344"/>
</g>
<!-- 25365537&#45;&gt;30383768 -->
<g id="edge314" class="edge">
<title>25365537:n&#45;&gt;30383768:s</title>
<path fill="none" stroke="black" d="M434.75,-281C434.75,-290.84 632.37,-952.5 639.75,-959 797.17,-1097.73 1570.75,-906.67 1570.75,-1116.5"/>
</g>
<!-- 25365537&#45;&gt;30423205 -->
<g id="edge315" class="edge">
<title>25365537:n&#45;&gt;30423205:s</title>
<path fill="none" stroke="black" d="M434.75,-281C434.75,-409.58 254.1,-325.55 191.75,-438 139.24,-532.68 194.71,-1306.67 219.75,-1412 236.52,-1482.58 281.75,-1490.45 281.75,-1563"/>
</g>
<!-- 25365537&#45;&gt;31022899 -->
<g id="edge316" class="edge">
<title>25365537:n&#45;&gt;31022899:s</title>
<path fill="none" stroke="black" d="M434.75,-281C434.75,-384.25 535.38,-1124.63 612.75,-1193 874,-1423.86 2173.75,-1001.36 2173.75,-1350"/>
</g>
<!-- 25365537&#45;&gt;32415705 -->
<g id="edge317" class="edge">
<title>25365537:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M434.75,-281C434.75,-399.32 278.08,-335.06 219.75,-438 153.43,-555.03 197.6,-605.5 199.75,-740 202.14,-889.83 180.45,-1282.44 255.75,-1412 313.33,-1511.08 464.75,-1448.4 464.75,-1563"/>
</g>
<!-- 25365537&#45;&gt;32676543 -->
<g id="edge318" class="edge">
<title>25365537:n&#45;&gt;32676543:s</title>
<path fill="none" stroke="black" d="M434.75,-281C434.75,-417.13 246.34,-324.12 171.75,-438 99.1,-548.9 99.63,-1537.62 193.75,-1631 456.25,-1891.46 1010.75,-1418.7 1010.75,-1788.5"/>
</g>
<!-- 25365537&#45;&gt;34280330 -->
<g id="edge319" class="edge">
<title>25365537:n&#45;&gt;34280330:s</title>
<path fill="none" stroke="black" d="M434.75,-281C434.75,-373.32 332.81,-352.2 298.75,-438 236.84,-593.94 194.46,-1064.84 302.75,-1193 467.74,-1388.26 678.86,-1161.38 857.75,-1344 879.55,-1366.25 851.4,-1391.37 874.75,-1412 1090.32,-1602.49 2159.75,-1281.32 2159.75,-1569"/>
</g>
<!-- 25365537&#45;&gt;34379219 -->
<g id="edge320" class="edge">
<title>25365537:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M434.75,-281C434.75,-424.84 231.65,-318.4 151.75,-438 107.66,-504 28.41,-1807.15 82.75,-1865 266.44,-2060.56 2492.75,-1747.7 2492.75,-2016"/>
</g>
<!-- 25365537&#45;&gt;34722686 -->
<g id="edge321" class="edge">
<title>25365537:n&#45;&gt;34722686:s</title>
<path fill="none" stroke="black" d="M434.75,-281C434.75,-414.47 246.06,-322.75 178.75,-438 145.3,-495.27 171.22,-1585.8 219.75,-1631 479.31,-1872.73 3407.75,-1440.81 3407.75,-1795.5"/>
</g>
<!-- 25587093&#45;&gt;27412905 -->
<g id="edge322" class="edge">
<title>25587093:n&#45;&gt;27412905:s</title>
<path fill="none" stroke="black" d="M3385.75,-733.5C3385.75,-1046.13 1987.75,-578.37 1987.75,-891"/>
</g>
<!-- 25587093&#45;&gt;28300870 -->
<g id="edge323" class="edge">
<title>25587093:n&#45;&gt;28300870:s</title>
<path fill="none" stroke="black" d="M3385.75,-733.5C3385.75,-823.24 3257.75,-1026.76 3257.75,-1116.5"/>
</g>
<!-- 25587093&#45;&gt;29373602 -->
<g id="edge324" class="edge">
<title>25587093:n&#45;&gt;29373602:s</title>
<path fill="none" stroke="black" d="M3385.75,-733.5C3385.75,-784.86 3370.04,-1154.77 3335.75,-1193 3127.26,-1425.37 2649.75,-1031.81 2649.75,-1344"/>
</g>
<!-- 25587093&#45;&gt;30571400 -->
<g id="edge325" class="edge">
<title>25587093:n&#45;&gt;30571400:s</title>
<path fill="none" stroke="black" d="M3385.75,-733.5C3385.75,-835.62 3447.26,-1107.29 3391.75,-1193 3302.52,-1330.75 3054.75,-1179.87 3054.75,-1344"/>
</g>
<!-- 25587093&#45;&gt;30924051 -->
<g id="edge326" class="edge">
<title>25587093:n&#45;&gt;30924051:s</title>
<path fill="none" stroke="black" d="M3385.75,-733.5C3385.75,-835.73 3424.68,-1110.92 3363.75,-1193 3244.26,-1353.95 2938.75,-1143.54 2938.75,-1344"/>
</g>
<!-- 25587093&#45;&gt;31112292 -->
<g id="edge327" class="edge">
<title>25587093:n&#45;&gt;31112292:s</title>
<path fill="none" stroke="black" d="M3385.75,-733.5C3385.75,-805.72 3416.62,-819.36 3425.75,-891 3442.7,-1024.15 3461.17,-1063.27 3426.75,-1193 3412.38,-1247.16 3344.72,-1376.04 3301.75,-1412 3148.01,-1540.64 2876.75,-1362.54 2876.75,-1563"/>
</g>
<!-- 25587093&#45;&gt;31195999 -->
<g id="edge328" class="edge">
<title>25587093:n&#45;&gt;31195999:s</title>
<path fill="none" stroke="black" d="M3385.75,-733.5C3385.75,-807.65 3419.02,-820.11 3440.75,-891 3481.44,-1023.75 3476.5,-1061.39 3520.75,-1193 3543.86,-1261.77 3582.75,-1271.45 3582.75,-1344"/>
</g>
<!-- 25587093&#45;&gt;33657116 -->
<g id="edge329" class="edge">
<title>25587093:n&#45;&gt;33657116:s</title>
<path fill="none" stroke="black" d="M3385.75,-733.5C3385.75,-804.12 3402.07,-820.54 3406.75,-891 3411.9,-968.57 3419.54,-1132.24 3404.75,-1193 3401.52,-1206.25 3304.81,-1404.02 3293.75,-1412 3108.96,-1545.25 2279.75,-1335.18 2279.75,-1563"/>
</g>
<!-- 25587093&#45;&gt;34398204 -->
<g id="edge330" class="edge">
<title>25587093:n&#45;&gt;34398204:s</title>
<path fill="none" stroke="black" d="M3385.75,-733.5C3385.75,-806.55 3421.04,-818.89 3432.75,-891 3454.27,-1023.52 3466.85,-1061.51 3439.75,-1193 3425,-1264.56 3400.49,-1275.62 3374.75,-1344 3365.74,-1367.94 3303.75,-1537.42 3303.75,-1563"/>
</g>
<!-- 25862791&#45;&gt;27412905 -->
<g id="edge331" class="edge">
<title>25862791:n&#45;&gt;27412905:s</title>
<path fill="none" stroke="black" d="M1039.75,-733.5C1039.75,-1160.61 1987.75,-463.89 1987.75,-891"/>
</g>
<!-- 25862791&#45;&gt;27550177 -->
<g id="edge332" class="edge">
<title>25862791:n&#45;&gt;27550177:s</title>
<path fill="none" stroke="black" d="M1039.75,-733.5C1039.75,-892.02 722.75,-738.48 722.75,-897"/>
</g>
<!-- 25862791&#45;&gt;27889397 -->
<g id="edge333" class="edge">
<title>25862791:n&#45;&gt;27889397:s</title>
<path fill="none" stroke="black" d="M1039.75,-733.5C1039.75,-926.63 1444.75,-697.87 1444.75,-891"/>
</g>
<!-- 25862791&#45;&gt;27933569 -->
<g id="edge334" class="edge">
<title>25862791:n&#45;&gt;27933569:s</title>
<path fill="none" stroke="black" d="M1039.75,-733.5C1039.75,-808.73 1087.07,-817.22 1101.75,-891 1121.3,-989.31 1105.75,-1016.26 1105.75,-1116.5"/>
</g>
<!-- 25862791&#45;&gt;28408716 -->
<g id="edge335" class="edge">
<title>25862791:n&#45;&gt;28408716:s</title>
<path fill="none" stroke="black" d="M1039.75,-733.5C1039.75,-880.95 1220.48,-794.25 1331.75,-891 1360.05,-915.61 1351.67,-936.58 1381.75,-959 1541.12,-1077.8 1802.75,-911.22 1802.75,-1110"/>
</g>
<!-- 25862791&#45;&gt;28956288 -->
<g id="edge336" class="edge">
<title>25862791:n&#45;&gt;28956288:s</title>
<path fill="none" stroke="black" d="M1039.75,-733.5C1039.75,-809.92 990.3,-817.12 970.75,-891 936.3,-1021.13 911.06,-1063.48 947.75,-1193 969.23,-1268.84 1040.75,-1265.18 1040.75,-1344"/>
</g>
<!-- 25862791&#45;&gt;29371284 -->
<g id="edge337" class="edge">
<title>25862791:n&#45;&gt;29371284:s</title>
<path fill="none" stroke="black" d="M1039.75,-733.5C1039.75,-835.7 1111.64,-860.4 1084.75,-959 1064.25,-1034.16 1016.25,-1034.84 995.75,-1110 986.04,-1145.59 972.21,-1164.6 995.75,-1193 1226.66,-1471.57 1795.75,-982.17 1795.75,-1344"/>
</g>
<!-- 25862791&#45;&gt;29973392 -->
<g id="edge338" class="edge">
<title>25862791:n&#45;&gt;29973392:s</title>
<path fill="none" stroke="black" d="M1039.75,-733.5C1039.75,-835.21 1105.99,-861.01 1078.75,-959 1048.86,-1066.51 925.96,-1100.08 987.75,-1193 1083.82,-1337.48 1347.75,-1170.5 1347.75,-1344"/>
</g>
<!-- 25862791&#45;&gt;31022899 -->
<g id="edge339" class="edge">
<title>25862791:n&#45;&gt;31022899:s</title>
<path fill="none" stroke="black" d="M1039.75,-733.5C1039.75,-807.08 1079.27,-818.32 1090.75,-891 1095.46,-920.85 1098.11,-929.69 1090.75,-959 1072.19,-1032.86 1028.31,-1036.14 1009.75,-1110 1000.76,-1145.78 985.47,-1165.23 1009.75,-1193 1181.53,-1389.51 2173.75,-1088.99 2173.75,-1350"/>
</g>
<!-- 25862791&#45;&gt;32415705 -->
<g id="edge340" class="edge">
<title>25862791:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M1039.75,-733.5C1039.75,-830.47 950.44,-816.18 888.75,-891 865.21,-919.54 864.93,-931.01 840.75,-959 742.1,-1073.19 704.12,-1089.04 594.75,-1193 524.11,-1260.14 474.2,-1254.45 435.75,-1344 416.13,-1389.69 464.75,-1537.8 464.75,-1563"/>
</g>
<!-- 25862791&#45;&gt;32676543 -->
<g id="edge341" class="edge">
<title>25862791:n&#45;&gt;32676543:s</title>
<path fill="none" stroke="black" d="M1039.75,-733.5C1039.75,-844.91 901.36,-795.05 844.75,-891 829.15,-917.43 849.72,-933.43 832.75,-959 764.27,-1062.11 688.29,-1024.55 598.75,-1110 506.31,-1198.21 478.9,-1225.25 431.75,-1344 419.91,-1373.8 382.12,-1605.65 401.75,-1631 572.9,-1852.05 1010.75,-1508.93 1010.75,-1788.5"/>
</g>
<!-- 25862791&#45;&gt;33093817 -->
<g id="edge342" class="edge">
<title>25862791:n&#45;&gt;33093817:s</title>
<path fill="none" stroke="black" d="M1039.75,-733.5C1039.75,-834.79 1101.73,-861.94 1072.75,-959 1040.44,-1067.2 921.42,-1092.93 973.75,-1193 1030.42,-1301.38 1199.75,-1227.7 1199.75,-1350"/>
</g>
<!-- 25862791&#45;&gt;33657116 -->
<g id="edge343" class="edge">
<title>25862791:n&#45;&gt;33657116:s</title>
<path fill="none" stroke="black" d="M1039.75,-733.5C1039.75,-813.26 977.31,-814.81 953.75,-891 913.98,-1019.57 918.13,-1059.11 931.75,-1193 936.77,-1242.43 940.12,-1378.43 976.75,-1412 1191.66,-1608.93 2279.75,-1271.51 2279.75,-1563"/>
</g>
<!-- 25862791&#45;&gt;34280330 -->
<g id="edge344" class="edge">
<title>25862791:n&#45;&gt;34280330:s</title>
<path fill="none" stroke="black" d="M1039.75,-733.5C1039.75,-817.63 962.23,-811.48 934.75,-891 890.84,-1018.06 907.4,-1058.96 917.75,-1193 919.64,-1217.55 934.12,-1394.8 951.75,-1412 1145.52,-1601.03 2159.75,-1298.3 2159.75,-1569"/>
</g>
<!-- 25862791&#45;&gt;34379219 -->
<g id="edge345" class="edge">
<title>25862791:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M1039.75,-733.5C1039.75,-849.1 909.5,-804.55 832.75,-891 809.47,-917.22 816.41,-933.12 792.75,-959 714.93,-1044.11 668.88,-1034.47 581.75,-1110 472.96,-1204.3 448.68,-1232.38 357.75,-1344 266.71,-1455.75 144.69,-1500.91 206.75,-1631 277.9,-1780.17 342.15,-1804 495.75,-1865 702.56,-1947.13 2492.75,-1793.48 2492.75,-2016"/>
</g>
<!-- 25910928&#45;&gt;26848150 -->
<g id="edge346" class="edge">
<title>25910928:n&#45;&gt;26848150:s</title>
<path fill="none" stroke="black" d="M831.75,-506C831.75,-734.75 1321.75,-434.75 1321.75,-663.5"/>
</g>
<!-- 25910928&#45;&gt;27412905 -->
<g id="edge347" class="edge">
<title>25910928:n&#45;&gt;27412905:s</title>
<path fill="none" stroke="black" d="M831.75,-506C831.75,-715.59 1577.12,-559.68 1762.75,-657 1826.64,-690.5 1987.75,-818.86 1987.75,-891"/>
</g>
<!-- 25910928&#45;&gt;27550177 -->
<g id="edge348" class="edge">
<title>25910928:n&#45;&gt;27550177:s</title>
<path fill="none" stroke="black" d="M831.75,-506C831.75,-596.2 722.75,-806.8 722.75,-897"/>
</g>
<!-- 25910928&#45;&gt;27933569 -->
<g id="edge349" class="edge">
<title>25910928:n&#45;&gt;27933569:s</title>
<path fill="none" stroke="black" d="M831.75,-506C831.75,-643.88 1031.38,-539.03 1102.75,-657 1155.6,-744.37 1105.75,-1014.39 1105.75,-1116.5"/>
</g>
<!-- 25910928&#45;&gt;28860793 -->
<g id="edge350" class="edge">
<title>25910928:n&#45;&gt;28860793:s</title>
<path fill="none" stroke="black" d="M831.75,-506C831.75,-606.67 866.49,-865.67 828.75,-959 795.33,-1041.64 728.08,-1026.55 696.75,-1110 683.78,-1144.53 672.21,-1165.45 696.75,-1193 897.91,-1418.87 2048.75,-1047.54 2048.75,-1350"/>
</g>
<!-- 25910928&#45;&gt;28874129 -->
<g id="edge351" class="edge">
<title>25910928:n&#45;&gt;28874129:s</title>
<path fill="none" stroke="black" d="M831.75,-506C831.75,-648.95 1021.51,-549.51 1115.75,-657 1141.71,-686.61 1124.48,-707.52 1146.75,-740 1203.89,-823.35 1273.3,-799.76 1316.75,-891 1359.88,-981.58 1326.75,-1016.18 1326.75,-1116.5"/>
</g>
<!-- 25910928&#45;&gt;29171208 -->
<g id="edge352" class="edge">
<title>25910928:n&#45;&gt;29171208:s</title>
<path fill="none" stroke="black" d="M831.75,-506C831.75,-573.64 846.52,-589.49 850.75,-657 855.27,-729.18 860.18,-929.51 849.75,-959 821.06,-1040.07 757.25,-1028.86 728.75,-1110 716.52,-1144.8 704,-1165.65 728.75,-1193 963.96,-1452.98 2297.75,-1007.41 2297.75,-1358"/>
</g>
<!-- 25910928&#45;&gt;29360144 -->
<g id="edge353" class="edge">
<title>25910928:n&#45;&gt;29360144:s</title>
<path fill="none" stroke="black" d="M831.75,-506C831.75,-518.62 802.25,-947.21 797.75,-959 756.31,-1067.43 607.75,-1103.56 681.75,-1193 910.18,-1469.09 1473.75,-985.66 1473.75,-1344"/>
</g>
<!-- 25910928&#45;&gt;29371284 -->
<g id="edge354" class="edge">
<title>25910928:n&#45;&gt;29371284:s</title>
<path fill="none" stroke="black" d="M831.75,-506C831.75,-606.71 854.96,-865.03 818.75,-959 776.04,-1069.81 611.66,-1103.53 689.75,-1193 852.86,-1379.89 1795.75,-1095.94 1795.75,-1344"/>
</g>
<!-- 25910928&#45;&gt;29525786 -->
<g id="edge355" class="edge">
<title>25910928:n&#45;&gt;29525786:s</title>
<path fill="none" stroke="black" d="M831.75,-506C831.75,-574.34 854.27,-588.97 860.75,-657 873.46,-790.62 887.2,-827.41 860.75,-959 845.79,-1033.41 794.75,-1040.6 794.75,-1116.5"/>
</g>
<!-- 25910928&#45;&gt;29973392 -->
<g id="edge356" class="edge">
<title>25910928:n&#45;&gt;29973392:s</title>
<path fill="none" stroke="black" d="M831.75,-506C831.75,-517.79 656.12,-879.7 652.75,-891 614.13,-1020.33 535.56,-1088.3 620.75,-1193 829.02,-1448.98 1347.75,-1013.99 1347.75,-1344"/>
</g>
<!-- 25910928&#45;&gt;30383768 -->
<g id="edge357" class="edge">
<title>25910928:n&#45;&gt;30383768:s</title>
<path fill="none" stroke="black" d="M831.75,-506C831.75,-656.07 1024,-554.65 1133.75,-657 1165.07,-686.22 1151.02,-711.22 1182.75,-740 1300.41,-846.75 1403.72,-770.06 1506.75,-891 1523.64,-910.83 1570.75,-1090.45 1570.75,-1116.5"/>
</g>
<!-- 25910928&#45;&gt;31022899 -->
<g id="edge358" class="edge">
<title>25910928:n&#45;&gt;31022899:s</title>
<path fill="none" stroke="black" d="M831.75,-506C831.75,-573.36 841.85,-589.7 844.75,-657 850.51,-791.13 884.26,-833.05 837.75,-959 797.19,-1068.83 638.52,-1105.89 716.75,-1193 934.33,-1435.29 2173.75,-1024.35 2173.75,-1350"/>
</g>
<!-- 25910928&#45;&gt;32415705 -->
<g id="edge359" class="edge">
<title>25910928:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M831.75,-506C831.75,-599.66 738.07,-580 684.75,-657 619.32,-751.47 619.8,-785.28 574.75,-891 490.26,-1089.26 440.7,-1132.03 401.75,-1344 396.28,-1373.72 395.81,-1382.37 401.75,-1412 416.02,-1483.3 464.75,-1490.28 464.75,-1563"/>
</g>
<!-- 25910928&#45;&gt;33587284 -->
<g id="edge360" class="edge">
<title>25910928:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M831.75,-506C831.75,-587.74 766.09,-585.35 726.75,-657 642.34,-810.74 387.79,-1274.56 496.75,-1412 686.75,-1651.67 1166.75,-1263.16 1166.75,-1569"/>
</g>
<!-- 25910928&#45;&gt;34173286 -->
<g id="edge361" class="edge">
<title>25910928:n&#45;&gt;34173286:s</title>
<path fill="none" stroke="black" d="M831.75,-506C831.75,-738.99 492.07,-489.87 329.75,-657 185.47,-805.55 254.36,-905.67 220.75,-1110 211.32,-1167.3 146.88,-1583.13 179.75,-1631 289.99,-1791.59 588.75,-1593.71 588.75,-1788.5"/>
</g>
<!-- 25910928&#45;&gt;34398204 -->
<g id="edge362" class="edge">
<title>25910928:n&#45;&gt;34398204:s</title>
<path fill="none" stroke="black" d="M831.75,-506C831.75,-573.44 822.97,-589.85 816.75,-657 813.64,-690.54 803.75,-927.93 790.75,-959 744.89,-1068.55 602.67,-1089.98 661.75,-1193 727.84,-1308.26 817.16,-1259.56 919.75,-1344 950.87,-1369.61 943.57,-1394.24 979.75,-1412 1212.03,-1526.03 3303.75,-1304.23 3303.75,-1563"/>
</g>
<!-- 26199338&#45;&gt;27412905 -->
<g id="edge363" class="edge">
<title>26199338:n&#45;&gt;27412905:s</title>
<path fill="none" stroke="black" d="M384.75,-740C384.75,-1097.8 1987.75,-533.2 1987.75,-891"/>
</g>
<!-- 26199338&#45;&gt;28408716 -->
<g id="edge364" class="edge">
<title>26199338:n&#45;&gt;28408716:s</title>
<path fill="none" stroke="black" d="M384.75,-740C384.75,-950.25 1163.92,-748.76 1318.75,-891 1341.69,-912.08 1314.48,-936.24 1335.75,-959 1484.68,-1118.38 1802.75,-891.86 1802.75,-1110"/>
</g>
<!-- 26199338&#45;&gt;29171208 -->
<g id="edge365" class="edge">
<title>26199338:n&#45;&gt;29171208:s</title>
<path fill="none" stroke="black" d="M384.75,-740C384.75,-798.6 604.87,-1162.24 654.75,-1193 967.08,-1385.61 2297.75,-991.05 2297.75,-1358"/>
</g>
<!-- 26199338&#45;&gt;29360144 -->
<g id="edge366" class="edge">
<title>26199338:n&#45;&gt;29360144:s</title>
<path fill="none" stroke="black" d="M384.75,-740C384.75,-752.3 413.18,-947.23 416.75,-959 450.1,-1069.17 435.63,-1123.97 527.75,-1193 698.11,-1320.66 1473.75,-1131.12 1473.75,-1344"/>
</g>
<!-- 26199338&#45;&gt;29525786 -->
<g id="edge367" class="edge">
<title>26199338:n&#45;&gt;29525786:s</title>
<path fill="none" stroke="black" d="M384.75,-740C384.75,-825.45 465.58,-814.55 503.75,-891 517.71,-918.97 502.75,-934.17 521.75,-959 606.87,-1070.25 794.75,-976.42 794.75,-1116.5"/>
</g>
<!-- 26199338&#45;&gt;30423205 -->
<g id="edge368" class="edge">
<title>26199338:n&#45;&gt;30423205:s</title>
<path fill="none" stroke="black" d="M384.75,-740C384.75,-814.74 329.19,-818.58 310.75,-891 273.85,-1035.85 281.75,-1413.53 281.75,-1563"/>
</g>
<!-- 26199338&#45;&gt;31022899 -->
<g id="edge369" class="edge">
<title>26199338:n&#45;&gt;31022899:s</title>
<path fill="none" stroke="black" d="M384.75,-740C384.75,-851.91 512.97,-1128.96 604.75,-1193 892.12,-1393.51 2173.75,-999.59 2173.75,-1350"/>
</g>
<!-- 26199338&#45;&gt;31390972 -->
<g id="edge370" class="edge">
<title>26199338:n&#45;&gt;31390972:s</title>
<path fill="none" stroke="black" d="M384.75,-740C384.75,-807.4 375.86,-823.79 370.75,-891 353.19,-1121.92 340.28,-1181.41 361.75,-1412 364.03,-1436.57 380.42,-1614.47 398.75,-1631 592.8,-1806.01 2745.75,-1520.68 2745.75,-1782"/>
</g>
<!-- 26199338&#45;&gt;32415705 -->
<g id="edge371" class="edge">
<title>26199338:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M384.75,-740C384.75,-807.26 379.11,-823.88 374.75,-891 367.23,-1006.53 338.42,-1301.43 372.75,-1412 396.04,-1487.05 464.75,-1484.41 464.75,-1563"/>
</g>
<!-- 26199338&#45;&gt;32676543 -->
<g id="edge372" class="edge">
<title>26199338:n&#45;&gt;32676543:s</title>
<path fill="none" stroke="black" d="M384.75,-740C384.75,-817.01 323.76,-817.83 299.75,-891 286.85,-930.3 191.5,-1599.03 217.75,-1631 445.74,-1908.73 1010.75,-1429.17 1010.75,-1788.5"/>
</g>
<!-- 26199338&#45;&gt;33093817 -->
<g id="edge373" class="edge">
<title>26199338:n&#45;&gt;33093817:s</title>
<path fill="none" stroke="black" d="M384.75,-740C384.75,-790.98 421.81,-1156.84 457.75,-1193 695.36,-1432.09 1199.75,-1012.92 1199.75,-1350"/>
</g>
<!-- 26199338&#45;&gt;33253294 -->
<g id="edge374" class="edge">
<title>26199338:n&#45;&gt;33253294:s</title>
<path fill="none" stroke="black" d="M384.75,-740C384.75,-841.18 366.43,-1114.89 430.75,-1193 569.68,-1361.72 716.43,-1223.47 898.75,-1344 932.12,-1366.07 921.95,-1394.12 957.75,-1412 1179.36,-1522.71 3181.75,-1321.27 3181.75,-1569"/>
</g>
<!-- 26199338&#45;&gt;33587284 -->
<g id="edge375" class="edge">
<title>26199338:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M384.75,-740C384.75,-889.65 322.6,-1306.51 428.75,-1412 666.6,-1648.39 1166.75,-1233.66 1166.75,-1569"/>
</g>
<!-- 26199338&#45;&gt;33657116 -->
<g id="edge376" class="edge">
<title>26199338:n&#45;&gt;33657116:s</title>
<path fill="none" stroke="black" d="M384.75,-740C384.75,-790.35 364.41,-1152.82 394.75,-1193 531.8,-1374.53 726.22,-1179.92 883.75,-1344 905.4,-1366.55 878.05,-1391.61 901.75,-1412 1135.25,-1612.94 2279.75,-1254.94 2279.75,-1563"/>
</g>
<!-- 26199338&#45;&gt;34173286 -->
<g id="edge377" class="edge">
<title>26199338:n&#45;&gt;34173286:s</title>
<path fill="none" stroke="black" d="M384.75,-740C384.75,-820.74 312.46,-815.54 283.75,-891 254.28,-968.45 144.16,-1562.46 190.75,-1631 297.69,-1788.33 588.75,-1598.26 588.75,-1788.5"/>
</g>
<!-- 26199338&#45;&gt;34379219 -->
<g id="edge378" class="edge">
<title>26199338:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M384.75,-740C384.75,-825.17 302.42,-813.66 266.75,-891 139.06,-1167.78 161.04,-1259.8 129.75,-1563 126.3,-1596.38 105.79,-1840.53 128.75,-1865 308.83,-2056.95 2492.75,-1752.8 2492.75,-2016"/>
</g>
<!-- 26199338&#45;&gt;34643934 -->
<g id="edge379" class="edge">
<title>26199338:n&#45;&gt;34643934:s</title>
<path fill="none" stroke="black" d="M384.75,-740C384.75,-809.31 355.58,-822.39 345.75,-891 312.89,-1120.22 316.75,-1181.79 341.75,-1412 344.43,-1436.7 368.2,-1614.47 386.75,-1631 535.11,-1763.28 2168.75,-1589.73 2168.75,-1788.5"/>
</g>
<!-- 26446456&#45;&gt;27412905 -->
<g id="edge380" class="edge">
<title>26446456:n&#45;&gt;27412905:s</title>
<path fill="none" stroke="black" d="M1706.75,-733.5C1706.75,-876.67 1987.75,-747.83 1987.75,-891"/>
</g>
<!-- 26446456&#45;&gt;27889397 -->
<g id="edge381" class="edge">
<title>26446456:n&#45;&gt;27889397:s</title>
<path fill="none" stroke="black" d="M1706.75,-733.5C1706.75,-869.37 1444.75,-755.13 1444.75,-891"/>
</g>
<!-- 26446456&#45;&gt;27933569 -->
<g id="edge382" class="edge">
<title>26446456:n&#45;&gt;27933569:s</title>
<path fill="none" stroke="black" d="M1706.75,-733.5C1706.75,-964.79 1363.08,-716.96 1210.75,-891 1190.53,-914.09 1209.39,-930.21 1198.75,-959 1170.56,-1035.25 1105.75,-1035.21 1105.75,-1116.5"/>
</g>
<!-- 26446456&#45;&gt;28408716 -->
<g id="edge383" class="edge">
<title>26446456:n&#45;&gt;28408716:s</title>
<path fill="none" stroke="black" d="M1706.75,-733.5C1706.75,-836.25 1731.73,-859.6 1757.75,-959 1775.48,-1026.75 1802.75,-1039.97 1802.75,-1110"/>
</g>
<!-- 26446456&#45;&gt;29371284 -->
<g id="edge384" class="edge">
<title>26446456:n&#45;&gt;29371284:s</title>
<path fill="none" stroke="black" d="M1706.75,-733.5C1706.75,-803.67 1713.91,-820.93 1717.75,-891 1721.42,-958.06 1714.7,-1127.54 1729.75,-1193 1746.15,-1264.38 1795.75,-1270.76 1795.75,-1344"/>
</g>
<!-- 26446456&#45;&gt;29973392 -->
<g id="edge385" class="edge">
<title>26446456:n&#45;&gt;29973392:s</title>
<path fill="none" stroke="black" d="M1706.75,-733.5C1706.75,-804.01 1693.37,-820.72 1687.75,-891 1685.07,-924.47 1694.42,-1165.09 1675.75,-1193 1586.52,-1326.39 1347.75,-1183.52 1347.75,-1344"/>
</g>
<!-- 26446456&#45;&gt;30383768 -->
<g id="edge386" class="edge">
<title>26446456:n&#45;&gt;30383768:s</title>
<path fill="none" stroke="black" d="M1706.75,-733.5C1706.75,-759.8 1643.7,-934.27 1634.75,-959 1609.01,-1030.04 1570.75,-1040.94 1570.75,-1116.5"/>
</g>
<!-- 26446456&#45;&gt;30571400 -->
<g id="edge387" class="edge">
<title>26446456:n&#45;&gt;30571400:s</title>
<path fill="none" stroke="black" d="M1706.75,-733.5C1706.75,-940.48 2478.04,-744.99 2624.75,-891 2646.5,-912.65 2619.26,-933.78 2636.75,-959 2712.02,-1067.55 2819.17,-1000.29 2892.75,-1110 2913.51,-1140.96 2888.11,-1159.65 2904.75,-1193 2946.98,-1277.64 3054.75,-1249.4 3054.75,-1344"/>
</g>
<!-- 26446456&#45;&gt;31195999 -->
<g id="edge388" class="edge">
<title>26446456:n&#45;&gt;31195999:s</title>
<path fill="none" stroke="black" d="M1706.75,-733.5C1706.75,-942.01 2441.87,-804.84 2631.75,-891 2772.14,-954.7 2805.81,-988.53 2900.75,-1110 2925.84,-1142.11 2908.08,-1167.34 2939.75,-1193 3167.8,-1377.83 3582.75,-1050.45 3582.75,-1344"/>
</g>
<!-- 26446456&#45;&gt;32415705 -->
<g id="edge389" class="edge">
<title>26446456:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M1706.75,-733.5C1706.75,-804.12 1694.02,-820.87 1685.75,-891 1684.76,-899.37 1659.82,-1186.27 1654.75,-1193 1546.08,-1337.12 1392.55,-1204.72 1277.75,-1344 1258.18,-1367.74 1286.53,-1390.27 1264.75,-1412 1008.59,-1667.56 464.75,-1201.17 464.75,-1563"/>
</g>
<!-- 26446456&#45;&gt;32676543 -->
<g id="edge390" class="edge">
<title>26446456:n&#45;&gt;32676543:s</title>
<path fill="none" stroke="black" d="M1706.75,-733.5C1706.75,-803.7 1698.81,-820.91 1694.75,-891 1690.86,-958.05 1702.48,-1128.8 1682.75,-1193 1659.52,-1268.56 1620.59,-1271.65 1588.75,-1344 1576.1,-1372.72 1584.5,-1384.31 1569.75,-1412 1509.56,-1524.95 1485.99,-1555.36 1382.75,-1631 1237.91,-1737.11 1010.75,-1608.96 1010.75,-1788.5"/>
</g>
<!-- 26446456&#45;&gt;33093817 -->
<g id="edge391" class="edge">
<title>26446456:n&#45;&gt;33093817:s</title>
<path fill="none" stroke="black" d="M1706.75,-733.5C1706.75,-805.72 1677.95,-819.65 1666.75,-891 1664.14,-907.61 1657.9,-1179.6 1647.75,-1193 1520.35,-1361.18 1199.75,-1139.02 1199.75,-1350"/>
</g>
<!-- 26446456&#45;&gt;33587284 -->
<g id="edge392" class="edge">
<title>26446456:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M1706.75,-733.5C1706.75,-804.01 1694.88,-820.85 1687.75,-891 1684.34,-924.5 1682.6,-1165.8 1662.75,-1193 1559.24,-1334.8 1415.12,-1213.45 1297.75,-1344 1276.68,-1367.43 1291.47,-1383.64 1277.75,-1412 1240.52,-1488.92 1166.75,-1483.54 1166.75,-1569"/>
</g>
<!-- 26446456&#45;&gt;33657116 -->
<g id="edge393" class="edge">
<title>26446456:n&#45;&gt;33657116:s</title>
<path fill="none" stroke="black" d="M1706.75,-733.5C1706.75,-898.83 1953.39,-752.55 2043.75,-891 2080.43,-947.21 2062.84,-1127.38 2048.75,-1193 2033.29,-1264.96 1996.2,-1272.04 1980.75,-1344 1974.4,-1373.55 1964.91,-1386.26 1980.75,-1412 2058.76,-1538.8 2279.75,-1414.13 2279.75,-1563"/>
</g>
<!-- 26446456&#45;&gt;33950207 -->
<g id="edge394" class="edge">
<title>26446456:n&#45;&gt;33950207:s</title>
<path fill="none" stroke="black" d="M1706.75,-733.5C1706.75,-835.61 1733.67,-1094.78 1705.75,-1193 1677.02,-1294.06 1567.8,-1319.04 1616.75,-1412 1672,-1516.94 1745.82,-1486.86 1836.75,-1563 1869.27,-1590.24 1866.97,-1609.85 1903.75,-1631 2138.02,-1765.72 2492.75,-1511.76 2492.75,-1782"/>
</g>
<!-- 26446456&#45;&gt;34379219 -->
<g id="edge395" class="edge">
<title>26446456:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M1706.75,-733.5C1706.75,-784.59 1704.46,-1144.07 1689.75,-1193 1659.35,-1294.1 1563.96,-1311.98 1597.75,-1412 1684.84,-1669.84 1775.31,-1726.78 2009.75,-1865 2203.49,-1979.23 2492.75,-1791.09 2492.75,-2016"/>
</g>
<!-- 26446456&#45;&gt;34643934 -->
<g id="edge396" class="edge">
<title>26446456:n&#45;&gt;34643934:s</title>
<path fill="none" stroke="black" d="M1706.75,-733.5C1706.75,-835.63 1725.59,-1094.74 1697.75,-1193 1669.11,-1294.09 1563.05,-1317.4 1608.75,-1412 1676.86,-1553 1754.5,-1544.07 1884.75,-1631 2004.79,-1711.13 2168.75,-1644.17 2168.75,-1788.5"/>
</g>
<!-- 26446456&#45;&gt;34722686 -->
<g id="edge397" class="edge">
<title>26446456:n&#45;&gt;34722686:s</title>
<path fill="none" stroke="black" d="M1706.75,-733.5C1706.75,-824.15 1839.65,-1022.61 1863.75,-1110 1871.52,-1138.19 1917.75,-1610.65 1938.75,-1631 2174.64,-1859.59 3407.75,-1467.02 3407.75,-1795.5"/>
</g>
<!-- 26446507&#45;&gt;27412905 -->
<g id="edge398" class="edge">
<title>26446507:n&#45;&gt;27412905:s</title>
<path fill="none" stroke="black" d="M1551.75,-733.5C1551.75,-939.53 1987.75,-684.97 1987.75,-891"/>
</g>
<!-- 26446507&#45;&gt;27889397 -->
<g id="edge399" class="edge">
<title>26446507:n&#45;&gt;27889397:s</title>
<path fill="none" stroke="black" d="M1551.75,-733.5C1551.75,-818.13 1444.75,-806.37 1444.75,-891"/>
</g>
<!-- 26446507&#45;&gt;27933569 -->
<g id="edge400" class="edge">
<title>26446507:n&#45;&gt;27933569:s</title>
<path fill="none" stroke="black" d="M1551.75,-733.5C1551.75,-903.27 1307.87,-756.91 1203.75,-891 1184.92,-915.24 1201.9,-930.04 1191.75,-959 1165.36,-1034.26 1105.75,-1036.74 1105.75,-1116.5"/>
</g>
<!-- 26446507&#45;&gt;28300870 -->
<g id="edge401" class="edge">
<title>26446507:n&#45;&gt;28300870:s</title>
<path fill="none" stroke="black" d="M1551.75,-733.5C1551.75,-974.72 2391.68,-832.69 2625.75,-891 2698.09,-909.02 3257.75,-1041.94 3257.75,-1116.5"/>
</g>
<!-- 26446507&#45;&gt;29371284 -->
<g id="edge402" class="edge">
<title>26446507:n&#45;&gt;29371284:s</title>
<path fill="none" stroke="black" d="M1551.75,-733.5C1551.75,-834.34 1547.38,-860.3 1526.75,-959 1512.36,-1027.8 1490.31,-1040.51 1479.75,-1110 1474.2,-1146.47 1460.07,-1161.8 1479.75,-1193 1562.76,-1324.67 1795.75,-1188.34 1795.75,-1344"/>
</g>
<!-- 26446507&#45;&gt;29373602 -->
<g id="edge403" class="edge">
<title>26446507:n&#45;&gt;29373602:s</title>
<path fill="none" stroke="black" d="M1551.75,-733.5C1551.75,-833.79 1557.84,-859.71 1543.75,-959 1534.02,-1027.52 1514.26,-1041.32 1505.75,-1110 1501.21,-1146.61 1481.43,-1165.26 1505.75,-1193 1674.79,-1385.82 2649.75,-1087.57 2649.75,-1344"/>
</g>
<!-- 26446507&#45;&gt;29525786 -->
<g id="edge404" class="edge">
<title>26446507:n&#45;&gt;29525786:s</title>
<path fill="none" stroke="black" d="M1551.75,-733.5C1551.75,-1010.49 1168.79,-722.76 948.75,-891 921.07,-912.16 928.71,-929.78 909.75,-959 862.56,-1031.7 794.75,-1029.83 794.75,-1116.5"/>
</g>
<!-- 26446507&#45;&gt;30383768 -->
<g id="edge405" class="edge">
<title>26446507:n&#45;&gt;30383768:s</title>
<path fill="none" stroke="black" d="M1551.75,-733.5C1551.75,-805.41 1580.47,-819.57 1588.75,-891 1600.32,-990.87 1570.75,-1015.96 1570.75,-1116.5"/>
</g>
<!-- 26446507&#45;&gt;30571400 -->
<g id="edge406" class="edge">
<title>26446507:n&#45;&gt;30571400:s</title>
<path fill="none" stroke="black" d="M1551.75,-733.5C1551.75,-972.96 2446.07,-724.06 2617.75,-891 2639.75,-912.39 2612.55,-933.58 2629.75,-959 2700.99,-1064.32 2795.42,-1009.06 2872.75,-1110 2896.17,-1140.58 2877.65,-1160.13 2897.75,-1193 2948.24,-1275.6 3054.75,-1247.19 3054.75,-1344"/>
</g>
<!-- 26446507&#45;&gt;30924051 -->
<g id="edge407" class="edge">
<title>26446507:n&#45;&gt;30924051:s</title>
<path fill="none" stroke="black" d="M1551.75,-733.5C1551.75,-971.42 2440.25,-725.05 2610.75,-891 2632.74,-912.41 2605.58,-933.56 2622.75,-959 2693.68,-1064.07 2795.45,-1003.84 2864.75,-1110 2885.12,-1141.21 2866.93,-1157.04 2876.75,-1193 2895.86,-1262.99 2938.75,-1271.45 2938.75,-1344"/>
</g>
<!-- 26446507&#45;&gt;31022899 -->
<g id="edge408" class="edge">
<title>26446507:n&#45;&gt;31022899:s</title>
<path fill="none" stroke="black" d="M1551.75,-733.5C1551.75,-833.97 1554.95,-860.38 1535.75,-959 1522.26,-1028.26 1497.77,-1040.31 1486.75,-1110 1480.98,-1146.44 1463.75,-1164.16 1486.75,-1193 1681.99,-1437.9 2173.75,-1036.79 2173.75,-1350"/>
</g>
<!-- 26446507&#45;&gt;32415705 -->
<g id="edge409" class="edge">
<title>26446507:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M1551.75,-733.5C1551.75,-1007.05 1155.14,-702.66 956.75,-891 950.36,-897.07 865.86,-1186.65 859.75,-1193 723.29,-1334.66 556.63,-1182.93 443.75,-1344 426.4,-1368.75 441.66,-1381.85 443.75,-1412 448.42,-1479.6 464.75,-1495.24 464.75,-1563"/>
</g>
<!-- 26446507&#45;&gt;33093817 -->
<g id="edge410" class="edge">
<title>26446507:n&#45;&gt;33093817:s</title>
<path fill="none" stroke="black" d="M1551.75,-733.5C1551.75,-759.09 1512.42,-934.58 1504.75,-959 1470.82,-1066.89 1474.14,-1103.69 1404.75,-1193 1334.34,-1283.62 1199.75,-1235.24 1199.75,-1350"/>
</g>
<!-- 26446507&#45;&gt;33587284 -->
<g id="edge411" class="edge">
<title>26446507:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M1551.75,-733.5C1551.75,-1001.9 1150.91,-693.89 968.75,-891 960.35,-900.09 928.89,-1097.67 927.75,-1110 915.32,-1243.94 880.91,-1295.26 947.75,-1412 1007.25,-1515.93 1166.75,-1449.24 1166.75,-1569"/>
</g>
<!-- 26446507&#45;&gt;34280330 -->
<g id="edge412" class="edge">
<title>26446507:n&#45;&gt;34280330:s</title>
<path fill="none" stroke="black" d="M1551.75,-733.5C1551.75,-784.25 1527.17,-909.56 1515.75,-959 1499.96,-1027.36 1480.08,-1040.61 1469.75,-1110 1464.31,-1146.49 1451.53,-1160.92 1469.75,-1193 1534.4,-1306.88 1648.41,-1236.2 1722.75,-1344 1740.17,-1369.26 1715.07,-1388.44 1734.75,-1412 1863.82,-1566.56 2159.75,-1367.63 2159.75,-1569"/>
</g>
<!-- 26848150&#45;&gt;27312796 -->
<g id="edge413" class="edge">
<title>26848150:n&#45;&gt;27312796:s</title>
<path fill="none" stroke="black" d="M1321.75,-733.5C1321.75,-1008.84 2550.75,-615.66 2550.75,-891"/>
</g>
<!-- 26848150&#45;&gt;28188243 -->
<g id="edge414" class="edge">
<title>26848150:n&#45;&gt;28188243:s</title>
<path fill="none" stroke="black" d="M1321.75,-733.5C1321.75,-1020.53 2412.14,-677.29 2603.75,-891 2620.47,-909.66 2606.75,-1091.44 2606.75,-1116.5"/>
</g>
<!-- 26848150&#45;&gt;29654196 -->
<g id="edge415" class="edge">
<title>26848150:n&#45;&gt;29654196:s</title>
<path fill="none" stroke="black" d="M1321.75,-733.5C1321.75,-833.97 1359.65,-860.94 1337.75,-959 1314.05,-1065.07 1205.41,-1103.28 1266.75,-1193 1375.23,-1351.69 1669.75,-1157.78 1669.75,-1350"/>
</g>
<!-- 26848150&#45;&gt;34173286 -->
<g id="edge416" class="edge">
<title>26848150:n&#45;&gt;34173286:s</title>
<path fill="none" stroke="black" d="M1321.75,-733.5C1321.75,-936.19 1064.8,-782.26 893.75,-891 849.06,-919.41 237.96,-1514.05 217.75,-1563 129.6,-1776.51 588.75,-1676.65 588.75,-1788.5"/>
</g>
<!-- 27312796&#45;&gt;27680880 -->
<g id="edge417" class="edge">
<title>27312796:n&#45;&gt;27680880:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1082.53 2321.75,-992.97 2321.75,-1116.5"/>
</g>
<!-- 27312796&#45;&gt;28188243 -->
<g id="edge418" class="edge">
<title>27312796:n&#45;&gt;28188243:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1033.29 2606.75,-1042.21 2606.75,-1116.5"/>
</g>
<!-- 27312796&#45;&gt;28614582 -->
<g id="edge419" class="edge">
<title>27312796:n&#45;&gt;28614582:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1171.32 3001.75,-904.18 3001.75,-1116.5"/>
</g>
<!-- 27312796&#45;&gt;28860793 -->
<g id="edge420" class="edge">
<title>27312796:n&#45;&gt;28860793:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1169.12 2241.9,-952.57 2102.75,-1110 2077.81,-1138.21 2093.84,-1156.23 2085.75,-1193 2070.33,-1263.01 2048.75,-1278.31 2048.75,-1350"/>
</g>
<!-- 27312796&#45;&gt;28956288 -->
<g id="edge421" class="edge">
<title>27312796:n&#45;&gt;28956288:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1233.98 2180.15,-958.37 1950.75,-1110 1912.11,-1135.54 1927.25,-1168.83 1887.75,-1193 1724.65,-1292.77 1040.75,-1152.81 1040.75,-1344"/>
</g>
<!-- 27312796&#45;&gt;29171208 -->
<g id="edge422" class="edge">
<title>27312796:n&#45;&gt;29171208:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1045.56 2473.46,-1036.5 2427.75,-1110 2406.32,-1144.45 2408.08,-1156.81 2389.75,-1193 2351.8,-1267.9 2297.75,-1274.04 2297.75,-1358"/>
</g>
<!-- 27312796&#45;&gt;29371284 -->
<g id="edge423" class="edge">
<title>27312796:n&#45;&gt;29371284:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1176.29 2265.62,-988.1 2085.75,-1110 2046.04,-1136.91 2052.23,-1160.71 2016.75,-1193 1928.76,-1273.07 1795.75,-1225.04 1795.75,-1344"/>
</g>
<!-- 27312796&#45;&gt;29373602 -->
<g id="edge424" class="edge">
<title>27312796:n&#45;&gt;29373602:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1063.97 2482.03,-1094.66 2518.75,-1193 2549.82,-1276.24 2649.75,-1255.15 2649.75,-1344"/>
</g>
<!-- 27312796&#45;&gt;29525786 -->
<g id="edge425" class="edge">
<title>27312796:n&#45;&gt;29525786:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1350.79 794.75,-724.71 794.75,-1116.5"/>
</g>
<!-- 27312796&#45;&gt;29622587 -->
<g id="edge426" class="edge">
<title>27312796:n&#45;&gt;29622587:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1091.64 2799.75,-990.86 2799.75,-1123.5"/>
</g>
<!-- 27312796&#45;&gt;29909576 -->
<g id="edge427" class="edge">
<title>27312796:n&#45;&gt;29909576:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1029.29 2514.46,-1040.53 2503.75,-1110 2487.89,-1212.79 2502.75,-1240 2502.75,-1344"/>
</g>
<!-- 27312796&#45;&gt;29973392 -->
<g id="edge428" class="edge">
<title>27312796:n&#45;&gt;29973392:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1205.64 2221.03,-971.81 2016.75,-1110 1978.16,-1136.1 1991.73,-1167.5 1952.75,-1193 1720.82,-1344.71 1347.75,-1066.86 1347.75,-1344"/>
</g>
<!-- 27312796&#45;&gt;30423205 -->
<g id="edge429" class="edge">
<title>27312796:n&#45;&gt;30423205:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1035.58 2501.27,-1041.15 2467.75,-1110 2451.77,-1142.81 2368.44,-1390.79 2338.75,-1412 2152.25,-1545.19 281.75,-1333.83 281.75,-1563"/>
</g>
<!-- 27312796&#45;&gt;31390972 -->
<g id="edge430" class="edge">
<title>27312796:n&#45;&gt;31390972:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1041.77 2620.31,-1037.23 2659.75,-1110 2678.58,-1144.76 2673.45,-1157.95 2691.75,-1193 2729.22,-1264.8 2770.04,-1266.56 2793.75,-1344 2803.63,-1376.28 2818.16,-1451.64 2790.75,-1631 2780.17,-1700.22 2745.75,-1711.97 2745.75,-1782"/>
</g>
<!-- 27312796&#45;&gt;32415705 -->
<g id="edge431" class="edge">
<title>27312796:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-965.73 2385.12,-1407.96 2379.75,-1412 2209.09,-1540.19 464.75,-1349.56 464.75,-1563"/>
</g>
<!-- 27312796&#45;&gt;32539675 -->
<g id="edge432" class="edge">
<title>27312796:n&#45;&gt;32539675:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1011.3 2503.08,-1145.87 2525.75,-1193 2572.35,-1289.89 2668.14,-1247.11 2714.75,-1344 2721.3,-1357.62 2724.2,-1400.21 2714.75,-1412 2513.32,-1663.06 2007.75,-1247.12 2007.75,-1569"/>
</g>
<!-- 27312796&#45;&gt;33093817 -->
<g id="edge433" class="edge">
<title>27312796:n&#45;&gt;33093817:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1230.97 2139.62,-907.8 1957.75,-1110 1932.82,-1137.71 1971.25,-1165.82 1945.75,-1193 1713.93,-1440.11 1199.75,-1011.18 1199.75,-1350"/>
</g>
<!-- 27312796&#45;&gt;33587284 -->
<g id="edge434" class="edge">
<title>27312796:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1028.31 2520.48,-1041.24 2511.75,-1110 2507.1,-1146.59 2505.44,-1156.65 2511.75,-1193 2523.93,-1263.23 2553.57,-1273.77 2565.75,-1344 2570.91,-1373.78 2585.89,-1389.47 2565.75,-1412 2357.23,-1645.22 1166.75,-1256.16 1166.75,-1569"/>
</g>
<!-- 27312796&#45;&gt;33950207 -->
<g id="edge435" class="edge">
<title>27312796:n&#45;&gt;33950207:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1011 2530.84,-1146.31 2553.75,-1193 2601.25,-1289.84 2696.86,-1246.86 2743.75,-1344 2756.88,-1371.22 2752.62,-1383.11 2743.75,-1412 2714.57,-1506.98 2492.75,-1682.64 2492.75,-1782"/>
</g>
<!-- 27312796&#45;&gt;34173286 -->
<g id="edge436" class="edge">
<title>27312796:n&#45;&gt;34173286:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1063.14 2494.47,-1098.74 2538.75,-1193 2592.55,-1307.55 2784.94,-1302.93 2720.75,-1412 2650.61,-1531.16 2554.61,-1474.06 2448.75,-1563 2418.99,-1588 2428.06,-1612.75 2393.75,-1631 2216.01,-1725.54 588.75,-1587.18 588.75,-1788.5"/>
</g>
<!-- 27312796&#45;&gt;34379219 -->
<g id="edge437" class="edge">
<title>27312796:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1046.69 2637.32,-1032.18 2677.75,-1110 2695.34,-1143.86 2683.96,-1158.26 2699.75,-1193 2733.26,-1266.73 2778.04,-1266.56 2801.75,-1344 2804.29,-1352.3 2815.42,-1838.38 2798.75,-1865 2718.25,-1993.53 2492.75,-1864.34 2492.75,-2016"/>
</g>
<!-- 27312796&#45;&gt;34643934 -->
<g id="edge438" class="edge">
<title>27312796:n&#45;&gt;34643934:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1011.01 2524.57,-1145.96 2546.75,-1193 2600.83,-1307.74 2792.08,-1301.53 2729.75,-1412 2665.96,-1525.05 2566.08,-1466.06 2479.75,-1563 2457.66,-1587.8 2471.22,-1606.54 2448.75,-1631 2352.15,-1736.14 2168.75,-1645.72 2168.75,-1788.5"/>
</g>
<!-- 27312796&#45;&gt;34722686 -->
<g id="edge439" class="edge">
<title>27312796:n&#45;&gt;34722686:s</title>
<path fill="none" stroke="black" d="M2550.75,-959C2550.75,-1052.04 2646.64,-1030.97 2695.75,-1110 2716.45,-1143.32 2708.54,-1157.75 2725.75,-1193 2760.53,-1264.25 2798.24,-1267.97 2820.75,-1344 2829.8,-1374.58 2805.32,-1605.71 2824.75,-1631 2988.72,-1844.53 3407.75,-1526.27 3407.75,-1795.5"/>
</g>
<!-- 27412905&#45;&gt;27680880 -->
<g id="edge440" class="edge">
<title>27412905:n&#45;&gt;27680880:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1123.12 2321.75,-952.38 2321.75,-1116.5"/>
</g>
<!-- 27412905&#45;&gt;27933569 -->
<g id="edge441" class="edge">
<title>27412905:n&#45;&gt;27933569:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1357.2 1105.75,-718.3 1105.75,-1116.5"/>
</g>
<!-- 27412905&#45;&gt;28300870 -->
<g id="edge442" class="edge">
<title>27412905:n&#45;&gt;28300870:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1243.38 3257.75,-832.12 3257.75,-1116.5"/>
</g>
<!-- 27412905&#45;&gt;28408716 -->
<g id="edge443" class="edge">
<title>27412905:n&#45;&gt;28408716:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1065.13 1802.75,-1003.87 1802.75,-1110"/>
</g>
<!-- 27412905&#45;&gt;28956288 -->
<g id="edge444" class="edge">
<title>27412905:n&#45;&gt;28956288:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1036.23 1934.84,-1040.22 1901.75,-1110 1884.8,-1145.72 1900.2,-1167.79 1869.75,-1193 1725.51,-1312.41 1040.75,-1156.75 1040.75,-1344"/>
</g>
<!-- 27412905&#45;&gt;29171208 -->
<g id="edge445" class="edge">
<title>27412905:n&#45;&gt;29171208:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1088.43 2165.32,-1002.07 2236.75,-1110 2257.32,-1141.08 2240.75,-1156.59 2248.75,-1193 2265.15,-1267.72 2297.75,-1281.5 2297.75,-1358"/>
</g>
<!-- 27412905&#45;&gt;29360144 -->
<g id="edge446" class="edge">
<title>27412905:n&#45;&gt;29360144:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1030.89 1950.31,-1041.11 1929.75,-1110 1918.95,-1146.17 1936.81,-1164.78 1911.75,-1193 1775.02,-1346.96 1473.75,-1138.09 1473.75,-1344"/>
</g>
<!-- 27412905&#45;&gt;29371284 -->
<g id="edge447" class="edge">
<title>27412905:n&#45;&gt;29371284:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1066.7 1974.96,-1097.72 1924.75,-1193 1883.6,-1271.09 1795.75,-1255.73 1795.75,-1344"/>
</g>
<!-- 27412905&#45;&gt;29373602 -->
<g id="edge448" class="edge">
<title>27412905:n&#45;&gt;29373602:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1155.69 2236.88,-1005.87 2403.75,-1110 2448.81,-1138.12 2451.32,-1156.33 2489.75,-1193 2560.48,-1260.51 2649.75,-1246.22 2649.75,-1344"/>
</g>
<!-- 27412905&#45;&gt;29525786 -->
<g id="edge449" class="edge">
<title>27412905:n&#45;&gt;29525786:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1226.41 794.75,-849.09 794.75,-1116.5"/>
</g>
<!-- 27412905&#45;&gt;29622587 -->
<g id="edge450" class="edge">
<title>27412905:n&#45;&gt;29622587:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1327.22 2799.75,-755.28 2799.75,-1123.5"/>
</g>
<!-- 27412905&#45;&gt;29909576 -->
<g id="edge451" class="edge">
<title>27412905:n&#45;&gt;29909576:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1149.86 2260.93,-969.18 2389.75,-1110 2415.58,-1138.24 2397.7,-1157.8 2412.75,-1193 2443.45,-1264.84 2502.75,-1265.87 2502.75,-1344"/>
</g>
<!-- 27412905&#45;&gt;30383768 -->
<g id="edge452" class="edge">
<title>27412905:n&#45;&gt;30383768:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1157.11 1570.75,-918.39 1570.75,-1116.5"/>
</g>
<!-- 27412905&#45;&gt;30571400 -->
<g id="edge453" class="edge">
<title>27412905:n&#45;&gt;30571400:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1275.1 2451.81,-894.16 2682.75,-1110 2710.8,-1136.22 2681.38,-1164.17 2706.75,-1193 2818.1,-1319.59 3054.75,-1175.4 3054.75,-1344"/>
</g>
<!-- 27412905&#45;&gt;30924051 -->
<g id="edge454" class="edge">
<title>27412905:n&#45;&gt;30924051:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1265.98 2424.19,-915.56 2661.75,-1110 2693,-1135.58 2672.29,-1162.48 2698.75,-1193 2781.3,-1288.22 2938.75,-1217.98 2938.75,-1344"/>
</g>
<!-- 27412905&#45;&gt;31112292 -->
<g id="edge455" class="edge">
<title>27412905:n&#45;&gt;31112292:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1083.15 2158.1,-1004.01 2222.75,-1110 2231.52,-1124.39 2240.7,-1399.27 2251.75,-1412 2439.05,-1627.83 2876.75,-1277.23 2876.75,-1563"/>
</g>
<!-- 27412905&#45;&gt;31195999 -->
<g id="edge456" class="edge">
<title>27412905:n&#45;&gt;31195999:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1281.18 2447.39,-905.99 2696.75,-1110 2727.87,-1135.46 2701.2,-1168.07 2732.75,-1193 2883.28,-1311.94 3582.75,-1152.15 3582.75,-1344"/>
</g>
<!-- 27412905&#45;&gt;31390972 -->
<g id="edge457" class="edge">
<title>27412905:n&#45;&gt;31390972:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1063.97 2039.48,-1089.9 2019.75,-1193 2000.78,-1292.12 1925.73,-1316.98 1959.75,-1412 1989.01,-1493.76 2047.46,-1484.11 2083.75,-1563 2096.57,-1590.88 2074.64,-1608.73 2095.75,-1631 2299.77,-1846.26 2745.75,-1485.42 2745.75,-1782"/>
</g>
<!-- 27412905&#45;&gt;32415705 -->
<g id="edge458" class="edge">
<title>27412905:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1064.58 1977.78,-1092.08 1946.75,-1193 1925.12,-1263.35 1905.23,-1275.33 1878.75,-1344 1867.32,-1373.64 1881.39,-1391.95 1856.75,-1412 1615.39,-1608.37 464.75,-1251.85 464.75,-1563"/>
</g>
<!-- 27412905&#45;&gt;32539675 -->
<g id="edge459" class="edge">
<title>27412905:n&#45;&gt;32539675:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1063.46 2030.54,-1090.63 2009.75,-1193 1995.23,-1264.43 1960.26,-1272.57 1945.75,-1344 1939.73,-1373.62 1940.1,-1382.31 1945.75,-1412 1959.77,-1485.7 2007.75,-1493.98 2007.75,-1569"/>
</g>
<!-- 27412905&#45;&gt;32676543 -->
<g id="edge460" class="edge">
<title>27412905:n&#45;&gt;32676543:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1063 2010.14,-1091.44 1987.75,-1193 1971.82,-1265.24 1937.78,-1272.79 1917.75,-1344 1900.36,-1405.8 1928.67,-1584.18 1884.75,-1631 1614.7,-1918.86 1010.75,-1393.8 1010.75,-1788.5"/>
</g>
<!-- 27412905&#45;&gt;33093817 -->
<g id="edge461" class="edge">
<title>27412905:n&#45;&gt;33093817:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1033.35 1939.79,-1039.64 1915.75,-1110 1903.54,-1145.72 1924.33,-1166.21 1897.75,-1193 1673.77,-1418.7 1199.75,-1032.03 1199.75,-1350"/>
</g>
<!-- 27412905&#45;&gt;33587284 -->
<g id="edge462" class="edge">
<title>27412905:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1011.09 1986.62,-1142.52 1973.75,-1193 1955.42,-1264.86 1930.9,-1275.39 1902.75,-1344 1890.58,-1373.65 1902.75,-1390.76 1878.75,-1412 1636.04,-1626.71 1166.75,-1244.95 1166.75,-1569"/>
</g>
<!-- 27412905&#45;&gt;33657116 -->
<g id="edge463" class="edge">
<title>27412905:n&#45;&gt;33657116:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1030.58 2031.1,-1039.55 2043.75,-1110 2050.26,-1146.31 2051.69,-1156.98 2043.75,-1193 2021.74,-1292.79 1919.8,-1325.22 1973.75,-1412 2053.82,-1540.8 2279.75,-1411.34 2279.75,-1563"/>
</g>
<!-- 27412905&#45;&gt;33950207 -->
<g id="edge464" class="edge">
<title>27412905:n&#45;&gt;33950207:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1063.69 2035.01,-1090.29 2014.75,-1193 1995.16,-1292.25 1918.65,-1316.76 1952.75,-1412 1982.01,-1493.76 2040.46,-1484.11 2076.75,-1563 2089.57,-1590.88 2069.12,-1607.41 2088.75,-1631 2211.34,-1778.36 2492.75,-1590.31 2492.75,-1782"/>
</g>
<!-- 27412905&#45;&gt;34173286 -->
<g id="edge465" class="edge">
<title>27412905:n&#45;&gt;34173286:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1011.02 1992.57,-1142.34 1980.75,-1193 1963.98,-1264.86 1937.09,-1274.7 1911.75,-1344 1900.97,-1373.47 1914.01,-1388.92 1892.75,-1412 1702.66,-1618.32 1569.89,-1551.85 1300.75,-1631 1145.28,-1676.72 588.75,-1626.45 588.75,-1788.5"/>
</g>
<!-- 27412905&#45;&gt;34379219 -->
<g id="edge466" class="edge">
<title>27412905:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1026.18 1993.19,-1042.83 1994.75,-1110 1995.6,-1146.88 2001.99,-1156.83 1994.75,-1193 1980.47,-1264.3 1947.32,-1272.97 1931.75,-1344 1904.41,-1468.64 1881.7,-1510.52 1923.75,-1631 1967.53,-1756.43 2002.98,-1785.94 2109.75,-1865 2256.8,-1973.88 2492.75,-1833.03 2492.75,-2016"/>
</g>
<!-- 27412905&#45;&gt;34398204 -->
<g id="edge467" class="edge">
<title>27412905:n&#45;&gt;34398204:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1085.78 2163.01,-1002.21 2229.75,-1110 2238.62,-1124.33 2247.12,-1399.8 2258.75,-1412 2420.65,-1581.83 3303.75,-1328.37 3303.75,-1563"/>
</g>
<!-- 27412905&#45;&gt;34643934 -->
<g id="edge468" class="edge">
<title>27412905:n&#45;&gt;34643934:s</title>
<path fill="none" stroke="black" d="M1987.75,-959C1987.75,-1026.4 1998.63,-1042.67 2001.75,-1110 2003.45,-1146.85 2008.68,-1156.77 2001.75,-1193 1988.17,-1263.93 1956.13,-1273.23 1941.75,-1344 1929.04,-1406.51 1906.88,-1574.63 1936.75,-1631 1995.09,-1741.13 2168.75,-1663.87 2168.75,-1788.5"/>
</g>
<!-- 27538358&#45;&gt;27933569 -->
<g id="edge469" class="edge">
<title>27538358:n&#45;&gt;27933569:s</title>
<path fill="none" stroke="black" d="M1263.75,-959C1263.75,-1058.15 1105.75,-1017.35 1105.75,-1116.5"/>
</g>
<!-- 27538358&#45;&gt;28300870 -->
<g id="edge470" class="edge">
<title>27538358:n&#45;&gt;28300870:s</title>
<path fill="none" stroke="black" d="M1263.75,-959C1263.75,-1403.49 3257.75,-672.01 3257.75,-1116.5"/>
</g>
<!-- 27538358&#45;&gt;28614582 -->
<g id="edge471" class="edge">
<title>27538358:n&#45;&gt;28614582:s</title>
<path fill="none" stroke="black" d="M1263.75,-959C1263.75,-1346.8 3001.75,-728.7 3001.75,-1116.5"/>
</g>
<!-- 27538358&#45;&gt;28860793 -->
<g id="edge472" class="edge">
<title>27538358:n&#45;&gt;28860793:s</title>
<path fill="none" stroke="black" d="M1263.75,-959C1263.75,-1011.04 1221.71,-1152.79 1254.75,-1193 1483.11,-1470.94 2048.75,-990.28 2048.75,-1350"/>
</g>
<!-- 27538358&#45;&gt;28874129 -->
<g id="edge473" class="edge">
<title>27538358:n&#45;&gt;28874129:s</title>
<path fill="none" stroke="black" d="M1263.75,-959C1263.75,-1034.39 1326.75,-1041.11 1326.75,-1116.5"/>
</g>
<!-- 27538358&#45;&gt;28956288 -->
<g id="edge474" class="edge">
<title>27538358:n&#45;&gt;28956288:s</title>
<path fill="none" stroke="black" d="M1263.75,-959C1263.75,-1031.89 1219.35,-1039.79 1199.75,-1110 1189.72,-1145.9 1204.22,-1159.57 1187.75,-1193 1146.35,-1277.02 1040.75,-1250.34 1040.75,-1344"/>
</g>
<!-- 27538358&#45;&gt;29171208 -->
<g id="edge475" class="edge">
<title>27538358:n&#45;&gt;29171208:s</title>
<path fill="none" stroke="black" d="M1263.75,-959C1263.75,-985 1245.83,-1173.25 1262.75,-1193 1414.27,-1369.88 2297.75,-1125.1 2297.75,-1358"/>
</g>
<!-- 27538358&#45;&gt;29373602 -->
<g id="edge476" class="edge">
<title>27538358:n&#45;&gt;29373602:s</title>
<path fill="none" stroke="black" d="M1263.75,-959C1263.75,-985.01 1252.14,-1173.86 1269.75,-1193 1478.61,-1420.04 2649.75,-1035.5 2649.75,-1344"/>
</g>
<!-- 27538358&#45;&gt;29973392 -->
<g id="edge477" class="edge">
<title>27538358:n&#45;&gt;29973392:s</title>
<path fill="none" stroke="black" d="M1263.75,-959C1263.75,-1063.8 1201.66,-1093.56 1234.75,-1193 1261.21,-1272.53 1347.75,-1260.18 1347.75,-1344"/>
</g>
<!-- 27538358&#45;&gt;30383768 -->
<g id="edge478" class="edge">
<title>27538358:n&#45;&gt;30383768:s</title>
<path fill="none" stroke="black" d="M1263.75,-959C1263.75,-1112.35 1570.75,-963.15 1570.75,-1116.5"/>
</g>
<!-- 27538358&#45;&gt;32341789 -->
<g id="edge479" class="edge">
<title>27538358:n&#45;&gt;32341789:s</title>
<path fill="none" stroke="black" d="M1263.75,-959C1263.75,-995.93 1466.19,-1177.59 1499.75,-1193 1698.39,-1284.22 3460.75,-1131.41 3460.75,-1350"/>
</g>
<!-- 27538358&#45;&gt;32539675 -->
<g id="edge480" class="edge">
<title>27538358:n&#45;&gt;32539675:s</title>
<path fill="none" stroke="black" d="M1263.75,-959C1263.75,-1028.78 1235.33,-1041.76 1220.75,-1110 1212.96,-1146.45 1219.75,-1157.39 1208.75,-1193 1186.69,-1264.41 1151.63,-1271.19 1134.75,-1344 1127.92,-1373.44 1115.36,-1388.82 1134.75,-1412 1387.63,-1714.42 2007.75,-1174.78 2007.75,-1569"/>
</g>
<!-- 27538358&#45;&gt;32676543 -->
<g id="edge481" class="edge">
<title>27538358:n&#45;&gt;32676543:s</title>
<path fill="none" stroke="black" d="M1263.75,-959C1263.75,-1033.16 1216.53,-1039.76 1192.75,-1110 1180.64,-1145.75 1201.38,-1166.25 1174.75,-1193 956.04,-1412.72 687.79,-1102.22 493.75,-1344 474.83,-1367.57 482.41,-1383.99 493.75,-1412 544.57,-1537.57 597.02,-1550.19 705.75,-1631 828.19,-1722.01 1010.75,-1635.94 1010.75,-1788.5"/>
</g>
<!-- 27538358&#45;&gt;33093817 -->
<g id="edge482" class="edge">
<title>27538358:n&#45;&gt;33093817:s</title>
<path fill="none" stroke="black" d="M1263.75,-959C1263.75,-1027.99 1239.76,-1042.06 1227.75,-1110 1223.07,-1136.44 1199.75,-1323.15 1199.75,-1350"/>
</g>
<!-- 27538358&#45;&gt;33587284 -->
<g id="edge483" class="edge">
<title>27538358:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M1263.75,-959C1263.75,-1029.69 1229.98,-1041.19 1213.75,-1110 1205.19,-1146.28 1212.75,-1157.39 1201.75,-1193 1179.69,-1264.41 1144.63,-1271.19 1127.75,-1344 1104.82,-1442.87 1166.75,-1467.51 1166.75,-1569"/>
</g>
<!-- 27538358&#45;&gt;34173286 -->
<g id="edge484" class="edge">
<title>27538358:n&#45;&gt;34173286:s</title>
<path fill="none" stroke="black" d="M1263.75,-959C1263.75,-1037.59 1198.35,-1036.05 1171.75,-1110 1159.13,-1145.07 1185.1,-1165.68 1159.75,-1193 948.86,-1420.24 672.79,-1102.22 478.75,-1344 459.83,-1367.57 471.92,-1382.56 478.75,-1412 495.63,-1484.81 530.16,-1491.76 552.75,-1563 568.08,-1611.37 588.75,-1737.75 588.75,-1788.5"/>
</g>
<!-- 27538358&#45;&gt;34379219 -->
<g id="edge485" class="edge">
<title>27538358:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M1263.75,-959C1263.75,-1036.01 1203.57,-1037.1 1178.75,-1110 1166.73,-1145.28 1192.1,-1165.68 1166.75,-1193 955.86,-1420.24 679.79,-1102.22 485.75,-1344 466.83,-1367.57 477.95,-1382.8 485.75,-1412 492.99,-1439.12 592.57,-1610.49 611.75,-1631 739.54,-1767.69 785.58,-1801.93 961.75,-1865 1122.68,-1922.62 2492.75,-1845.06 2492.75,-2016"/>
</g>
<!-- 27538358&#45;&gt;34643934 -->
<g id="edge486" class="edge">
<title>27538358:n&#45;&gt;34643934:s</title>
<path fill="none" stroke="black" d="M1263.75,-959C1263.75,-1030.73 1224.65,-1040.54 1206.75,-1110 1197.44,-1146.09 1205.56,-1157.33 1194.75,-1193 1173.18,-1264.15 1140.64,-1271.83 1122.75,-1344 1099.31,-1438.55 1115.75,-1465.61 1113.75,-1563 1113.13,-1593.22 1094.02,-1608.11 1113.75,-1631 1268.49,-1810.56 2168.75,-1551.46 2168.75,-1788.5"/>
</g>
<!-- 27550177&#45;&gt;29171208 -->
<g id="edge487" class="edge">
<title>27550177:n&#45;&gt;29171208:s</title>
<path fill="none" stroke="black" d="M722.75,-953C722.75,-1060.04 630.87,-1113.69 702.75,-1193 942.04,-1457.04 2297.75,-1001.66 2297.75,-1358"/>
</g>
<!-- 27550177&#45;&gt;29371284 -->
<g id="edge488" class="edge">
<title>27550177:n&#45;&gt;29371284:s</title>
<path fill="none" stroke="black" d="M722.75,-953C722.75,-1065.87 565.29,-1108.18 639.75,-1193 810.66,-1387.69 1795.75,-1084.93 1795.75,-1344"/>
</g>
<!-- 27550177&#45;&gt;29373602 -->
<g id="edge489" class="edge">
<title>27550177:n&#45;&gt;29373602:s</title>
<path fill="none" stroke="black" d="M722.75,-953C722.75,-1059.7 655.34,-1115.56 728.75,-1193 876.04,-1348.38 2649.75,-1129.9 2649.75,-1344"/>
</g>
<!-- 27550177&#45;&gt;32415705 -->
<g id="edge490" class="edge">
<title>27550177:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M722.75,-953C722.75,-1046.2 642.69,-1037.81 583.75,-1110 542.59,-1160.4 428.36,-1282.29 407.75,-1344 375.88,-1439.39 464.75,-1462.42 464.75,-1563"/>
</g>
<!-- 27550177&#45;&gt;32676543 -->
<g id="edge491" class="edge">
<title>27550177:n&#45;&gt;32676543:s</title>
<path fill="none" stroke="black" d="M722.75,-953C722.75,-1068.82 588.21,-1020.46 514.75,-1110 441.49,-1199.29 429.56,-1231.91 401.75,-1344 378.29,-1438.53 395.52,-1465.62 393.75,-1563 393.19,-1593.22 375.21,-1607.13 393.75,-1631 567.36,-1854.5 1010.75,-1505.48 1010.75,-1788.5"/>
</g>
<!-- 27550177&#45;&gt;34379219 -->
<g id="edge492" class="edge">
<title>27550177:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M722.75,-953C722.75,-1106.25 533.82,-1012.3 415.75,-1110 233.39,-1260.89 185.17,-1331.53 135.75,-1563 128.74,-1595.82 112.79,-1840.53 135.75,-1865 315.28,-2056.4 2492.75,-1753.57 2492.75,-2016"/>
</g>
<!-- 27680880&#45;&gt;28860793 -->
<g id="edge493" class="edge">
<title>27680880:n&#45;&gt;28860793:s</title>
<path fill="none" stroke="black" d="M2321.75,-1186.5C2321.75,-1327.93 2048.75,-1208.57 2048.75,-1350"/>
</g>
<!-- 27680880&#45;&gt;28956288 -->
<g id="edge494" class="edge">
<title>27680880:n&#45;&gt;28956288:s</title>
<path fill="none" stroke="black" d="M2321.75,-1186.5C2321.75,-1473.31 1040.75,-1057.19 1040.75,-1344"/>
</g>
<!-- 27680880&#45;&gt;29171208 -->
<g id="edge495" class="edge">
<title>27680880:n&#45;&gt;29171208:s</title>
<path fill="none" stroke="black" d="M2321.75,-1186.5C2321.75,-1263.46 2297.75,-1281.04 2297.75,-1358"/>
</g>
<!-- 27680880&#45;&gt;29373602 -->
<g id="edge496" class="edge">
<title>27680880:n&#45;&gt;29373602:s</title>
<path fill="none" stroke="black" d="M2321.75,-1186.5C2321.75,-1348.21 2649.75,-1182.29 2649.75,-1344"/>
</g>
<!-- 27680880&#45;&gt;31022899 -->
<g id="edge497" class="edge">
<title>27680880:n&#45;&gt;31022899:s</title>
<path fill="none" stroke="black" d="M2321.75,-1186.5C2321.75,-1284.52 2173.75,-1251.98 2173.75,-1350"/>
</g>
<!-- 27680880&#45;&gt;32415705 -->
<g id="edge498" class="edge">
<title>27680880:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M2321.75,-1186.5C2321.75,-1211.61 2353.77,-1393.54 2336.75,-1412 2195.25,-1565.37 464.75,-1354.32 464.75,-1563"/>
</g>
<!-- 27680880&#45;&gt;32676543 -->
<g id="edge499" class="edge">
<title>27680880:n&#45;&gt;32676543:s</title>
<path fill="none" stroke="black" d="M2321.75,-1186.5C2321.75,-1257.68 2344.28,-1273.12 2350.75,-1344 2358.8,-1432.24 2334.76,-1629.94 2333.75,-1631 2128.73,-1844.61 1010.75,-1492.42 1010.75,-1788.5"/>
</g>
<!-- 27680880&#45;&gt;33093817 -->
<g id="edge500" class="edge">
<title>27680880:n&#45;&gt;33093817:s</title>
<path fill="none" stroke="black" d="M2321.75,-1186.5C2321.75,-1438.47 1199.75,-1098.03 1199.75,-1350"/>
</g>
<!-- 27680880&#45;&gt;33587284 -->
<g id="edge501" class="edge">
<title>27680880:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M2321.75,-1186.5C2321.75,-1236.85 2376.91,-1374.12 2343.75,-1412 2169.93,-1610.54 1166.75,-1305.13 1166.75,-1569"/>
</g>
<!-- 27680880&#45;&gt;33950207 -->
<g id="edge502" class="edge">
<title>27680880:n&#45;&gt;33950207:s</title>
<path fill="none" stroke="black" d="M2321.75,-1186.5C2321.75,-1264.61 2374.1,-1270.22 2399.75,-1344 2465.08,-1531.97 2492.75,-1582.99 2492.75,-1782"/>
</g>
<!-- 27680880&#45;&gt;34379219 -->
<g id="edge503" class="edge">
<title>27680880:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M2321.75,-1186.5C2321.75,-1259.3 2352.13,-1272.68 2366.75,-1344 2413.61,-1572.65 2374.52,-1638.97 2432.75,-1865 2450.76,-1934.93 2492.75,-1943.78 2492.75,-2016"/>
</g>
<!-- 27680880&#45;&gt;34643934 -->
<g id="edge504" class="edge">
<title>27680880:n&#45;&gt;34643934:s</title>
<path fill="none" stroke="black" d="M2321.75,-1186.5C2321.75,-1258.41 2350.47,-1272.57 2358.75,-1344 2373.43,-1470.71 2413,-1515.56 2358.75,-1631 2312.09,-1730.27 2168.75,-1678.81 2168.75,-1788.5"/>
</g>
<!-- 27742807&#45;&gt;27933569 -->
<g id="edge505" class="edge">
<title>27742807:n&#45;&gt;27933569:s</title>
<path fill="none" stroke="black" d="M1021.75,-959C1021.75,-1038.33 1105.75,-1037.17 1105.75,-1116.5"/>
</g>
<!-- 27742807&#45;&gt;28956288 -->
<g id="edge506" class="edge">
<title>27742807:n&#45;&gt;28956288:s</title>
<path fill="none" stroke="black" d="M1021.75,-959C1021.75,-1032.6 969.2,-1038.04 953.75,-1110 946,-1146.07 944.21,-1157.36 953.75,-1193 973.76,-1267.82 1040.75,-1266.55 1040.75,-1344"/>
</g>
<!-- 27742807&#45;&gt;29171208 -->
<g id="edge507" class="edge">
<title>27742807:n&#45;&gt;29171208:s</title>
<path fill="none" stroke="black" d="M1021.75,-959C1021.75,-1011.79 945.72,-1153.5 980.75,-1193 1176.45,-1413.68 2297.75,-1063.05 2297.75,-1358"/>
</g>
<!-- 27742807&#45;&gt;29373602 -->
<g id="edge508" class="edge">
<title>27742807:n&#45;&gt;29373602:s</title>
<path fill="none" stroke="black" d="M1021.75,-959C1021.75,-1011.04 994.97,-1155.21 1030.75,-1193 1279.19,-1455.38 2649.75,-982.66 2649.75,-1344"/>
</g>
<!-- 27742807&#45;&gt;29909576 -->
<g id="edge509" class="edge">
<title>27742807:n&#45;&gt;29909576:s</title>
<path fill="none" stroke="black" d="M1021.75,-959C1021.75,-1063.03 946,-1115.81 1015.75,-1193 1238.43,-1439.44 2502.75,-1011.86 2502.75,-1344"/>
</g>
<!-- 27742807&#45;&gt;32415705 -->
<g id="edge510" class="edge">
<title>27742807:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M1021.75,-959C1021.75,-1046.12 937.48,-1032.98 896.75,-1110 878.79,-1143.95 899.04,-1165.02 872.75,-1193 736.33,-1338.16 565.45,-1181.14 450.75,-1344 433.34,-1368.71 449.35,-1381.81 450.75,-1412 453.86,-1479.33 464.75,-1495.6 464.75,-1563"/>
</g>
<!-- 27742807&#45;&gt;32539675 -->
<g id="edge511" class="edge">
<title>27742807:n&#45;&gt;32539675:s</title>
<path fill="none" stroke="black" d="M1021.75,-959C1021.75,-1033.74 964.63,-1037.19 947.75,-1110 928.61,-1192.55 969.31,-1404.42 976.75,-1412 1139.02,-1577.46 2007.75,-1337.25 2007.75,-1569"/>
</g>
<!-- 27742807&#45;&gt;32676543 -->
<g id="edge512" class="edge">
<title>27742807:n&#45;&gt;32676543:s</title>
<path fill="none" stroke="black" d="M1021.75,-959C1021.75,-1038.05 961.5,-1038.51 927.75,-1110 911.13,-1145.21 926.95,-1165.15 899.75,-1193 762.61,-1333.42 597.33,-1183.23 484.75,-1344 467.41,-1368.76 478.32,-1382.47 484.75,-1412 500.44,-1484.1 526.11,-1494.59 553.75,-1563 565.75,-1592.72 555.19,-1608.23 577.75,-1631 721.85,-1776.49 1010.75,-1583.72 1010.75,-1788.5"/>
</g>
<!-- 27742807&#45;&gt;33093817 -->
<g id="edge513" class="edge">
<title>27742807:n&#45;&gt;33093817:s</title>
<path fill="none" stroke="black" d="M1021.75,-959C1021.75,-1031.38 974.56,-1038.95 960.75,-1110 953.71,-1146.21 943.23,-1160.54 960.75,-1193 1021.1,-1304.85 1199.75,-1222.91 1199.75,-1350"/>
</g>
<!-- 27742807&#45;&gt;33587284 -->
<g id="edge514" class="edge">
<title>27742807:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M1021.75,-959C1021.75,-1036.9 953.25,-1034.84 932.75,-1110 911.06,-1189.51 954.91,-1395.12 964.75,-1412 1021.99,-1510.24 1166.75,-1455.29 1166.75,-1569"/>
</g>
<!-- 27742807&#45;&gt;34379219 -->
<g id="edge515" class="edge">
<title>27742807:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M1021.75,-959C1021.75,-1043.9 940.63,-1033.06 904.75,-1110 888.79,-1144.21 911.53,-1164.53 886.75,-1193 758.99,-1339.8 587.13,-1184.42 475.75,-1344 430.9,-1408.26 542.01,-1546.07 545.75,-1563 574.71,-1694.33 435.36,-1766.33 526.75,-1865 675.62,-2025.74 2492.75,-1796.91 2492.75,-2016"/>
</g>
<!-- 27889397&#45;&gt;28956288 -->
<g id="edge516" class="edge">
<title>27889397:n&#45;&gt;28956288:s</title>
<path fill="none" stroke="black" d="M1444.75,-959C1444.75,-1028.66 1419.08,-1042.28 1402.75,-1110 1393.92,-1146.61 1409.43,-1163.72 1385.75,-1193 1280.48,-1323.13 1040.75,-1176.62 1040.75,-1344"/>
</g>
<!-- 27889397&#45;&gt;29909576 -->
<g id="edge517" class="edge">
<title>27889397:n&#45;&gt;29909576:s</title>
<path fill="none" stroke="black" d="M1444.75,-959C1444.75,-985.4 1466.84,-1174.58 1485.75,-1193 1649.4,-1352.44 2502.75,-1115.52 2502.75,-1344"/>
</g>
<!-- 27889397&#45;&gt;31022899 -->
<g id="edge518" class="edge">
<title>27889397:n&#45;&gt;31022899:s</title>
<path fill="none" stroke="black" d="M1444.75,-959C1444.75,-985.09 1447.56,-1173.37 1464.75,-1193 1677.33,-1435.84 2173.75,-1027.26 2173.75,-1350"/>
</g>
<!-- 27889397&#45;&gt;32415705 -->
<g id="edge519" class="edge">
<title>27889397:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M1444.75,-959C1444.75,-964.1 1166.32,-1190.75 1161.75,-1193 888.55,-1327.2 699,-1119.24 493.75,-1344 427.54,-1416.5 464.75,-1464.82 464.75,-1563"/>
</g>
<!-- 27889397&#45;&gt;32676543 -->
<g id="edge520" class="edge">
<title>27889397:n&#45;&gt;32676543:s</title>
<path fill="none" stroke="black" d="M1444.75,-959C1444.75,-1063 1409.68,-1094.74 1443.75,-1193 1480.03,-1297.66 1607.04,-1310.47 1562.75,-1412 1505.53,-1543.15 1444.42,-1549.59 1326.75,-1631 1197.7,-1720.28 1010.75,-1631.58 1010.75,-1788.5"/>
</g>
<!-- 27889397&#45;&gt;33093817 -->
<g id="edge521" class="edge">
<title>27889397:n&#45;&gt;33093817:s</title>
<path fill="none" stroke="black" d="M1444.75,-959C1444.75,-1027.89 1422.46,-1042.29 1409.75,-1110 1402.87,-1146.63 1416.33,-1160.69 1397.75,-1193 1341.75,-1290.35 1199.75,-1237.69 1199.75,-1350"/>
</g>
<!-- 27889397&#45;&gt;33587284 -->
<g id="edge522" class="edge">
<title>27889397:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M1444.75,-959C1444.75,-1011.72 1427.36,-1144.92 1405.75,-1193 1370.38,-1271.7 1322.23,-1266.78 1283.75,-1344 1269.85,-1371.88 1279.05,-1383.38 1266.75,-1412 1234.07,-1488 1166.75,-1486.27 1166.75,-1569"/>
</g>
<!-- 27889397&#45;&gt;33950207 -->
<g id="edge523" class="edge">
<title>27889397:n&#45;&gt;33950207:s</title>
<path fill="none" stroke="black" d="M1444.75,-959C1444.75,-1011.02 1434.07,-1144.07 1451.75,-1193 1480.68,-1273.11 1521.83,-1273.59 1569.75,-1344 1589.47,-1372.99 1586.51,-1385.74 1609.75,-1412 1715.85,-1531.88 1751.63,-1561.27 1895.75,-1631 2142.12,-1750.2 2492.75,-1508.31 2492.75,-1782"/>
</g>
<!-- 27933569&#45;&gt;28956288 -->
<g id="edge524" class="edge">
<title>27933569:n&#45;&gt;28956288:s</title>
<path fill="none" stroke="black" d="M1105.75,-1186.5C1105.75,-1262.23 1040.75,-1268.27 1040.75,-1344"/>
</g>
<!-- 28188243&#45;&gt;29171208 -->
<g id="edge525" class="edge">
<title>28188243:n&#45;&gt;29171208:s</title>
<path fill="none" stroke="black" d="M2606.75,-1186.5C2606.75,-1343.57 2297.75,-1200.93 2297.75,-1358"/>
</g>
<!-- 28188243&#45;&gt;29373602 -->
<g id="edge526" class="edge">
<title>28188243:n&#45;&gt;29373602:s</title>
<path fill="none" stroke="black" d="M2606.75,-1186.5C2606.75,-1259.06 2649.75,-1271.44 2649.75,-1344"/>
</g>
<!-- 28188243&#45;&gt;29909576 -->
<g id="edge527" class="edge">
<title>28188243:n&#45;&gt;29909576:s</title>
<path fill="none" stroke="black" d="M2606.75,-1186.5C2606.75,-1270.38 2502.75,-1260.12 2502.75,-1344"/>
</g>
<!-- 28188243&#45;&gt;29973392 -->
<g id="edge528" class="edge">
<title>28188243:n&#45;&gt;29973392:s</title>
<path fill="none" stroke="black" d="M2606.75,-1186.5C2606.75,-1468.46 1347.75,-1062.04 1347.75,-1344"/>
</g>
<!-- 28188243&#45;&gt;31022899 -->
<g id="edge529" class="edge">
<title>28188243:n&#45;&gt;31022899:s</title>
<path fill="none" stroke="black" d="M2606.75,-1186.5C2606.75,-1392.21 2173.75,-1144.29 2173.75,-1350"/>
</g>
<!-- 28188243&#45;&gt;31390972 -->
<g id="edge530" class="edge">
<title>28188243:n&#45;&gt;31390972:s</title>
<path fill="none" stroke="black" d="M2606.75,-1186.5C2606.75,-1292.13 2741.36,-1247.69 2784.75,-1344 2810.94,-1402.15 2792.79,-1567.73 2784.75,-1631 2776.01,-1699.76 2745.75,-1712.69 2745.75,-1782"/>
</g>
<!-- 28188243&#45;&gt;32341789 -->
<g id="edge531" class="edge">
<title>28188243:n&#45;&gt;32341789:s</title>
<path fill="none" stroke="black" d="M2606.75,-1186.5C2606.75,-1572.95 3460.75,-963.55 3460.75,-1350"/>
</g>
<!-- 28188243&#45;&gt;32415705 -->
<g id="edge532" class="edge">
<title>28188243:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M2606.75,-1186.5C2606.75,-1298.01 2792.91,-1330.56 2716.75,-1412 2545.45,-1595.17 464.75,-1312.22 464.75,-1563"/>
</g>
<!-- 28188243&#45;&gt;32539675 -->
<g id="edge533" class="edge">
<title>28188243:n&#45;&gt;32539675:s</title>
<path fill="none" stroke="black" d="M2606.75,-1186.5C2606.75,-1281.05 2715.68,-1255.8 2749.75,-1344 2760.64,-1372.19 2768.78,-1388.52 2749.75,-1412 2537.49,-1673.86 2007.75,-1231.92 2007.75,-1569"/>
</g>
<!-- 28188243&#45;&gt;33253294 -->
<g id="edge534" class="edge">
<title>28188243:n&#45;&gt;33253294:s</title>
<path fill="none" stroke="black" d="M2606.75,-1186.5C2606.75,-1302.1 2729.09,-1265.28 2813.75,-1344 2843.26,-1371.45 2841.9,-1387.3 2873.75,-1412 2995.16,-1506.16 3181.75,-1415.35 3181.75,-1569"/>
</g>
<!-- 28188243&#45;&gt;34379219 -->
<g id="edge535" class="edge">
<title>28188243:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M2606.75,-1186.5C2606.75,-1281.35 2716.42,-1255.58 2750.75,-1344 2761.68,-1372.17 2756.71,-1382.37 2750.75,-1412 2707.68,-1626.04 2647.8,-1664.78 2560.75,-1865 2531.4,-1932.5 2492.75,-1942.4 2492.75,-2016"/>
</g>
<!-- 28188243&#45;&gt;34643934 -->
<g id="edge536" class="edge">
<title>28188243:n&#45;&gt;34643934:s</title>
<path fill="none" stroke="black" d="M2606.75,-1186.5C2606.75,-1283.17 2720.85,-1254.25 2756.75,-1344 2767.97,-1372.06 2770.01,-1384.84 2756.75,-1412 2687.25,-1554.27 2609.22,-1545.82 2475.75,-1631 2346.48,-1713.5 2168.75,-1635.15 2168.75,-1788.5"/>
</g>
<!-- 28188243&#45;&gt;34722686 -->
<g id="edge537" class="edge">
<title>28188243:n&#45;&gt;34722686:s</title>
<path fill="none" stroke="black" d="M2606.75,-1186.5C2606.75,-1295.16 2743.85,-1247.47 2793.75,-1344 2823.14,-1400.85 2776.95,-1581.69 2817.75,-1631 2991.27,-1840.75 3407.75,-1523.28 3407.75,-1795.5"/>
</g>
<!-- 28300870&#45;&gt;29360144 -->
<g id="edge538" class="edge">
<title>28300870:n&#45;&gt;29360144:s</title>
<path fill="none" stroke="black" d="M3257.75,-1186.5C3257.75,-1584.49 1473.75,-946.01 1473.75,-1344"/>
</g>
<!-- 28300870&#45;&gt;29371284 -->
<g id="edge539" class="edge">
<title>28300870:n&#45;&gt;29371284:s</title>
<path fill="none" stroke="black" d="M3257.75,-1186.5C3257.75,-1513.27 1795.75,-1017.23 1795.75,-1344"/>
</g>
<!-- 28300870&#45;&gt;29373602 -->
<g id="edge540" class="edge">
<title>28300870:n&#45;&gt;29373602:s</title>
<path fill="none" stroke="black" d="M3257.75,-1186.5C3257.75,-1465.64 2649.75,-1064.86 2649.75,-1344"/>
</g>
<!-- 28300870&#45;&gt;29909576 -->
<g id="edge541" class="edge">
<title>28300870:n&#45;&gt;29909576:s</title>
<path fill="none" stroke="black" d="M3257.75,-1186.5C3257.75,-1529.28 2502.75,-1001.22 2502.75,-1344"/>
</g>
<!-- 28300870&#45;&gt;29973392 -->
<g id="edge542" class="edge">
<title>28300870:n&#45;&gt;29973392:s</title>
<path fill="none" stroke="black" d="M3257.75,-1186.5C3257.75,-1612.39 1347.75,-918.11 1347.75,-1344"/>
</g>
<!-- 28300870&#45;&gt;30571400 -->
<g id="edge543" class="edge">
<title>28300870:n&#45;&gt;30571400:s</title>
<path fill="none" stroke="black" d="M3257.75,-1186.5C3257.75,-1300.69 3054.75,-1229.81 3054.75,-1344"/>
</g>
<!-- 28300870&#45;&gt;30924051 -->
<g id="edge544" class="edge">
<title>28300870:n&#45;&gt;30924051:s</title>
<path fill="none" stroke="black" d="M3257.75,-1186.5C3257.75,-1344.62 2938.75,-1185.88 2938.75,-1344"/>
</g>
<!-- 28300870&#45;&gt;31022899 -->
<g id="edge545" class="edge">
<title>28300870:n&#45;&gt;31022899:s</title>
<path fill="none" stroke="black" d="M3257.75,-1186.5C3257.75,-1430.11 2173.75,-1106.39 2173.75,-1350"/>
</g>
<!-- 28300870&#45;&gt;31112292 -->
<g id="edge546" class="edge">
<title>28300870:n&#45;&gt;31112292:s</title>
<path fill="none" stroke="black" d="M3257.75,-1186.5C3257.75,-1236.72 3301.24,-1370.64 3272.75,-1412 3165.88,-1567.11 2876.75,-1374.64 2876.75,-1563"/>
</g>
<!-- 28300870&#45;&gt;31195999 -->
<g id="edge547" class="edge">
<title>28300870:n&#45;&gt;31195999:s</title>
<path fill="none" stroke="black" d="M3257.75,-1186.5C3257.75,-1347.01 3582.75,-1183.49 3582.75,-1344"/>
</g>
<!-- 28300870&#45;&gt;32341789 -->
<g id="edge548" class="edge">
<title>28300870:n&#45;&gt;32341789:s</title>
<path fill="none" stroke="black" d="M3257.75,-1186.5C3257.75,-1302.35 3460.75,-1234.15 3460.75,-1350"/>
</g>
<!-- 28300870&#45;&gt;32676543 -->
<g id="edge549" class="edge">
<title>28300870:n&#45;&gt;32676543:s</title>
<path fill="none" stroke="black" d="M3257.75,-1186.5C3257.75,-1236.85 3305.04,-1368.47 3279.75,-1412 3211.64,-1529.2 3126.69,-1486.55 3014.75,-1563 2975.08,-1590.09 2975.33,-1613.13 2930.75,-1631 2732.06,-1710.63 1010.75,-1574.45 1010.75,-1788.5"/>
</g>
<!-- 28300870&#45;&gt;33587284 -->
<g id="edge550" class="edge">
<title>28300870:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M3257.75,-1186.5C3257.75,-1211.57 3282.8,-1393.62 3265.75,-1412 3106.66,-1583.43 1166.75,-1335.13 1166.75,-1569"/>
</g>
<!-- 28300870&#45;&gt;33950207 -->
<g id="edge551" class="edge">
<title>28300870:n&#45;&gt;33950207:s</title>
<path fill="none" stroke="black" d="M3257.75,-1186.5C3257.75,-1287.61 3331.48,-1320.84 3287.75,-1412 3254.1,-1482.12 3083.77,-1595.17 3014.75,-1631 2800.4,-1742.27 2492.75,-1540.49 2492.75,-1782"/>
</g>
<!-- 28300870&#45;&gt;34379219 -->
<g id="edge552" class="edge">
<title>28300870:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M3257.75,-1186.5C3257.75,-1258.61 3288.02,-1272.42 3296.75,-1344 3300.41,-1374 3301.2,-1382.11 3296.75,-1412 3286.41,-1481.39 3269.48,-1495.39 3250.75,-1563 3242.43,-1593.02 3248.19,-1603.4 3233.75,-1631 3169.63,-1753.5 3145.67,-1791.21 3028.75,-1865 2819.45,-1997.09 2492.75,-1768.51 2492.75,-2016"/>
</g>
<!-- 28300870&#45;&gt;34398204 -->
<g id="edge553" class="edge">
<title>28300870:n&#45;&gt;34398204:s</title>
<path fill="none" stroke="black" d="M3257.75,-1186.5C3257.75,-1262.06 3307.26,-1269.84 3321.75,-1344 3340.48,-1439.85 3303.75,-1465.34 3303.75,-1563"/>
</g>
<!-- 28408716&#45;&gt;33587284 -->
<g id="edge554" class="edge">
<title>28408716:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M1802.75,-1193C1802.75,-1292.74 1913.9,-1333.99 1851.75,-1412 1657.12,-1656.28 1166.75,-1256.66 1166.75,-1569"/>
</g>
<!-- 28408716&#45;&gt;33950207 -->
<g id="edge555" class="edge">
<title>28408716:n&#45;&gt;33950207:s</title>
<path fill="none" stroke="black" d="M1802.75,-1193C1802.75,-1266.97 1849.71,-1273.71 1872.75,-1344 1893.01,-1405.83 1886.21,-1583.56 1930.75,-1631 2107.77,-1819.56 2492.75,-1523.36 2492.75,-1782"/>
</g>
<!-- 28408716&#45;&gt;34643934 -->
<g id="edge556" class="edge">
<title>28408716:n&#45;&gt;34643934:s</title>
<path fill="none" stroke="black" d="M1802.75,-1193C1802.75,-1265.38 1843.52,-1274.5 1863.75,-1344 1900,-1468.54 1843.78,-1523.75 1916.75,-1631 1991.04,-1740.2 2168.75,-1656.42 2168.75,-1788.5"/>
</g>
<!-- 28614582&#45;&gt;29654196 -->
<g id="edge557" class="edge">
<title>28614582:n&#45;&gt;29654196:s</title>
<path fill="none" stroke="black" d="M3001.75,-1186.5C3001.75,-1484.72 1669.75,-1051.78 1669.75,-1350"/>
</g>
<!-- 28614582&#45;&gt;29973392 -->
<g id="edge558" class="edge">
<title>28614582:n&#45;&gt;29973392:s</title>
<path fill="none" stroke="black" d="M3001.75,-1186.5C3001.75,-1555.72 1347.75,-974.78 1347.75,-1344"/>
</g>
<!-- 28614582&#45;&gt;30299591 -->
<g id="edge559" class="edge">
<title>28614582:n&#45;&gt;30299591:s</title>
<path fill="none" stroke="black" d="M3001.75,-1186.5C3001.75,-1293.47 3183.75,-1237.03 3183.75,-1344"/>
</g>
<!-- 28655814&#45;&gt;31390972 -->
<g id="edge560" class="edge">
<title>28655814:n&#45;&gt;31390972:s</title>
<path fill="none" stroke="black" d="M3842.75,-1179.5C3842.75,-1381.93 3924.99,-1486.97 3782.75,-1631 3619.11,-1796.69 2745.75,-1549.13 2745.75,-1782"/>
</g>
<!-- 28655814&#45;&gt;32341789 -->
<g id="edge561" class="edge">
<title>28655814:n&#45;&gt;32341789:s</title>
<path fill="none" stroke="black" d="M3842.75,-1179.5C3842.75,-1365.42 3460.75,-1164.08 3460.75,-1350"/>
</g>
<!-- 28655814&#45;&gt;34379219 -->
<g id="edge562" class="edge">
<title>28655814:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M3842.75,-1179.5C3842.75,-1283.25 3898.46,-1314.22 3863.75,-1412 3776.97,-1656.45 3720.98,-1736.34 3495.75,-1865 3300.03,-1976.8 2492.75,-1790.6 2492.75,-2016"/>
</g>
<!-- 28668628&#45;&gt;31022899 -->
<g id="edge563" class="edge">
<title>28668628:n&#45;&gt;31022899:s</title>
<path fill="none" stroke="black" d="M2163.75,-1179.5C2163.75,-1255.41 2173.75,-1274.09 2173.75,-1350"/>
</g>
<!-- 28668628&#45;&gt;33657116 -->
<g id="edge564" class="edge">
<title>28668628:n&#45;&gt;33657116:s</title>
<path fill="none" stroke="black" d="M2163.75,-1179.5C2163.75,-1258.78 2210.39,-1267.94 2232.75,-1344 2241.4,-1373.44 2238.61,-1381.93 2244.75,-1412 2258.52,-1479.5 2279.75,-1494.11 2279.75,-1563"/>
</g>
<!-- 28860793&#45;&gt;33657116 -->
<g id="edge565" class="edge">
<title>28860793:n&#45;&gt;33657116:s</title>
<path fill="none" stroke="black" d="M2048.75,-1406C2048.75,-1530.13 2279.75,-1438.87 2279.75,-1563"/>
</g>
<!-- 28874129&#45;&gt;30924051 -->
<g id="edge566" class="edge">
<title>28874129:n&#45;&gt;30924051:s</title>
<path fill="none" stroke="black" d="M1326.75,-1186.5C1326.75,-1546.43 2938.75,-984.07 2938.75,-1344"/>
</g>
<!-- 28874129&#45;&gt;31022899 -->
<g id="edge567" class="edge">
<title>28874129:n&#45;&gt;31022899:s</title>
<path fill="none" stroke="black" d="M1326.75,-1186.5C1326.75,-1569.89 2173.75,-966.61 2173.75,-1350"/>
</g>
<!-- 28874129&#45;&gt;32676543 -->
<g id="edge568" class="edge">
<title>28874129:n&#45;&gt;32676543:s</title>
<path fill="none" stroke="black" d="M1326.75,-1186.5C1326.75,-1560.66 738.29,-1055.74 499.75,-1344 490.11,-1355.64 492.93,-1398.51 499.75,-1412 626.98,-1663.78 1010.75,-1506.4 1010.75,-1788.5"/>
</g>
<!-- 28874129&#45;&gt;33587284 -->
<g id="edge569" class="edge">
<title>28874129:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M1326.75,-1186.5C1326.75,-1297.56 1180.5,-1243.73 1132.75,-1344 1110.85,-1389.98 1166.75,-1533.65 1166.75,-1569"/>
</g>
<!-- 29360144&#45;&gt;29360144 -->
<g id="edge570" class="edge">
<title>29360144:n&#45;&gt;29360144:s</title>
<path fill="none" stroke="black" d="M1473.75,-1412C1498.75,-1466.5 1548.75,-1466.5 1548.75,-1378 1548.75,-1289.5 1498.75,-1289.5 1473.75,-1344"/>
</g>
<!-- 29373602&#45;&gt;33587284 -->
<g id="edge571" class="edge">
<title>29373602:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M2649.75,-1412C2649.75,-1743.4 1166.75,-1237.6 1166.75,-1569"/>
</g>
<!-- 29373602&#45;&gt;33950207 -->
<g id="edge572" class="edge">
<title>29373602:n&#45;&gt;33950207:s</title>
<path fill="none" stroke="black" d="M2649.75,-1412C2649.75,-1590.64 2492.75,-1603.36 2492.75,-1782"/>
</g>
<!-- 29525786&#45;&gt;33587284 -->
<g id="edge573" class="edge">
<title>29525786:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M794.75,-1186.5C794.75,-1301.74 843.55,-1328.28 922.75,-1412 1011.37,-1505.68 1166.75,-1440.05 1166.75,-1569"/>
</g>
<!-- 29622587&#45;&gt;30423205 -->
<g id="edge574" class="edge">
<title>29622587:n&#45;&gt;30423205:s</title>
<path fill="none" stroke="black" d="M2799.75,-1179.5C2799.75,-1289.22 2804.43,-1346.04 2716.75,-1412 2500.12,-1574.95 281.75,-1291.92 281.75,-1563"/>
</g>
<!-- 29622587&#45;&gt;31390972 -->
<g id="edge575" class="edge">
<title>29622587:n&#45;&gt;31390972:s</title>
<path fill="none" stroke="black" d="M2799.75,-1179.5C2799.75,-1255.66 2830.44,-1269.83 2847.75,-1344 2854.72,-1373.89 2850.08,-1382.87 2859.75,-1412 2883.41,-1483.31 2918.39,-1489.9 2935.75,-1563 2942.73,-1592.4 2948.88,-1603.78 2935.75,-1631 2888.86,-1728.14 2745.75,-1674.14 2745.75,-1782"/>
</g>
<!-- 29622587&#45;&gt;33253294 -->
<g id="edge576" class="edge">
<title>29622587:n&#45;&gt;33253294:s</title>
<path fill="none" stroke="black" d="M2799.75,-1179.5C2799.75,-1258.78 2846.39,-1267.94 2868.75,-1344 2877.4,-1373.44 2862.61,-1387.24 2880.75,-1412 2969.92,-1533.71 3181.75,-1418.12 3181.75,-1569"/>
</g>
<!-- 29622587&#45;&gt;33950207 -->
<g id="edge577" class="edge">
<title>29622587:n&#45;&gt;33950207:s</title>
<path fill="none" stroke="black" d="M2799.75,-1179.5C2799.75,-1254.85 2825.08,-1270.3 2840.75,-1344 2847.13,-1374.02 2843.08,-1382.87 2852.75,-1412 2876.41,-1483.31 2911.39,-1489.9 2928.75,-1563 2935.73,-1592.4 2946.27,-1606.38 2928.75,-1631 2809.81,-1798.06 2492.75,-1576.93 2492.75,-1782"/>
</g>
<!-- 29622587&#45;&gt;34379219 -->
<g id="edge578" class="edge">
<title>29622587:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M2799.75,-1179.5C2799.75,-1256.59 2834.72,-1269.56 2854.75,-1344 2862.76,-1373.8 2858.84,-1382.78 2868.75,-1412 2892.67,-1482.6 2925.1,-1490.34 2941.75,-1563 2948.49,-1592.46 2949.56,-1601.81 2941.75,-1631 2910.69,-1746.98 2894.77,-1783.34 2806.75,-1865 2693.22,-1970.31 2492.75,-1861.15 2492.75,-2016"/>
</g>
<!-- 29654196&#45;&gt;30423205 -->
<g id="edge579" class="edge">
<title>29654196:n&#45;&gt;30423205:s</title>
<path fill="none" stroke="black" d="M1669.75,-1406C1669.75,-1716.41 281.75,-1252.59 281.75,-1563"/>
</g>
<!-- 29654196&#45;&gt;31390972 -->
<g id="edge580" class="edge">
<title>29654196:n&#45;&gt;31390972:s</title>
<path fill="none" stroke="black" d="M1669.75,-1406C1669.75,-1529.4 1818.8,-1469 1898.75,-1563 1920.39,-1588.44 1904.3,-1610.6 1930.75,-1631 2076.59,-1743.51 2745.75,-1597.81 2745.75,-1782"/>
</g>
<!-- 29654196&#45;&gt;34280330 -->
<g id="edge581" class="edge">
<title>29654196:n&#45;&gt;34280330:s</title>
<path fill="none" stroke="black" d="M1669.75,-1406C1669.75,-1635.51 2159.75,-1339.49 2159.75,-1569"/>
</g>
<!-- 29663521&#45;&gt;33587284 -->
<g id="edge582" class="edge">
<title>29663521:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M563.75,-1412C563.75,-1688.93 1166.75,-1292.07 1166.75,-1569"/>
</g>
<!-- 29909576&#45;&gt;34643934 -->
<g id="edge583" class="edge">
<title>29909576:n&#45;&gt;34643934:s</title>
<path fill="none" stroke="black" d="M2502.75,-1412C2502.75,-1515.78 2487.33,-1550.57 2421.75,-1631 2338.04,-1733.65 2168.75,-1656.05 2168.75,-1788.5"/>
</g>
<!-- 29973392&#45;&gt;32415705 -->
<g id="edge584" class="edge">
<title>29973392:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M1347.75,-1412C1347.75,-1810.14 464.75,-1164.86 464.75,-1563"/>
</g>
<!-- 29973392&#45;&gt;32539675 -->
<g id="edge585" class="edge">
<title>29973392:n&#45;&gt;32539675:s</title>
<path fill="none" stroke="black" d="M1347.75,-1412C1347.75,-1713.52 2007.75,-1267.48 2007.75,-1569"/>
</g>
<!-- 29973392&#45;&gt;32676543 -->
<g id="edge586" class="edge">
<title>29973392:n&#45;&gt;32676543:s</title>
<path fill="none" stroke="black" d="M1347.75,-1412C1347.75,-1511.02 1365.36,-1551.19 1306.75,-1631 1218.54,-1751.11 1010.75,-1639.48 1010.75,-1788.5"/>
</g>
<!-- 29973392&#45;&gt;33587284 -->
<g id="edge587" class="edge">
<title>29973392:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M1347.75,-1412C1347.75,-1518.49 1166.75,-1462.51 1166.75,-1569"/>
</g>
<!-- 29973392&#45;&gt;33950207 -->
<g id="edge588" class="edge">
<title>29973392:n&#45;&gt;33950207:s</title>
<path fill="none" stroke="black" d="M1347.75,-1412C1347.75,-1414.37 1606.6,-1630.01 1608.75,-1631 1789.59,-1714.74 2492.75,-1582.71 2492.75,-1782"/>
</g>
<!-- 29973392&#45;&gt;34173286 -->
<g id="edge589" class="edge">
<title>29973392:n&#45;&gt;34173286:s</title>
<path fill="none" stroke="black" d="M1347.75,-1412C1347.75,-1424.63 1295.9,-1622.29 1286.75,-1631 1056.35,-1850.22 588.75,-1470.48 588.75,-1788.5"/>
</g>
<!-- 29973392&#45;&gt;34643934 -->
<g id="edge590" class="edge">
<title>29973392:n&#45;&gt;34643934:s</title>
<path fill="none" stroke="black" d="M1347.75,-1412C1347.75,-1558.71 1465.75,-1561.1 1594.75,-1631 1827.33,-1757.04 2168.75,-1523.96 2168.75,-1788.5"/>
</g>
<!-- 30020424&#45;&gt;33587284 -->
<g id="edge591" class="edge">
<title>30020424:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M688.75,-1412C688.75,-1635.61 1166.75,-1345.39 1166.75,-1569"/>
</g>
<!-- 30299591&#45;&gt;30299591 -->
<g id="edge592" class="edge">
<title>30299591:n&#45;&gt;30299591:s</title>
<path fill="none" stroke="black" d="M3183.75,-1412C3206.41,-1466.5 3251.75,-1466.5 3251.75,-1378 3251.75,-1289.5 3206.41,-1289.5 3183.75,-1344"/>
</g>
<!-- 30383768&#45;&gt;33657116 -->
<g id="edge593" class="edge">
<title>30383768:n&#45;&gt;33657116:s</title>
<path fill="none" stroke="black" d="M1570.75,-1186.5C1570.75,-1285.97 1683.6,-1255.88 1729.75,-1344 1743.98,-1371.19 1721.15,-1389.25 1741.75,-1412 1908.46,-1596.08 2279.75,-1314.65 2279.75,-1563"/>
</g>
<!-- 30383768&#45;&gt;34173286 -->
<g id="edge594" class="edge">
<title>30383768:n&#45;&gt;34173286:s</title>
<path fill="none" stroke="black" d="M1570.75,-1186.5C1570.75,-1327.35 1381.15,-1232 1295.75,-1344 1293.25,-1347.27 1224.67,-1628.1 1221.75,-1631 1015.88,-1835.13 588.75,-1498.59 588.75,-1788.5"/>
</g>
<!-- 30423205&#45;&gt;30423205 -->
<g id="edge595" class="edge">
<title>30423205:n&#45;&gt;30423205:s</title>
<path fill="none" stroke="black" d="M281.75,-1631C303.58,-1685.5 347.25,-1685.5 347.25,-1597 347.25,-1508.5 303.58,-1508.5 281.75,-1563"/>
</g>
<!-- 30423205&#45;&gt;31390972 -->
<g id="edge596" class="edge">
<title>30423205:n&#45;&gt;31390972:s</title>
<path fill="none" stroke="black" d="M281.75,-1631C281.75,-1905.29 2745.75,-1507.71 2745.75,-1782"/>
</g>
<!-- 30423205&#45;&gt;32676543 -->
<g id="edge597" class="edge">
<title>30423205:n&#45;&gt;32676543:s</title>
<path fill="none" stroke="black" d="M281.75,-1631C281.75,-1962.48 1010.75,-1457.02 1010.75,-1788.5"/>
</g>
<!-- 30423205&#45;&gt;34173286 -->
<g id="edge598" class="edge">
<title>30423205:n&#45;&gt;34173286:s</title>
<path fill="none" stroke="black" d="M281.75,-1631C281.75,-1784.35 588.75,-1635.15 588.75,-1788.5"/>
</g>
<!-- 30423205&#45;&gt;34643934 -->
<g id="edge599" class="edge">
<title>30423205:n&#45;&gt;34643934:s</title>
<path fill="none" stroke="black" d="M281.75,-1631C281.75,-2051.79 2168.75,-1367.71 2168.75,-1788.5"/>
</g>
<!-- 30571400&#45;&gt;31112292 -->
<g id="edge600" class="edge">
<title>30571400:n&#45;&gt;31112292:s</title>
<path fill="none" stroke="black" d="M3054.75,-1412C3054.75,-1515.74 2876.75,-1459.26 2876.75,-1563"/>
</g>
<!-- 30571400&#45;&gt;32539675 -->
<g id="edge601" class="edge">
<title>30571400:n&#45;&gt;32539675:s</title>
<path fill="none" stroke="black" d="M3054.75,-1412C3054.75,-1647.27 2007.75,-1333.73 2007.75,-1569"/>
</g>
<!-- 30571400&#45;&gt;33253294 -->
<g id="edge602" class="edge">
<title>30571400:n&#45;&gt;33253294:s</title>
<path fill="none" stroke="black" d="M3054.75,-1412C3054.75,-1501.75 3181.75,-1479.25 3181.75,-1569"/>
</g>
<!-- 30571400&#45;&gt;33587284 -->
<g id="edge603" class="edge">
<title>30571400:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M3054.75,-1412C3054.75,-1833 1166.75,-1148 1166.75,-1569"/>
</g>
<!-- 30571400&#45;&gt;33950207 -->
<g id="edge604" class="edge">
<title>30571400:n&#45;&gt;33950207:s</title>
<path fill="none" stroke="black" d="M3054.75,-1412C3054.75,-1513.92 3058.97,-1559.09 2986.75,-1631 2824.05,-1792.98 2492.75,-1552.42 2492.75,-1782"/>
</g>
<!-- 30571400&#45;&gt;34280330 -->
<g id="edge605" class="edge">
<title>30571400:n&#45;&gt;34280330:s</title>
<path fill="none" stroke="black" d="M3054.75,-1412C3054.75,-1815.85 2159.75,-1165.15 2159.75,-1569"/>
</g>
<!-- 30571400&#45;&gt;34398204 -->
<g id="edge606" class="edge">
<title>30571400:n&#45;&gt;34398204:s</title>
<path fill="none" stroke="black" d="M3054.75,-1412C3054.75,-1541.43 3303.75,-1433.57 3303.75,-1563"/>
</g>
<!-- 30571400&#45;&gt;34643934 -->
<g id="edge607" class="edge">
<title>30571400:n&#45;&gt;34643934:s</title>
<path fill="none" stroke="black" d="M3054.75,-1412C3054.75,-1467.93 2975.95,-1598.06 2930.75,-1631 2651.25,-1834.66 2168.75,-1442.67 2168.75,-1788.5"/>
</g>
<!-- 30571400&#45;&gt;34722686 -->
<g id="edge608" class="edge">
<title>30571400:n&#45;&gt;34722686:s</title>
<path fill="none" stroke="black" d="M3054.75,-1412C3054.75,-1515.4 3177.28,-1475.1 3231.75,-1563 3248.16,-1589.48 3233.63,-1603.76 3248.75,-1631 3298.09,-1719.91 3407.75,-1693.82 3407.75,-1795.5"/>
</g>
<!-- 30597611&#45;&gt;33587284 -->
<g id="edge609" class="edge">
<title>30597611:n&#45;&gt;33587284:s</title>
<path fill="none" stroke="black" d="M802.75,-1412C802.75,-1588.18 1166.75,-1392.82 1166.75,-1569"/>
</g>
<!-- 31022899&#45;&gt;33657116 -->
<g id="edge610" class="edge">
<title>31022899:n&#45;&gt;33657116:s</title>
<path fill="none" stroke="black" d="M2173.75,-1406C2173.75,-1490.19 2279.75,-1478.81 2279.75,-1563"/>
</g>
<!-- 31195999&#45;&gt;34643934 -->
<g id="edge611" class="edge">
<title>31195999:n&#45;&gt;34643934:s</title>
<path fill="none" stroke="black" d="M3582.75,-1412C3582.75,-1540.86 3506.32,-1570.12 3392.75,-1631 3151.04,-1760.57 2168.75,-1514.26 2168.75,-1788.5"/>
</g>
<!-- 31195999&#45;&gt;34722686 -->
<g id="edge612" class="edge">
<title>31195999:n&#45;&gt;34722686:s</title>
<path fill="none" stroke="black" d="M3582.75,-1412C3582.75,-1599.35 3407.75,-1608.15 3407.75,-1795.5"/>
</g>
<!-- 31549153&#45;&gt;32453608 -->
<g id="edge613" class="edge">
<title>31549153:n&#45;&gt;32453608:s</title>
<path fill="none" stroke="black" d="M4024.75,-68C4024.75,-137.78 4024.75,-155.22 4024.75,-225"/>
</g>
<!-- 32341789&#45;&gt;34379219 -->
<g id="edge614" class="edge">
<title>32341789:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M3460.75,-1406C3460.75,-1610.03 3601.53,-1710.09 3468.75,-1865 3325.91,-2031.63 2492.75,-1796.53 2492.75,-2016"/>
</g>
<!-- 32341789&#45;&gt;34722686 -->
<g id="edge615" class="edge">
<title>32341789:n&#45;&gt;34722686:s</title>
<path fill="none" stroke="black" d="M3460.75,-1406C3460.75,-1580.71 3407.75,-1620.79 3407.75,-1795.5"/>
</g>
<!-- 32415705&#45;&gt;32415705 -->
<g id="edge616" class="edge">
<title>32415705:n&#45;&gt;32415705:s</title>
<path fill="none" stroke="black" d="M464.75,-1631C487.08,-1685.5 531.75,-1685.5 531.75,-1597 531.75,-1508.5 487.08,-1508.5 464.75,-1563"/>
</g>
<!-- 32539675&#45;&gt;33950207 -->
<g id="edge617" class="edge">
<title>32539675:n&#45;&gt;33950207:s</title>
<path fill="none" stroke="black" d="M2007.75,-1625C2007.75,-1851.57 2492.75,-1555.43 2492.75,-1782"/>
</g>
<!-- 32676543&#45;&gt;34379219 -->
<g id="edge618" class="edge">
<title>32676543:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M1010.75,-1858.5C1010.75,-2189.69 2492.75,-1684.81 2492.75,-2016"/>
</g>
<!-- 33253294&#45;&gt;34379219 -->
<g id="edge619" class="edge">
<title>33253294:n&#45;&gt;34379219:s</title>
<path fill="none" stroke="black" d="M3181.75,-1625C3181.75,-1770.91 3080.83,-1786.64 2957.75,-1865 2774.45,-1981.69 2492.75,-1798.71 2492.75,-2016"/>
</g>
<!-- 33253294&#45;&gt;34722686 -->
<g id="edge620" class="edge">
<title>33253294:n&#45;&gt;34722686:s</title>
<path fill="none" stroke="black" d="M3181.75,-1625C3181.75,-1750.82 3407.75,-1669.68 3407.75,-1795.5"/>
</g>
<!-- 34173286&#45;&gt;34173286 -->
<g id="edge621" class="edge">
<title>34173286:n&#45;&gt;34173286:s</title>
<path fill="none" stroke="black" d="M588.75,-1857.5C610.58,-1914 654.25,-1914 654.25,-1823.5 654.25,-1733 610.58,-1733 588.75,-1789.5"/>
</g>
<!-- 17577005 -->
<g id="node1" class="node">
<title>17577005</title>
<g id="a_node1"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/17577005/" xlink:title="Date: 2007 Jun 19&#10;Title: Meta&#45;analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.&#10;By: Hart, Pearce, Aguilar&#10;~&#10;Abstract: Atrial fibrillation is a strong independent risk factor for stroke.&#10;~&#10;PMID: 17577005&#10;Journal: Annals of internal medicine" target="_blank">
<polygon fill="transparent" stroke="black" points="2679.75,-279.5 2593.75,-279.5 2593.75,-226.5 2685.75,-226.5 2685.75,-273.5 2679.75,-279.5"/>
<polyline fill="none" stroke="black" points="2679.75,-279.5 2679.75,-273.5 "/>
<polyline fill="none" stroke="black" points="2685.75,-273.5 2679.75,-273.5 "/>
<text text-anchor="middle" x="2639.75" y="-264.3" font-family="Times New Roman,serif" font-size="14.00">Hart, Pearce,</text>
<text text-anchor="middle" x="2639.75" y="-249.3" font-family="Times New Roman,serif" font-size="14.00">Aguilar</text>
<text text-anchor="middle" x="2639.75" y="-234.3" font-family="Times New Roman,serif" font-size="14.00">(2007 Jun 19)</text>
</a>
</g>
</g>
<!-- 19717844 -->
<g id="node2" class="node">
<title>19717844</title>
<g id="a_node2"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/19717844/" xlink:title="Date: 2009 Sep 17&#10;Title: Dabigatran versus warfarin in patients with atrial fibrillation.&#10;By: Connolly, Ezekowitz, Yusuf, Eikelboom, Oldgren, Parekh, Pogue, Reilly, Themeles, Varrone, Wang, Alings, Xavier, Zhu, Diaz, Lewis, Darius, Diener, Joyner, Wallentin, None&#10;~&#10;Abstract: Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor.&#10;~&#10;PMID: 19717844&#10;Journal: The New England journal of medicine" target="_blank">
<polygon fill="transparent" stroke="black" points="2327.25,-68 2204.25,-68 2204.25,0 2333.25,0 2333.25,-62 2327.25,-68"/>
<polyline fill="none" stroke="black" points="2327.25,-68 2327.25,-62 "/>
<polyline fill="none" stroke="black" points="2333.25,-62 2327.25,-62 "/>
<text text-anchor="middle" x="2268.75" y="-52.8" font-family="Times New Roman,serif" font-size="14.00">Connolly,</text>
<text text-anchor="middle" x="2268.75" y="-37.8" font-family="Times New Roman,serif" font-size="14.00">Ezekowitz, Yusuf,</text>
<text text-anchor="middle" x="2268.75" y="-22.8" font-family="Times New Roman,serif" font-size="14.00">Eikelboom, Oldgren</text>
<text text-anchor="middle" x="2268.75" y="-7.8" font-family="Times New Roman,serif" font-size="14.00">(2009 Sep 17)</text>
</a>
</g>
</g>
<!-- 19757444 -->
<g id="node3" class="node">
<title>19757444</title>
<g id="a_node3"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/19757444/" xlink:title="Date: 2009 Nov 10&#10;Title: Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity&#45;score matched samples.&#10;By: Austin&#10;~&#10;Abstract: The propensity score is a subject&#39;s probability of treatment, conditional on observed baseline covariates. Conditional on the true propensity score, treated and untreated subjects have similar distributions of observed baseline covariates. Propensity&#45;score matching is a popular method of using the propensity score in the medical literature. Using this approach, matched sets of treated and untreated subjects with similar values of the propensity score are formed. Inferences about treatment effect made using propensity&#45;score matching are valid only if, in the matched sample, treated and untreated subjects have similar distributions of measured baseline covariates. In this paper we discuss the following methods for assessing whether the propensity score model has been correctly specified: comparing means and prevalences of baseline characteristics using standardized differences; ratios comparing the variance of continuous covariates between treated and untreated subjects; comparison of higher order moments and interactions; five&#45;number summaries; and graphical methods such as quantile&#45;quantile plots, side&#45;by&#45;side boxplots, and non&#45;parametric density plots for comparing the distribution of baseline covariates between treatment groups. We describe methods to determine the sampling distribution of the standardized difference when the true standardized difference is equal to zero, thereby allowing one to determine the range of standardized differences that are plausible with the propensity score model having been correctly specified. We highlight the limitations of some previously used methods for assessing the adequacy of the specification of the propensity&#45;score model. In particular, methods based on comparing the distribution of the estimated propensity score between treated and untreated subjects are uninformative.&#10;~&#10;PMID: 19757444&#10;Journal: Statistics in medicine" target="_blank">
<polygon fill="transparent" stroke="black" points="3393.75,-491 3301.75,-491 3301.75,-453 3399.75,-453 3399.75,-485 3393.75,-491"/>
<polyline fill="none" stroke="black" points="3393.75,-491 3393.75,-485 "/>
<polyline fill="none" stroke="black" points="3399.75,-485 3393.75,-485 "/>
<text text-anchor="middle" x="3350.75" y="-475.8" font-family="Times New Roman,serif" font-size="14.00">Austin</text>
<text text-anchor="middle" x="3350.75" y="-460.8" font-family="Times New Roman,serif" font-size="14.00">(2009 Nov 10)</text>
</a>
</g>
</g>
<!-- 20299623 -->
<g id="node4" class="node">
<title>20299623</title>
<g id="a_node4"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/20299623/" xlink:title="Date: 2010 Nov&#10;Title: A novel user&#45;friendly score (HAS&#45;BLED) to assess 1&#45;year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.&#10;By: Pisters, Lane, Nieuwlaat, de Vos, Crijns, Lip&#10;~&#10;Abstract: Despite extensive use of oral anticoagulation (OAC) in patients with atrial fibrillation (AF) and the increased bleeding risk associated with such OAC use, no handy quantification tool for assessing this risk exists. We aimed to develop a practical risk score to estimate the 1&#45;year risk for major bleeding (intracranial, hospitalization, hemoglobin decrease &gt;2 g/L, and/or transfusion) in a cohort of real&#45;world patients with AF.&#10;~&#10;PMID: 20299623&#10;Journal: Chest" target="_blank">
<polygon fill="transparent" stroke="black" points="1936.75,-287 1820.75,-287 1820.75,-219 1942.75,-219 1942.75,-281 1936.75,-287"/>
<polyline fill="none" stroke="black" points="1936.75,-287 1936.75,-281 "/>
<polyline fill="none" stroke="black" points="1942.75,-281 1936.75,-281 "/>
<text text-anchor="middle" x="1881.75" y="-271.8" font-family="Times New Roman,serif" font-size="14.00">Pisters, Lane,</text>
<text text-anchor="middle" x="1881.75" y="-256.8" font-family="Times New Roman,serif" font-size="14.00">Nieuwlaat, de Vos,</text>
<text text-anchor="middle" x="1881.75" y="-241.8" font-family="Times New Roman,serif" font-size="14.00">Crijns</text>
<text text-anchor="middle" x="1881.75" y="-226.8" font-family="Times New Roman,serif" font-size="14.00">(2010 Nov)</text>
</a>
</g>
</g>
<!-- 21387461 -->
<g id="node5" class="node">
<title>21387461</title>
<g id="a_node5"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/21387461/" xlink:title="Date: 2011 Jun&#10;Title: An automated database case definition for serious bleeding related to oral anticoagulant use.&#10;By: Cunningham, Stein, Chung, Daugherty, Smalley, Ray&#10;~&#10;Abstract: Bleeding complications are a serious adverse effect of medications that prevent abnormal blood clotting. To facilitate epidemiologic investigations of bleeding complications, we developed and validated an automated database case definition for bleeding&#45;related hospitalizations.&#10;~&#10;PMID: 21387461&#10;Journal: Pharmacoepidemiology and drug safety" target="_blank">
<polygon fill="transparent" stroke="black" points="2808.25,-732.5 2689.25,-732.5 2689.25,-664.5 2814.25,-664.5 2814.25,-726.5 2808.25,-732.5"/>
<polyline fill="none" stroke="black" points="2808.25,-732.5 2808.25,-726.5 "/>
<polyline fill="none" stroke="black" points="2814.25,-726.5 2808.25,-726.5 "/>
<text text-anchor="middle" x="2751.75" y="-717.3" font-family="Times New Roman,serif" font-size="14.00">Cunningham, Stein,</text>
<text text-anchor="middle" x="2751.75" y="-702.3" font-family="Times New Roman,serif" font-size="14.00">Chung, Daugherty,</text>
<text text-anchor="middle" x="2751.75" y="-687.3" font-family="Times New Roman,serif" font-size="14.00">Smalley</text>
<text text-anchor="middle" x="2751.75" y="-672.3" font-family="Times New Roman,serif" font-size="14.00">(2011 Jun)</text>
</a>
</g>
</g>
<!-- 21830957 -->
<g id="node6" class="node">
<title>21830957</title>
<g id="a_node6"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/21830957/" xlink:title="Date: 2011 Sep 08&#10;Title: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.&#10;By: Patel, Mahaffey, Garg, Pan, Singer, Hacke, Breithardt, Halperin, Hankey, Piccini, Becker, Nessel, Paolini, Berkowitz, Fox, Califf, None&#10;~&#10;Abstract: The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin.&#10;~&#10;PMID: 21830957&#10;Journal: The New England journal of medicine" target="_blank">
<polygon fill="transparent" stroke="black" points="3087.75,-279.5 2977.75,-279.5 2977.75,-226.5 3093.75,-226.5 3093.75,-273.5 3087.75,-279.5"/>
<polyline fill="none" stroke="black" points="3087.75,-279.5 3087.75,-273.5 "/>
<polyline fill="none" stroke="black" points="3093.75,-273.5 3087.75,-273.5 "/>
<text text-anchor="middle" x="3035.75" y="-264.3" font-family="Times New Roman,serif" font-size="14.00">Patel, Mahaffey,</text>
<text text-anchor="middle" x="3035.75" y="-249.3" font-family="Times New Roman,serif" font-size="14.00">Garg, Pan, Singer</text>
<text text-anchor="middle" x="3035.75" y="-234.3" font-family="Times New Roman,serif" font-size="14.00">(2011 Sep 08)</text>
</a>
</g>
</g>
<!-- 21870978 -->
<g id="node7" class="node">
<title>21870978</title>
<g id="a_node7"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/21870978/" xlink:title="Date: 2011 Sep 15&#10;Title: Apixaban versus warfarin in patients with atrial fibrillation.&#10;By: Granger, Alexander, McMurray, Lopes, Hylek, Hanna, Al&#45;Khalidi, Ansell, Atar, Avezum, Bahit, Diaz, Easton, Ezekowitz, Flaker, Garcia, Geraldes, Gersh, Golitsyn, Goto, Hermosillo, Hohnloser, Horowitz, Mohan, Jansky, Lewis, Lopez&#45;Sendon, Pais, Parkhomenko, Verheugt, Zhu, Wallentin, None&#10;~&#10;Abstract: Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin.&#10;~&#10;PMID: 21870978&#10;Journal: The New England journal of medicine" target="_blank">
<polygon fill="transparent" stroke="black" points="2469.25,-506 2346.25,-506 2346.25,-438 2475.25,-438 2475.25,-500 2469.25,-506"/>
<polyline fill="none" stroke="black" points="2469.25,-506 2469.25,-500 "/>
<polyline fill="none" stroke="black" points="2475.25,-500 2469.25,-500 "/>
<text text-anchor="middle" x="2410.75" y="-490.8" font-family="Times New Roman,serif" font-size="14.00">Granger, Alexander,</text>
<text text-anchor="middle" x="2410.75" y="-475.8" font-family="Times New Roman,serif" font-size="14.00">McMurray, Lopes,</text>
<text text-anchor="middle" x="2410.75" y="-460.8" font-family="Times New Roman,serif" font-size="14.00">Hylek</text>
<text text-anchor="middle" x="2410.75" y="-445.8" font-family="Times New Roman,serif" font-size="14.00">(2011 Sep 15)</text>
</a>
</g>
</g>
<!-- 23562920 -->
<g id="node8" class="node">
<title>23562920</title>
<g id="a_node8"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/23562920/" xlink:title="Date: 2013 Jun 04&#10;Title: Efficacy and safety of dabigatran etexilate and warfarin in &#39;real&#45;world&#39; patients with atrial fibrillation: a prospective nationwide cohort study.&#10;By: Larsen, Rasmussen, Skjth, Due, Callrus, Rosenzweig, Lip&#10;~&#10;Abstract: The aim of this study was to assess the efficacy and safety in an &#39;everyday clinical practice&#39; population of anticoagulant&#45;nave patients with atrial fibrillation (AF) treated with dabigatran etexilate after its post&#45;approval availability in Denmark, compared with warfarin.&#10;~&#10;PMID: 23562920&#10;Journal: Journal of the American College of Cardiology" target="_blank">
<polygon fill="transparent" stroke="black" points="242.25,-68 119.25,-68 119.25,0 248.25,0 248.25,-62 242.25,-68"/>
<polyline fill="none" stroke="black" points="242.25,-68 242.25,-62 "/>
<polyline fill="none" stroke="black" points="248.25,-62 242.25,-62 "/>
<text text-anchor="middle" x="183.75" y="-52.8" font-family="Times New Roman,serif" font-size="14.00">Larsen, Rasmussen,</text>
<text text-anchor="middle" x="183.75" y="-37.8" font-family="Times New Roman,serif" font-size="14.00">Skjth, Due,</text>
<text text-anchor="middle" x="183.75" y="-22.8" font-family="Times New Roman,serif" font-size="14.00">Callrus</text>
<text text-anchor="middle" x="183.75" y="-7.8" font-family="Times New Roman,serif" font-size="14.00">(2013 Jun 04)</text>
</a>
</g>
</g>
<!-- 24251359 -->
<g id="node9" class="node">
<title>24251359</title>
<g id="a_node9"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/24251359/" xlink:title="Date: 2013 Nov 28&#10;Title: Edoxaban versus warfarin in patients with atrial fibrillation.&#10;By: Giugliano, Ruff, Braunwald, Murphy, Wiviott, Halperin, Waldo, Ezekowitz, Weitz, pinar, Ruzyllo, Ruda, Koretsune, Betcher, Shi, Grip, Patel, Patel, Hanyok, Mercuri, Antman, None&#10;~&#10;Abstract: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long&#45;term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known.&#10;~&#10;PMID: 24251359&#10;Journal: The New England journal of medicine" target="_blank">
<polygon fill="transparent" stroke="black" points="3236.25,-506 3111.25,-506 3111.25,-438 3242.25,-438 3242.25,-500 3236.25,-506"/>
<polyline fill="none" stroke="black" points="3236.25,-506 3236.25,-500 "/>
<polyline fill="none" stroke="black" points="3242.25,-500 3236.25,-500 "/>
<text text-anchor="middle" x="3176.75" y="-490.8" font-family="Times New Roman,serif" font-size="14.00">Giugliano, Ruff,</text>
<text text-anchor="middle" x="3176.75" y="-475.8" font-family="Times New Roman,serif" font-size="14.00">Braunwald, Murphy,</text>
<text text-anchor="middle" x="3176.75" y="-460.8" font-family="Times New Roman,serif" font-size="14.00">Wiviott</text>
<text text-anchor="middle" x="3176.75" y="-445.8" font-family="Times New Roman,serif" font-size="14.00">(2013 Nov 28)</text>
</a>
</g>
</g>
<!-- 24315724 -->
<g id="node10" class="node">
<title>24315724</title>
<g id="a_node10"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/24315724/" xlink:title="Date: 2014 Mar 15&#10;Title: Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta&#45;analysis of randomised trials.&#10;By: Ruff, Giugliano, Braunwald, Hoffman, Deenadayalu, Ezekowitz, Camm, Weitz, Lewis, Parkhomenko, Yamashita, Antman&#10;~&#10;Abstract: Four new oral anticoagulants compare favourably with warfarin for stroke prevention in patients with atrial fibrillation; however, the balance between efficacy and safety in subgroups needs better definition. We aimed to assess the relative benefit of new oral anticoagulants in key subgroups, and the effects on important secondary outcomes.&#10;~&#10;PMID: 24315724&#10;Journal: Lancet (London, England)" target="_blank">
<polygon fill="transparent" stroke="black" points="960.25,-287 829.25,-287 829.25,-219 966.25,-219 966.25,-281 960.25,-287"/>
<polyline fill="none" stroke="black" points="960.25,-287 960.25,-281 "/>
<polyline fill="none" stroke="black" points="966.25,-281 960.25,-281 "/>
<text text-anchor="middle" x="897.75" y="-271.8" font-family="Times New Roman,serif" font-size="14.00">Ruff, Giugliano,</text>
<text text-anchor="middle" x="897.75" y="-256.8" font-family="Times New Roman,serif" font-size="14.00">Braunwald, Hoffman,</text>
<text text-anchor="middle" x="897.75" y="-241.8" font-family="Times New Roman,serif" font-size="14.00">Deenadayalu</text>
<text text-anchor="middle" x="897.75" y="-226.8" font-family="Times New Roman,serif" font-size="14.00">(2014 Mar 15)</text>
</a>
</g>
</g>
<!-- 25359164 -->
<g id="node11" class="node">
<title>25359164</title>
<g id="a_node11"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/25359164/" xlink:title="Date: 2015 Jan 13&#10;Title: Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.&#10;By: Graham, Reichman, Wernecke, Zhang, Southworth, Levenson, Sheu, Mott, Goulding, Houstoun, MaCurdy, Worrall, Kelman&#10;~&#10;Abstract: The comparative safety of dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice settings has not been established.&#10;~&#10;PMID: 25359164&#10;Journal: Circulation" target="_blank">
<polygon fill="transparent" stroke="black" points="615.75,-287 493.75,-287 493.75,-219 621.75,-219 621.75,-281 615.75,-287"/>
<polyline fill="none" stroke="black" points="615.75,-287 615.75,-281 "/>
<polyline fill="none" stroke="black" points="621.75,-281 615.75,-281 "/>
<text text-anchor="middle" x="557.75" y="-271.8" font-family="Times New Roman,serif" font-size="14.00">Graham, Reichman,</text>
<text text-anchor="middle" x="557.75" y="-256.8" font-family="Times New Roman,serif" font-size="14.00">Wernecke, Zhang,</text>
<text text-anchor="middle" x="557.75" y="-241.8" font-family="Times New Roman,serif" font-size="14.00">Southworth</text>
<text text-anchor="middle" x="557.75" y="-226.8" font-family="Times New Roman,serif" font-size="14.00">(2015 Jan 13)</text>
</a>
</g>
</g>
<!-- 25365537 -->
<g id="node12" class="node">
<title>25365537</title>
<g id="a_node12"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/25365537/" xlink:title="Date: 2015 Jan&#10;Title: Risk of bleeding with dabigatran in atrial fibrillation.&#10;By: Hernandez, Baik, Piera, Zhang&#10;~&#10;Abstract: It remains unclear whether dabigatran etexilate mesylate is associated with higher risk of bleeding than warfarin sodium in real&#45;world clinical practice.&#10;~&#10;PMID: 25365537&#10;Journal: JAMA internal medicine" target="_blank">
<polygon fill="transparent" stroke="black" points="484.75,-279.5 378.75,-279.5 378.75,-226.5 490.75,-226.5 490.75,-273.5 484.75,-279.5"/>
<polyline fill="none" stroke="black" points="484.75,-279.5 484.75,-273.5 "/>
<polyline fill="none" stroke="black" points="490.75,-273.5 484.75,-273.5 "/>
<text text-anchor="middle" x="434.75" y="-264.3" font-family="Times New Roman,serif" font-size="14.00">Hernandez, Baik,</text>
<text text-anchor="middle" x="434.75" y="-249.3" font-family="Times New Roman,serif" font-size="14.00">Piera, Zhang</text>
<text text-anchor="middle" x="434.75" y="-234.3" font-family="Times New Roman,serif" font-size="14.00">(2015 Jan)</text>
</a>
</g>
</g>
<!-- 25587093 -->
<g id="node13" class="node">
<title>25587093</title>
<g id="a_node13"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/25587093/" xlink:title="Date: 2015 Jan&#10;Title: Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation.&#10;By: Thigpen, Dillon, Forster, Henault, Quinn, Tripodis, Berger, Hylek, Limdi&#10;~&#10;Abstract: Because of its association with death and disability, stroke is a focus of outcomes in atrial fibrillation (AF) research. International Classification of Disease&#45;Ninth Revision (ICD&#45;9) edition codes are commonly used to identify stroke in research, particularly in large administrative data. We sought to assess the validity of ICD&#45;9 codes in stroke case ascertainment and for AF across 3 institutions.&#10;~&#10;PMID: 25587093&#10;Journal: Circulation. Cardiovascular quality and outcomes" target="_blank">
<polygon fill="transparent" stroke="black" points="3434.75,-732.5 3330.75,-732.5 3330.75,-664.5 3440.75,-664.5 3440.75,-726.5 3434.75,-732.5"/>
<polyline fill="none" stroke="black" points="3434.75,-732.5 3434.75,-726.5 "/>
<polyline fill="none" stroke="black" points="3440.75,-726.5 3434.75,-726.5 "/>
<text text-anchor="middle" x="3385.75" y="-717.3" font-family="Times New Roman,serif" font-size="14.00">Thigpen, Dillon,</text>
<text text-anchor="middle" x="3385.75" y="-702.3" font-family="Times New Roman,serif" font-size="14.00">Forster, Henault,</text>
<text text-anchor="middle" x="3385.75" y="-687.3" font-family="Times New Roman,serif" font-size="14.00">Quinn</text>
<text text-anchor="middle" x="3385.75" y="-672.3" font-family="Times New Roman,serif" font-size="14.00">(2015 Jan)</text>
</a>
</g>
</g>
<!-- 25862791 -->
<g id="node14" class="node">
<title>25862791</title>
<g id="a_node14"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/25862791/" xlink:title="Date: 2015 Apr 10&#10;Title: Effectiveness and safety of dabigatran and warfarin in real&#45;world US patients with non&#45;valvular atrial fibrillation: a retrospective cohort study.&#10;By: Lauffenburger, Farley, Gehi, Rhoney, Brookhart, Fang&#10;~&#10;Abstract: The recent availability of dabigatran, a novel oral anticoagulant, provided a new treatment option for stroke prevention in atrial fibrillation beyond warfarin, the main therapy for years. Little is known about their real&#45;world comparative effectiveness and safety, even less among patient demographic and clinical subgroups.&#10;~&#10;PMID: 25862791&#10;Journal: Journal of the American Heart Association" target="_blank">
<polygon fill="transparent" stroke="black" points="1095.75,-732.5 977.75,-732.5 977.75,-664.5 1101.75,-664.5 1101.75,-726.5 1095.75,-732.5"/>
<polyline fill="none" stroke="black" points="1095.75,-732.5 1095.75,-726.5 "/>
<polyline fill="none" stroke="black" points="1101.75,-726.5 1095.75,-726.5 "/>
<text text-anchor="middle" x="1039.75" y="-717.3" font-family="Times New Roman,serif" font-size="14.00">Lauffenburger,</text>
<text text-anchor="middle" x="1039.75" y="-702.3" font-family="Times New Roman,serif" font-size="14.00">Farley, Gehi,</text>
<text text-anchor="middle" x="1039.75" y="-687.3" font-family="Times New Roman,serif" font-size="14.00">Rhoney, Brookhart</text>
<text text-anchor="middle" x="1039.75" y="-672.3" font-family="Times New Roman,serif" font-size="14.00">(2015 Apr 10)</text>
</a>
</g>
</g>
<!-- 25910928 -->
<g id="node15" class="node">
<title>25910928</title>
<g id="a_node15"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/25910928/" xlink:title="Date: 2015 Apr 24&#10;Title: Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.&#10;By: Abraham, Singh, Alexander, Heien, Haas, Crown, Shah&#10;~&#10;Abstract: To determine the real world risk of gastrointestinal bleeding associated with the use of the novel oral anticoagulants dabigatran and rivaroxaban compared with warfarin.&#10;~&#10;PMID: 25910928&#10;Journal: BMJ (Clinical research ed.)" target="_blank">
<polygon fill="transparent" stroke="black" points="883.75,-506 773.75,-506 773.75,-438 889.75,-438 889.75,-500 883.75,-506"/>
<polyline fill="none" stroke="black" points="883.75,-506 883.75,-500 "/>
<polyline fill="none" stroke="black" points="889.75,-500 883.75,-500 "/>
<text text-anchor="middle" x="831.75" y="-490.8" font-family="Times New Roman,serif" font-size="14.00">Abraham, Singh,</text>
<text text-anchor="middle" x="831.75" y="-475.8" font-family="Times New Roman,serif" font-size="14.00">Alexander, Heien,</text>
<text text-anchor="middle" x="831.75" y="-460.8" font-family="Times New Roman,serif" font-size="14.00">Haas</text>
<text text-anchor="middle" x="831.75" y="-445.8" font-family="Times New Roman,serif" font-size="14.00">(2015 Apr 24)</text>
</a>
</g>
</g>
<!-- 26199338 -->
<g id="node16" class="node">
<title>26199338</title>
<g id="a_node16"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/26199338/" xlink:title="Date: 2015 Sep 29&#10;Title: Comparison of the short&#45;term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity&#45;matched cohort study.&#10;By: Maura, Blotire, Bouillon, Billionnet, Ricordeau, Alla, Zureik&#10;~&#10;Abstract: The safety and effectiveness of non&#45;vitamin K antagonist (VKA) oral anticoagulants, dabigatran or rivaroxaban, were compared with VKA in anticoagulant&#45;naive patients with nonvalvular atrial fibrillation during the early phase of anticoagulant therapy.&#10;~&#10;PMID: 26199338&#10;Journal: Circulation" target="_blank">
<polygon fill="transparent" stroke="black" points="431.75,-740 331.75,-740 331.75,-657 437.75,-657 437.75,-734 431.75,-740"/>
<polyline fill="none" stroke="black" points="431.75,-740 431.75,-734 "/>
<polyline fill="none" stroke="black" points="437.75,-734 431.75,-734 "/>
<text text-anchor="middle" x="384.75" y="-724.8" font-family="Times New Roman,serif" font-size="14.00">Maura, Blotire,</text>
<text text-anchor="middle" x="384.75" y="-709.8" font-family="Times New Roman,serif" font-size="14.00">Bouillon,</text>
<text text-anchor="middle" x="384.75" y="-694.8" font-family="Times New Roman,serif" font-size="14.00">Billionnet,</text>
<text text-anchor="middle" x="384.75" y="-679.8" font-family="Times New Roman,serif" font-size="14.00">Ricordeau</text>
<text text-anchor="middle" x="384.75" y="-664.8" font-family="Times New Roman,serif" font-size="14.00">(2015 Sep 29)</text>
</a>
</g>
</g>
<!-- 26446456 -->
<g id="node17" class="node">
<title>26446456</title>
<g id="a_node17"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/26446456/" xlink:title="Date: 2015 Nov 25&#10;Title: A comparison of the safety and effectiveness of dabigatran and warfarin in non&#45;valvular atrial fibrillation patients in a large healthcare system.&#10;By: Villines, Schnee, Fraeman, Siu, Reynolds, Collins, Schwartzman&#10;~&#10;Abstract: Dabigatran is approved for stroke risk reduction in patients with nonvalvular atrial fibrillation (NVAF). Data from diverse clinical practice settings will help establish whether the risk:benefit ratio seen in clinical trials is comparable with routine clinical care. This study aimed to compare the safety and effectiveness of dabigatran and warfarin in clinical practice. We undertook a propensity score&#45;matched (PSM) cohort study (N=12,793 per group; mean age 74) comparing treatment with dabigatran or warfarin in the US Department of Defense claims database, October 2009 to July 2013. Treatment&#45;nave patients with first prescription claim for dabigatran (either FDA&#45;approved dose) or warfarin between October 2010 and July 2012 (index) and a diagnosis of NVAF during the 12 months before index date were included. Primary outcomes were stroke and major bleeding. Secondary outcomes included ischaemic and haemorrhagic stroke, major gastrointestinal (GI), urogenital or other bleeding, myocardial infarction (MI) and death. Time&#45;to&#45;event was investigated using Kaplan&#45;Meier survival analyses. Outcomes comparisons were made utilising Cox&#45;proportional hazards models of PSM groups. Dabigatran users experienced fewer strokes (adjusted hazard ratio [95% confidence intervals] 0.73 [0.55&#45;0.97]), major intracranial (0.49 [0.30&#45;0.79]), urogenital (0.36 [0.18&#45;0.74]) and other (0.38 [0.22&#45;0.66]) bleeding, MI (0.65 [0.45&#45;0.95]) and deaths (0.64 [0.55&#45;0.74]) than the warfarin group. Major bleeding (0.87 [0.74&#45;1.03]) and major GI bleeding (1.13 [0.94&#45;1.37]) was similar between groups and major lower GI bleeding events were more frequent (1.30 [1.04&#45;1.62]) with dabigatran. In conclusion, compared with warfarin, dabigatran treatment was associated with a lower risk of stroke and most outcomes measured, but increased incidence of major lower GI bleeding.&#10;~&#10;PMID: 26446456&#10;Journal: Thrombosis and haemostasis" target="_blank">
<polygon fill="transparent" stroke="black" points="1755.25,-732.5 1652.25,-732.5 1652.25,-664.5 1761.25,-664.5 1761.25,-726.5 1755.25,-732.5"/>
<polyline fill="none" stroke="black" points="1755.25,-732.5 1755.25,-726.5 "/>
<polyline fill="none" stroke="black" points="1761.25,-726.5 1755.25,-726.5 "/>
<text text-anchor="middle" x="1706.75" y="-717.3" font-family="Times New Roman,serif" font-size="14.00">Villines, Schnee,</text>
<text text-anchor="middle" x="1706.75" y="-702.3" font-family="Times New Roman,serif" font-size="14.00">Fraeman, Siu,</text>
<text text-anchor="middle" x="1706.75" y="-687.3" font-family="Times New Roman,serif" font-size="14.00">Reynolds</text>
<text text-anchor="middle" x="1706.75" y="-672.3" font-family="Times New Roman,serif" font-size="14.00">(2015 Nov 25)</text>
</a>
</g>
</g>
<!-- 26446507 -->
<g id="node18" class="node">
<title>26446507</title>
<g id="a_node18"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/26446507/" xlink:title="Date: 2015 Nov 25&#10;Title: Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation.&#10;By: Seeger, Bykov, Bartels, Huybrechts, Zint, Schneeweiss&#10;~&#10;Abstract: The RE&#45;LY study demonstrated the safety and efficacy of dabigatran relative to warfarin for stroke prevention in non&#45;valvular atrial fibrillation. It is important to further evaluate safety and effectiveness of drugs in routine care. This study used a sequential cohort design with propensity score matching to compare dabigatran with warfarin among patients in two commercial health insurance databases. New users of these anticoagulants were followed from initiation until discontinuation, the end of the study, or the occurrence of a study outcome (primary study outcomes were stroke and major bleeding). Proportional hazards regression was conducted separately within each data source and results were pooled. Among 19,189 matched dabigatran and warfarin initiators (mean age: 68 years, 36% female), as&#45;treated follow&#45;up (average of 5 months for dabigatran, 4 months for warfarin) identified 62 and 69 strokes, respectively (pooled HR = 0.77; 95% CI = 0.54 to 1.09), and 354 and 395 major haemorrhages, respectively (HR = 0.75; 0.65 to 0.87). No meaningful heterogeneity was identified across subgroups, but numeric trends suggest more pronounced stroke prevention by dabigatran relative to warfarin among patients age 75+ (HR = 0.57; 0.33 to 0.97) or with &lt;6 months of use (HR = 0.51; 0.19 to 1.42). Major bleeds were reduced more by dabigatran among patients aged &lt;55 (HR = 0.51; 0.30 to 0.87) and with CHADS2 &lt;2 (HR = 0.58; 0.44 to 0.77). In conclusion, in routine care of patients with non&#45;valvular atrial fibrillation, dabigatran treatment resulted in improved health outcomes compared with warfarin.&#10;~&#10;PMID: 26446507&#10;Journal: Thrombosis and haemostasis" target="_blank">
<polygon fill="transparent" stroke="black" points="1600.75,-732.5 1496.75,-732.5 1496.75,-664.5 1606.75,-664.5 1606.75,-726.5 1600.75,-732.5"/>
<polyline fill="none" stroke="black" points="1600.75,-732.5 1600.75,-726.5 "/>
<polyline fill="none" stroke="black" points="1606.75,-726.5 1600.75,-726.5 "/>
<text text-anchor="middle" x="1551.75" y="-717.3" font-family="Times New Roman,serif" font-size="14.00">Seeger, Bykov,</text>
<text text-anchor="middle" x="1551.75" y="-702.3" font-family="Times New Roman,serif" font-size="14.00">Bartels,</text>
<text text-anchor="middle" x="1551.75" y="-687.3" font-family="Times New Roman,serif" font-size="14.00">Huybrechts, Zint</text>
<text text-anchor="middle" x="1551.75" y="-672.3" font-family="Times New Roman,serif" font-size="14.00">(2015 Nov 25)</text>
</a>
</g>
</g>
<!-- 26848150 -->
<g id="node19" class="node">
<title>26848150</title>
<g id="a_node19"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/26848150/" xlink:title="Date: 2017 Mar 21&#10;Title: Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non&#45;valvular atrial fibrillation: part 2.&#10;By: Diener, Aisenberg, Ansell, Atar, Breithardt, Eikelboom, Ezekowitz, Granger, Halperin, Hohnloser, Hylek, Kirchhof, Lane, Verheugt, Veltkamp, Lip&#10;~&#10;Abstract: The choice of oral anticoagulant (OAC) for patients with atrial fibrillation (AF) may be influenced by individual clinical features or by patterns of risk factors and comorbidities. We reviewed analyses of subgroups of patients from trials of vitamin K antagonists vs. non&#45;vitamin K oral anticoagulants (NOACs) for stroke prevention in AF with the aim to identify patient groups who might benefit from a particular OAC more than from another. In addition, we discuss the timing of initiation of anticoagulation. In the second of a two&#45;part review, we discuss the use of NOAC for stroke prevention in the following subgroups of patients with AF: (vii) secondary stroke prevention in patients after stroke or transient ischaemic attack (TIA), (viii) patients with acute stroke requiring thrombolysis or thrombectomy, (ix) those initiating or restarting OAC treatment after stroke or TIA, (x) those with renal impairment on dialysis, (xi) the elderly, (xii) those at high risk of gastrointestinal bleeding, and (xiii) those with hypertension. In addition, we discuss adherence and compliance. Finally, we present a summary of treatment suggestions. In specific subgroups of patients with AF, evidence supports the use of particular NOACs and/or particular doses of anticoagulant. The appropriate choice of treatment for these subgroups will help to promote optimal clinical outcomes.&#10;~&#10;PMID: 26848150&#10;Journal: European heart journal" target="_blank">
<polygon fill="transparent" stroke="black" points="1375.75,-732.5 1261.75,-732.5 1261.75,-664.5 1381.75,-664.5 1381.75,-726.5 1375.75,-732.5"/>
<polyline fill="none" stroke="black" points="1375.75,-732.5 1375.75,-726.5 "/>
<polyline fill="none" stroke="black" points="1381.75,-726.5 1375.75,-726.5 "/>
<text text-anchor="middle" x="1321.75" y="-717.3" font-family="Times New Roman,serif" font-size="14.00">Diener, Aisenberg,</text>
<text text-anchor="middle" x="1321.75" y="-702.3" font-family="Times New Roman,serif" font-size="14.00">Ansell, Atar,</text>
<text text-anchor="middle" x="1321.75" y="-687.3" font-family="Times New Roman,serif" font-size="14.00">Breithardt</text>
<text text-anchor="middle" x="1321.75" y="-672.3" font-family="Times New Roman,serif" font-size="14.00">(2017 Mar 21)</text>
</a>
</g>
</g>
<!-- 27312796 -->
<g id="node20" class="node">
<title>27312796</title>
<g id="a_node20"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/27312796/" xlink:title="Date: 2016 Jun 16&#10;Title: Comparative effectiveness and safety of non&#45;vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.&#10;By: Larsen, Skjth, Nielsen, Kjldgaard, Lip&#10;~&#10;Abstract: To study the effectiveness and safety of the non&#45;vitamin K antagonist oral anticoagulants (novel oral anticoagulants, NOACs) dabigatran, rivaroxaban, and apixaban compared with warfarin in anticoagulant nave patients with atrial fibrillation.&#10;~&#10;PMID: 27312796&#10;Journal: BMJ (Clinical research ed.)" target="_blank">
<polygon fill="transparent" stroke="black" points="2598.25,-959 2497.25,-959 2497.25,-891 2604.25,-891 2604.25,-953 2598.25,-959"/>
<polyline fill="none" stroke="black" points="2598.25,-959 2598.25,-953 "/>
<polyline fill="none" stroke="black" points="2604.25,-953 2598.25,-953 "/>
<text text-anchor="middle" x="2550.75" y="-943.8" font-family="Times New Roman,serif" font-size="14.00">Larsen, Skjth,</text>
<text text-anchor="middle" x="2550.75" y="-928.8" font-family="Times New Roman,serif" font-size="14.00">Nielsen,</text>
<text text-anchor="middle" x="2550.75" y="-913.8" font-family="Times New Roman,serif" font-size="14.00">Kjldgaard, Lip</text>
<text text-anchor="middle" x="2550.75" y="-898.8" font-family="Times New Roman,serif" font-size="14.00">(2016 Jun 16)</text>
</a>
</g>
</g>
<!-- 27412905 -->
<g id="node21" class="node">
<title>27412905</title>
<g id="a_node21"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/27412905/" xlink:title="Date: 2016 06 13&#10;Title: Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.&#10;By: Yao, Abraham, Sangaralingham, Bellolio, McBane, Shah, Noseworthy&#10;~&#10;Abstract: The introduction of non&#45;vitamin K antagonist oral anticoagulants has been a major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in clinical trials may not translate to routine practice. We aimed to evaluate the effectiveness and safety of dabigatran, rivaroxaban, and apixaban by comparing each agent with warfarin.&#10;~&#10;PMID: 27412905&#10;Journal: Journal of the American Heart Association" target="_blank">
<polygon fill="transparent" stroke="black" points="2038.25,-959 1931.25,-959 1931.25,-891 2044.25,-891 2044.25,-953 2038.25,-959"/>
<polyline fill="none" stroke="black" points="2038.25,-959 2038.25,-953 "/>
<polyline fill="none" stroke="black" points="2044.25,-953 2038.25,-953 "/>
<text text-anchor="middle" x="1987.75" y="-943.8" font-family="Times New Roman,serif" font-size="14.00">Yao, Abraham,</text>
<text text-anchor="middle" x="1987.75" y="-928.8" font-family="Times New Roman,serif" font-size="14.00">Sangaralingham,</text>
<text text-anchor="middle" x="1987.75" y="-913.8" font-family="Times New Roman,serif" font-size="14.00">Bellolio, McBane</text>
<text text-anchor="middle" x="1987.75" y="-898.8" font-family="Times New Roman,serif" font-size="14.00">(2016 06 13)</text>
</a>
</g>
</g>
<!-- 27538358 -->
<g id="node22" class="node">
<title>27538358</title>
<g id="a_node22"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/27538358/" xlink:title="Date: 2016 Oct 28&#10;Title: Real&#45;world comparison of major bleeding risk among non&#45;valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.&#10;By: Lip, Keshishian, Kamble, Pan, Mardekian, Horblyuk, Hamilton&#10;~&#10;Abstract: In addition to warfarin, there are four non&#45;vitamin K antagonist oral anticoagulants (NOACs) available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited data on the comparative risks of major bleeding among newly anticoagulated NVAF patients who initiate warfarin, apixaban, dabigatran, or rivaroxaban, when used in &#39;real world&#39; clinical practice. The study used the Truven MarketScan Commercial &amp; Medicare supplemental US claims database. NVAF patients aged 18 years newly prescribed an oral anticoagulant 01JAN2013&#45;31DEC2014, with a 1&#45;year baseline period, were included (study period: 01JAN2012&#45;31DEC2014). Major bleeding was defined as bleeding requiring hospitalisation. Propensity score matching (PSM) was used to balance age, sex, region, baseline comorbidities, and comedications. Cox proportional hazards models were used to estimate the PSM hazard ratio (HR) of major bleeding. Among 45,361 newly anticoagulated NVAF patients, 15,461 (34.1%) initiated warfarin, 7,438 (16.4%) initiated apixaban, 17,801 (39.2%) initiated rivaroxaban, and 4,661 (10.3%) initiated dabigatran. Compared to matched warfarin initiators, apixaban (HR: 0.53; 95% CI: 0.39&#45;0.71) and dabigatran (HR: 0.69; 95% CI: 0.50&#45;0.96) initiators had a significantly lower risk of major bleeding. Patients initiating rivaroxaban (HR: 0.98; 95% CI: 0.83&#45;1.17) had a non&#45;significant difference in major bleeding risk compared to matched warfarin patients. When comparisons were made between NOACs, matched rivaroxaban patients had a significantly higher risk of major bleeding (HR: 1.82; 95% CI: 1.36&#45;2.43) compared to apixaban patients. The differences for apixaban&#45;dabigatran and dabigatran&#45;rivaroxaban matched cohorts were not statistically significant. Among newly anticoagulated NVAF patients in the real&#45;world setting, apixaban and dabigatran initiation was associated with significantly lower risk of major bleeding compared to warfarin initiation. When compared to apixaban, rivaroxaban initiation was associated with significantly higher risk of major bleeding.&#10;~&#10;PMID: 27538358&#10;Journal: Thrombosis and haemostasis" target="_blank">
<polygon fill="transparent" stroke="black" points="1311.25,-959 1210.25,-959 1210.25,-891 1317.25,-891 1317.25,-953 1311.25,-959"/>
<polyline fill="none" stroke="black" points="1311.25,-959 1311.25,-953 "/>
<polyline fill="none" stroke="black" points="1317.25,-953 1311.25,-953 "/>
<text text-anchor="middle" x="1263.75" y="-943.8" font-family="Times New Roman,serif" font-size="14.00">Lip, Keshishian,</text>
<text text-anchor="middle" x="1263.75" y="-928.8" font-family="Times New Roman,serif" font-size="14.00">Kamble, Pan,</text>
<text text-anchor="middle" x="1263.75" y="-913.8" font-family="Times New Roman,serif" font-size="14.00">Mardekian</text>
<text text-anchor="middle" x="1263.75" y="-898.8" font-family="Times New Roman,serif" font-size="14.00">(2016 Oct 28)</text>
</a>
</g>
</g>
<!-- 27550177 -->
<g id="node23" class="node">
<title>27550177</title>
<g id="a_node23"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/27550177/" xlink:title="Date: 2016 Sep&#10;Title: Major bleeding risk among non&#45;valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a &#39;real&#45;world&#39; observational study in the United States.&#10;By: Lip, Pan, Kamble, Kawabata, Mardekian, Masseria, Bruno, Phatak&#10;~&#10;Abstract: Limited data are available about the real&#45;world safety of non&#45;vitamin K antagonist oral anticoagulants (NOACs).&#10;~&#10;PMID: 27550177&#10;Journal: International journal of clinical practice" target="_blank">
<polygon fill="transparent" stroke="black" points="785.25,-951.5 654.25,-951.5 654.25,-898.5 791.25,-898.5 791.25,-945.5 785.25,-951.5"/>
<polyline fill="none" stroke="black" points="785.25,-951.5 785.25,-945.5 "/>
<polyline fill="none" stroke="black" points="791.25,-945.5 785.25,-945.5 "/>
<text text-anchor="middle" x="722.75" y="-936.3" font-family="Times New Roman,serif" font-size="14.00">Lip, Pan, Kamble,</text>
<text text-anchor="middle" x="722.75" y="-921.3" font-family="Times New Roman,serif" font-size="14.00">Kawabata, Mardekian</text>
<text text-anchor="middle" x="722.75" y="-906.3" font-family="Times New Roman,serif" font-size="14.00">(2016 Sep)</text>
</a>
</g>
</g>
<!-- 27680880 -->
<g id="node24" class="node">
<title>27680880</title>
<g id="a_node24"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/27680880/" xlink:title="Date: 2017 01&#10;Title: A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.&#10;By: Halvorsen, Ghanima, Fride Tvete, Hoxmark, Falck, Solli, Jonasson&#10;~&#10;Abstract: We aimed to evaluate bleeding risk in clinical practice in patients with atrial fibrillation (AF) being prescribed dabigatran, rivaroxaban, or apixaban compared with warfarin.&#10;~&#10;PMID: 27680880&#10;Journal: European heart journal. Cardiovascular pharmacotherapy" target="_blank">
<polygon fill="transparent" stroke="black" points="2382.75,-1185.5 2254.75,-1185.5 2254.75,-1117.5 2388.75,-1117.5 2388.75,-1179.5 2382.75,-1185.5"/>
<polyline fill="none" stroke="black" points="2382.75,-1185.5 2382.75,-1179.5 "/>
<polyline fill="none" stroke="black" points="2388.75,-1179.5 2382.75,-1179.5 "/>
<text text-anchor="middle" x="2321.75" y="-1170.3" font-family="Times New Roman,serif" font-size="14.00">Halvorsen, Ghanima,</text>
<text text-anchor="middle" x="2321.75" y="-1155.3" font-family="Times New Roman,serif" font-size="14.00">Fride Tvete,</text>
<text text-anchor="middle" x="2321.75" y="-1140.3" font-family="Times New Roman,serif" font-size="14.00">Hoxmark, Falck</text>
<text text-anchor="middle" x="2321.75" y="-1125.3" font-family="Times New Roman,serif" font-size="14.00">(2017 01)</text>
</a>
</g>
</g>
<!-- 27742807 -->
<g id="node25" class="node">
<title>27742807</title>
<g id="a_node25"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/27742807/" xlink:title="Date: 2017 Mar 21&#10;Title: Ischaemic and haemorrhagic stroke associated with non&#45;vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study.&#10;By: Staerk, Fosbl, Lip, Lamberts, Bonde, Torp&#45;Pedersen, Ozenne, Gerds, Gislason, Olesen&#10;~&#10;Abstract: Non&#45;vitamin K antagonist (VKA) oral anticoagulants (NOACs) are widely used as stroke prophylaxis in non&#45;valvular atrial fibrillation (AF), but comparative data are sparse.&#10;~&#10;PMID: 27742807&#10;Journal: European heart journal" target="_blank">
<polygon fill="transparent" stroke="black" points="1067.25,-959 970.25,-959 970.25,-891 1073.25,-891 1073.25,-953 1067.25,-959"/>
<polyline fill="none" stroke="black" points="1067.25,-959 1067.25,-953 "/>
<polyline fill="none" stroke="black" points="1073.25,-953 1067.25,-953 "/>
<text text-anchor="middle" x="1021.75" y="-943.8" font-family="Times New Roman,serif" font-size="14.00">Staerk, Fosbl,</text>
<text text-anchor="middle" x="1021.75" y="-928.8" font-family="Times New Roman,serif" font-size="14.00">Lip, Lamberts,</text>
<text text-anchor="middle" x="1021.75" y="-913.8" font-family="Times New Roman,serif" font-size="14.00">Bonde</text>
<text text-anchor="middle" x="1021.75" y="-898.8" font-family="Times New Roman,serif" font-size="14.00">(2017 Mar 21)</text>
</a>
</g>
</g>
<!-- 27889397 -->
<g id="node26" class="node">
<title>27889397</title>
<g id="a_node26"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/27889397/" xlink:title="Date: 2017 Jun&#10;Title: Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non&#45;valvular atrial fibrillation.&#10;By: Bengtson, Lutsey, Chen, MacLehose, Alonso&#10;~&#10;Abstract: Effectiveness data on novel oral anticoagulants (NOACs) versus warfarin for stroke prevention in non&#45;valvular atrial fibrillation (NVAF) by prior warfarin use are limited.&#10;~&#10;PMID: 27889397&#10;Journal: Journal of cardiology" target="_blank">
<polygon fill="transparent" stroke="black" points="1499.75,-959 1383.75,-959 1383.75,-891 1505.75,-891 1505.75,-953 1499.75,-959"/>
<polyline fill="none" stroke="black" points="1499.75,-959 1499.75,-953 "/>
<polyline fill="none" stroke="black" points="1505.75,-953 1499.75,-953 "/>
<text text-anchor="middle" x="1444.75" y="-943.8" font-family="Times New Roman,serif" font-size="14.00">Bengtson, Lutsey,</text>
<text text-anchor="middle" x="1444.75" y="-928.8" font-family="Times New Roman,serif" font-size="14.00">Chen, MacLehose,</text>
<text text-anchor="middle" x="1444.75" y="-913.8" font-family="Times New Roman,serif" font-size="14.00">Alonso</text>
<text text-anchor="middle" x="1444.75" y="-898.8" font-family="Times New Roman,serif" font-size="14.00">(2017 Jun)</text>
</a>
</g>
</g>
<!-- 27933569 -->
<g id="node27" class="node">
<title>27933569</title>
<g id="a_node27"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/27933569/" xlink:title="Date: 2017 02&#10;Title: Decision&#45;Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non&#45;valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor.&#10;By: Potpara, Dagres, Mujovi, Vasi, Aanin, Nedeljkovic, Marin, Fauchier, Blomstrom&#45;Lundqvist, Lip&#10;~&#10;Abstract: Approximately 1 in 3&#45;4 patients presenting with an ischemic stroke will also have atrial fibrillation (AF), and AF&#45;related strokes can be effectively prevented using oral anticoagulant therapy (OAC), either with well&#45;controlled vitamin K antagonists (VKAs) or non&#45;vitamin K antagonist oral anticoagulants (NOACs). In addition, OAC use (both VKAs and NOACs) is associated with a 26% reduction in all&#45;cause mortality (VKAs) or an additional 10% mortality reduction with NOACs relative to VKAs. The decision to use OAC in individual AF patient is based on the estimated balance of the benefit from ischemic stroke reduction against the risk of major OAC&#45;related bleeding [essentially intracranial hemorrhage (ICH)]. Better appreciation of the importance of VKAs&#39; anticoagulation quality [a target time in therapeutic range (TTR) of 70%] and the availability of NOACs (which offer better safety compared to VKAs) have decreased the estimated threshold for OAC treatment in AF patients towards lower stroke risk levels. Still, contemporary registry&#45;based data show that OAC is often underused in AF patients at increased risk of stroke. The uncertainty whether to use OAC may be particularly pronounced in AF patients with a single additional stroke risk factor, who are often (mis)perceived as having a &#39;borderline&#39; or insufficient stroke risk to trigger the use of OAC. However, observational data from real&#45;world AF cohorts show that the annual stroke rates in such patients are higher than in patients with no additional stroke risk factors, and OAC use has been associated with reduction in stroke, systemic embolism, or death in comparison to no therapy or aspirin, with no increase in the risk of bleeding relative to aspirin. In this review article, we summarize the basic principles of stroke risk stratification in AF patients and discuss contemporary real&#45;world evidence on OAC use and outcomes of OAC treatment in AF patients with a single additional stroke risk factor in various real&#45;world AF cohorts.&#10;~&#10;PMID: 27933569&#10;Journal: Advances in therapy" target="_blank">
<polygon fill="transparent" stroke="black" points="1154.75,-1185.5 1050.75,-1185.5 1050.75,-1117.5 1160.75,-1117.5 1160.75,-1179.5 1154.75,-1185.5"/>
<polyline fill="none" stroke="black" points="1154.75,-1185.5 1154.75,-1179.5 "/>
<polyline fill="none" stroke="black" points="1160.75,-1179.5 1154.75,-1179.5 "/>
<text text-anchor="middle" x="1105.75" y="-1170.3" font-family="Times New Roman,serif" font-size="14.00">Potpara, Dagres,</text>
<text text-anchor="middle" x="1105.75" y="-1155.3" font-family="Times New Roman,serif" font-size="14.00">Mujovi, Vasi,</text>
<text text-anchor="middle" x="1105.75" y="-1140.3" font-family="Times New Roman,serif" font-size="14.00">Aanin</text>
<text text-anchor="middle" x="1105.75" y="-1125.3" font-family="Times New Roman,serif" font-size="14.00">(2017 02)</text>
</a>
</g>
</g>
<!-- 28188243 -->
<g id="node28" class="node">
<title>28188243</title>
<g id="a_node28"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/28188243/" xlink:title="Date: 2017 Feb 10&#10;Title: Effectiveness and safety of reduced dose non&#45;vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.&#10;By: Nielsen, Skjth, Sgaard, Kjldgaard, Lip, Larsen&#10;~&#10;Abstract: ObjectiveTo examine clinical effectiveness and safety of apixaban 2.5 mg, dabigatran 110 mg, and rivaroxaban 15 mg compared with warfarin among patients with atrial fibrillation who had not previously taken an oral anticoagulant.DesignPropensity weighted (inverse probability of treatment weighted) nationwide cohort study.SettingIndividual linked data from three nationwide registries in Denmark.ParticipantsPatients with non&#45;valvular atrial fibrillation filling a first prescription for an oral anticoagulant from August 2011 to February 2016. Patients who filled a prescription for a standard dose non&#45;vitamin K antagonist oral anticoagulant (novel oral anticoagulants, NOACs) were excluded. To control for baseline differences in the population, a propensity score for receipt of either of the four treatment alternatives was calculated to apply an inverse probability treatment weight.InterventionInitiated anticoagulant treatment (dabigatran 110 mg, rivaroxaban 15 mg, apixaban 2.5 mg, and warfarin).Main outcome measuresPatients were followed in the registries from onset of treatment for the primary effectiveness outcome of ischaemic stroke/systemic embolism and for the principal safety outcome of any bleeding events.ResultsAmong 55644 patients with atrial fibrillation who met inclusion criteria, the cohort was distributed according to treatment: apixaban n=4400; dabigatran n=8875; rivaroxaban n=3476; warfarin n=38893. The overall mean age was 73.9 (SD 12.7), ranging from a mean of 71.0 (warfarin) to 83.9 (apixaban). During one year of follow&#45;up, apixaban was associated with higher (weighted) event rate of ischaemic stroke/systemic embolism (4.8%), while dabigatran, rivaroxaban, and warfarin had event rates of 3.3%, 3.5%, and 3.7%, respectively. In the comparison between a non&#45;vitamin K antagonist oral anticoagulant and warfarin in the inverse probability of treatment weighted analyses and investigation of the effectiveness outcome, the hazard ratios were 1.19 (95% confidence interval 0.95 to 1.49) for apixaban, 0.89 (0.77 to 1.03) for dabigatran, and 0.89 (0.69 to 1.16) for rivaroxaban. For the principal safety outcome versus warfarin, the hazard ratios were 0.96 (0.73 to 1.27) for apixaban, 0.80 (0.70 to 0.92) for dabigatran, and 1.06 (0.87 to 1.29) for rivaroxaban.ConclusionIn this propensity weighted nationwide study of reduced dose non&#45;vitamin K antagonist oral anticoagulant regimens, apixaban 2.5 mg twice a day was associated with a trend towards higher rates of ischaemic stroke/systemic embolism compared with warfarin, while rivaroxaban 15 mg once a day and dabigatran 110 mg twice a day showed a trend towards lower thromboembolic rates. The results were not significantly different. Rates of bleeding (the principal safety outcome) were significantly lower for dabigatran, but not significantly different for apixaban and rivaroxaban compared with warfarin.&#10;~&#10;PMID: 28188243&#10;Journal: BMJ (Clinical research ed.)" target="_blank">
<polygon fill="transparent" stroke="black" points="2654.25,-1185.5 2553.25,-1185.5 2553.25,-1117.5 2660.25,-1117.5 2660.25,-1179.5 2654.25,-1185.5"/>
<polyline fill="none" stroke="black" points="2654.25,-1185.5 2654.25,-1179.5 "/>
<polyline fill="none" stroke="black" points="2660.25,-1179.5 2654.25,-1179.5 "/>
<text text-anchor="middle" x="2606.75" y="-1170.3" font-family="Times New Roman,serif" font-size="14.00">Nielsen, Skjth,</text>
<text text-anchor="middle" x="2606.75" y="-1155.3" font-family="Times New Roman,serif" font-size="14.00">Sgaard,</text>
<text text-anchor="middle" x="2606.75" y="-1140.3" font-family="Times New Roman,serif" font-size="14.00">Kjldgaard, Lip</text>
<text text-anchor="middle" x="2606.75" y="-1125.3" font-family="Times New Roman,serif" font-size="14.00">(2017 Feb 10)</text>
</a>
</g>
</g>
<!-- 28300870 -->
<g id="node29" class="node">
<title>28300870</title>
<g id="a_node29"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/28300870/" xlink:title="Date: 2017 06 02&#10;Title: Effectiveness and safety of apixaban versus warfarin in non&#45;valvular atrial fibrillation patients in &#39;real&#45;world&#39; clinical practice. A propensity&#45;matched analysis of 76,940 patients.&#10;By: Li, Deitelzweig, Keshishian, Hamilton, Horblyuk, Gupta, Luo, Mardekian, Friend, Nadkarni, Pan, Lip&#10;~&#10;Abstract: The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major bleeding in non&#45;valvular atrial fibrillation (NVAF) patients treated with apixaban compared to warfarin. This retrospective study used four large US claims databases (MarketScan, PharMetrics, Optum, and Humana) of NVAF patients newly initiating apixaban or warfarin from January 1, 2013 to September 30, 2015. After 1:1 warfarin&#45;apixaban propensity score matching (PSM) within each database, the resulting patient records were pooled. Kaplan&#45;Meier curves and Cox proportional hazards models were used to estimate the cumulative incidence and hazard ratios (HRs) of stroke/SE and major bleeding (identified using the first listed diagnosis of inpatient claims) within one year of therapy initiation. The study included a total of 76,940 (38,470 warfarin and 38,470 apixaban) patients. Among the 38,470 matched pairs, 14,563 were from MarketScan, 7,683 were from PharMetrics, 7,894 were from Optum, and 8,330 were from Humana. Baseline characteristics were balanced between the two cohorts with a mean (standard deviation [SD]) age of 71 (12) years and a mean (SD) CHA2DS2&#45;VASc score of 3.2 (1.7). Apixaban initiators had a significantly lower risk of stroke/SE (HR: 0.67, 95% CI: 0.59&#45;0.76) and major bleeding (HR: 0.60, 95% CI: 0.54&#45;0.65) than warfarin initiators. Different types of stroke/SE and major bleeding &#45; including ischaemic stroke, haemorrhagic stroke, SE, intracranial haemorrhage, gastrointestinal bleeding, and other major bleeding &#45; were all significantly lower for apixaban compared to warfarin treatment. Subgroup analyses (apixaban dosage, age strata, CHA2DS2&#45;VASc or HAS&#45;BLED score strata, or dataset source) all show consistently lower risks of stroke/SE and major bleeding associated with apixaban as compared to warfarin treatment. This is the largest &#39;real&#45;world&#39; study on apixaban effectiveness and safety to date, showing that apixaban initiation was associated with significant risk reductions in stroke/SE and major bleeding compared to warfarin initiation after PSM. These benefits were consistent across various high&#45;risk subgroups and both the standard&#45; and low&#45;dose apixaban dose regimens.&#10;~&#10;PMID: 28300870&#10;Journal: Thrombosis and haemostasis" target="_blank">
<polygon fill="transparent" stroke="black" points="3315.25,-1185.5 3194.25,-1185.5 3194.25,-1117.5 3321.25,-1117.5 3321.25,-1179.5 3315.25,-1185.5"/>
<polyline fill="none" stroke="black" points="3315.25,-1185.5 3315.25,-1179.5 "/>
<polyline fill="none" stroke="black" points="3321.25,-1179.5 3315.25,-1179.5 "/>
<text text-anchor="middle" x="3257.75" y="-1170.3" font-family="Times New Roman,serif" font-size="14.00">Li, Deitelzweig,</text>
<text text-anchor="middle" x="3257.75" y="-1155.3" font-family="Times New Roman,serif" font-size="14.00">Keshishian,</text>
<text text-anchor="middle" x="3257.75" y="-1140.3" font-family="Times New Roman,serif" font-size="14.00">Hamilton, Horblyuk</text>
<text text-anchor="middle" x="3257.75" y="-1125.3" font-family="Times New Roman,serif" font-size="14.00">(2017 06 02)</text>
</a>
</g>
</g>
<!-- 28408716 -->
<g id="node30" class="node">
<title>28408716</title>
<g id="a_node30"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/28408716/" xlink:title="Date: 2017 04&#10;Title: Sex&#45;Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.&#10;By: Palamaner Subash Shantha, Bhave, Girotra, Hodgson&#45;Zingman, Mazur, Giudici, Chrischilles, Vaughan Sarrazin&#10;~&#10;Abstract: Sex&#45;specific comparative effectiveness of direct oral anticoagulants among patients with nonvalvular atrial fibrillation is not known. Via this retrospective cohort study, we assessed the sex&#45;specific, comparative effectiveness of direct oral anticoagulants (rivaroxaban and dabigatran), compared to each other and to warfarin among patients with atrial fibrillation.&#10;~&#10;PMID: 28408716&#10;Journal: Circulation. Cardiovascular quality and outcomes" target="_blank">
<polygon fill="transparent" stroke="black" points="1856.75,-1193 1742.75,-1193 1742.75,-1110 1862.75,-1110 1862.75,-1187 1856.75,-1193"/>
<polyline fill="none" stroke="black" points="1856.75,-1193 1856.75,-1187 "/>
<polyline fill="none" stroke="black" points="1862.75,-1187 1856.75,-1187 "/>
<text text-anchor="middle" x="1802.75" y="-1177.8" font-family="Times New Roman,serif" font-size="14.00">Palamaner Subash</text>
<text text-anchor="middle" x="1802.75" y="-1162.8" font-family="Times New Roman,serif" font-size="14.00">Shantha, Bhave,</text>
<text text-anchor="middle" x="1802.75" y="-1147.8" font-family="Times New Roman,serif" font-size="14.00">Girotra, Hodgson&#45;</text>
<text text-anchor="middle" x="1802.75" y="-1132.8" font-family="Times New Roman,serif" font-size="14.00">Zingman, Mazur</text>
<text text-anchor="middle" x="1802.75" y="-1117.8" font-family="Times New Roman,serif" font-size="14.00">(2017 04)</text>
</a>
</g>
</g>
<!-- 28614582 -->
<g id="node31" class="node">
<title>28614582</title>
<g id="a_node31"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/28614582/" xlink:title="Date: 2017 08 01&#10;Title: Effectiveness and Safety of Standard&#45;Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.&#10;By: Lip, Skjth, Nielsen, Kjldgaard, Larsen&#10;~&#10;Abstract: The randomized clinical trials comparing nonvitamin K antagonist oral anticoagulants (NOACs) vs warfarin largely focused on recruiting high&#45;risk patients with atrial fibrillation with more than 2 stroke risk factors, with only the trials testing dabigatran or apixaban including few patients with 1 stroke risk factor. Despite this, regulatory approvals of all NOACs have been based on stroke prevention for patients with atrial fibrillation with 1 or more stroke risk factors.&#10;~&#10;PMID: 28614582&#10;Journal: JAMA cardiology" target="_blank">
<polygon fill="transparent" stroke="black" points="3058.25,-1185.5 2939.25,-1185.5 2939.25,-1117.5 3064.25,-1117.5 3064.25,-1179.5 3058.25,-1185.5"/>
<polyline fill="none" stroke="black" points="3058.25,-1185.5 3058.25,-1179.5 "/>
<polyline fill="none" stroke="black" points="3064.25,-1179.5 3058.25,-1179.5 "/>
<text text-anchor="middle" x="3001.75" y="-1170.3" font-family="Times New Roman,serif" font-size="14.00">Lip, Skjth,</text>
<text text-anchor="middle" x="3001.75" y="-1155.3" font-family="Times New Roman,serif" font-size="14.00">Nielsen,</text>
<text text-anchor="middle" x="3001.75" y="-1140.3" font-family="Times New Roman,serif" font-size="14.00">Kjldgaard, Larsen</text>
<text text-anchor="middle" x="3001.75" y="-1125.3" font-family="Times New Roman,serif" font-size="14.00">(2017 08 01)</text>
</a>
</g>
</g>
<!-- 28655814 -->
<g id="node32" class="node">
<title>28655814</title>
<g id="a_node32"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/28655814/" xlink:title="Date: 2017 08&#10;Title: Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.&#10;By: Coleman, Peacock, Bunz, Alberts&#10;~&#10;Abstract: Limited real&#45;world data exist comparing each non&#45;vitamin K antagonist oral anticoagulant (NOAC) to warfarin in patients with nonvalvular atrial fibrillation who have had a previous ischemic stroke or transient ischemic attack.&#10;~&#10;PMID: 28655814&#10;Journal: Stroke" target="_blank">
<polygon fill="transparent" stroke="black" points="3899.25,-1178 3780.25,-1178 3780.25,-1125 3905.25,-1125 3905.25,-1172 3899.25,-1178"/>
<polyline fill="none" stroke="black" points="3899.25,-1178 3899.25,-1172 "/>
<polyline fill="none" stroke="black" points="3905.25,-1172 3899.25,-1172 "/>
<text text-anchor="middle" x="3842.75" y="-1162.8" font-family="Times New Roman,serif" font-size="14.00">Coleman, Peacock,</text>
<text text-anchor="middle" x="3842.75" y="-1147.8" font-family="Times New Roman,serif" font-size="14.00">Bunz, Alberts</text>
<text text-anchor="middle" x="3842.75" y="-1132.8" font-family="Times New Roman,serif" font-size="14.00">(2017 08)</text>
</a>
</g>
</g>
<!-- 28668628 -->
<g id="node33" class="node">
<title>28668628</title>
<g id="a_node33"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/28668628/" xlink:title="Date: 2017 Jul&#10;Title: Effectiveness and Safety of Non&#45;vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta&#45;analyses.&#10;By: Almutairi, Zhou, Gellad, Lee, Slack, Martin, Lo&#45;Ciganic&#10;~&#10;Abstract: The findings from the observational studies comparing the effectiveness and safety of non&#45;vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) for atrial fibrillation (AF) and venous thromboembolism (VTE) are inconsistent. We conducted separate meta&#45;analyses examining the efficacy/effectiveness and safety of NOACs versus VKAs by disease (AF vs VTE), study design (randomized controlled trials [RCTs] vs observational studies), and NOAC (dabigatran, rivaroxaban, apixaban, and edoxaban).&#10;~&#10;PMID: 28668628&#10;Journal: Clinical therapeutics" target="_blank">
<polygon fill="transparent" stroke="black" points="2217.25,-1178 2104.25,-1178 2104.25,-1125 2223.25,-1125 2223.25,-1172 2217.25,-1178"/>
<polyline fill="none" stroke="black" points="2217.25,-1178 2217.25,-1172 "/>
<polyline fill="none" stroke="black" points="2223.25,-1172 2217.25,-1172 "/>
<text text-anchor="middle" x="2163.75" y="-1162.8" font-family="Times New Roman,serif" font-size="14.00">Almutairi, Zhou,</text>
<text text-anchor="middle" x="2163.75" y="-1147.8" font-family="Times New Roman,serif" font-size="14.00">Gellad, Lee, Slack</text>
<text text-anchor="middle" x="2163.75" y="-1132.8" font-family="Times New Roman,serif" font-size="14.00">(2017 Jul)</text>
</a>
</g>
</g>
<!-- 28860793 -->
<g id="node34" class="node">
<title>28860793</title>
<g id="a_node34"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/28860793/" xlink:title="Date: 2017&#10;Title: Evaluation of bleeding in patients receiving direct oral anticoagulants.&#10;By: Hellenbart, Faulkenberg, Finks&#10;~&#10;Abstract: Direct oral anticoagulants (DOACs) are recognized by evidence&#45;based treatment guidelines as the first&#45;line option for the treatment of venous thromboembolism and prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. As use of these anticoagulants has become favored over the past several years, reported bleeding&#45;related adverse drug events with these agents has increased. In randomized clinical trials, all DOACs have a reduced risk for intracranial hemorrhage, while major and other bleeding results have varied among the agents compared to vitamin K antagonists. We have reviewed the bleeding incidence and severity from randomized and real&#45;world data in patients receiving DOACs in an effort to provide the clinician with a critical review of bleeding and offer practical considerations for avoiding adverse events with these anticoagulants.&#10;~&#10;PMID: 28860793&#10;Journal: Vascular health and risk management" target="_blank">
<polygon fill="transparent" stroke="black" points="2104.25,-1404.5 1987.25,-1404.5 1987.25,-1351.5 2110.25,-1351.5 2110.25,-1398.5 2104.25,-1404.5"/>
<polyline fill="none" stroke="black" points="2104.25,-1404.5 2104.25,-1398.5 "/>
<polyline fill="none" stroke="black" points="2110.25,-1398.5 2104.25,-1398.5 "/>
<text text-anchor="middle" x="2048.75" y="-1389.3" font-family="Times New Roman,serif" font-size="14.00">Hellenbart,</text>
<text text-anchor="middle" x="2048.75" y="-1374.3" font-family="Times New Roman,serif" font-size="14.00">Faulkenberg, Finks</text>
<text text-anchor="middle" x="2048.75" y="-1359.3" font-family="Times New Roman,serif" font-size="14.00">(2017)</text>
</a>
</g>
</g>
<!-- 28874129 -->
<g id="node35" class="node">
<title>28874129</title>
<g id="a_node35"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/28874129/" xlink:title="Date: 2017 09 06&#10;Title: Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non&#45;valvular atrial fibrillation.&#10;By: Norby, Bengtson, Lutsey, Chen, MacLehose, Chamberlain, Rapson, Alonso&#10;~&#10;Abstract: Rivaroxaban is an oral anticoagulant approved in the US for prevention of stroke and systemic embolism in patients with non&#45;valvular atrial fibrillation (NVAF). We determined the effectiveness and associated risks of rivaroxaban versus other oral anticoagulants in a large real&#45;world population.&#10;~&#10;PMID: 28874129&#10;Journal: BMC cardiovascular disorders" target="_blank">
<polygon fill="transparent" stroke="black" points="1378.75,-1185.5 1268.75,-1185.5 1268.75,-1117.5 1384.75,-1117.5 1384.75,-1179.5 1378.75,-1185.5"/>
<polyline fill="none" stroke="black" points="1378.75,-1185.5 1378.75,-1179.5 "/>
<polyline fill="none" stroke="black" points="1384.75,-1179.5 1378.75,-1179.5 "/>
<text text-anchor="middle" x="1326.75" y="-1170.3" font-family="Times New Roman,serif" font-size="14.00">Norby, Bengtson,</text>
<text text-anchor="middle" x="1326.75" y="-1155.3" font-family="Times New Roman,serif" font-size="14.00">Lutsey, Chen,</text>
<text text-anchor="middle" x="1326.75" y="-1140.3" font-family="Times New Roman,serif" font-size="14.00">MacLehose</text>
<text text-anchor="middle" x="1326.75" y="-1125.3" font-family="Times New Roman,serif" font-size="14.00">(2017 09 06)</text>
</a>
</g>
</g>
<!-- 28956288 -->
<g id="node36" class="node">
<title>28956288</title>
<g id="a_node36"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/28956288/" xlink:title="Date: 2017 10&#10;Title: Pharmacological and Non&#45;pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation.&#10;By: Ueberham, Dagres, Potpara, Bollmann, Hindricks&#10;~&#10;Abstract: Atrial fibrillation (AF) is associated with significant risk of stroke and other thromboembolic events, which can be effectively prevented using oral anticoagulation (OAC) with either vitamin K antagonists (VKAs) or non&#45;VKA oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban, or edoxaban. Until recently, VKAs were the only available means for OAC treatment. NOACs had similar efficacy and were safer than or as safe as warfarin with respect to reduced rates of hemorrhagic stroke or other intracranial bleeding in the respective pivotal randomized clinical trials (RCTs) of stroke prevention in non&#45;valvular AF patients. Increasing &#39;real&#45;world&#39; evidence on NOACs broadly confirms the results of the RCTs. However, individual patient characteristics including renal function, age, or prior bleeding should be taken into account when choosing the OAC with best risk&#45;benefit profile. In patients ineligible for OACs, surgical or interventional stroke prevention strategies should be considered. In patients undergoing cardiac surgery for other reasons, the left atrial appendage excision, ligation, or amputation may be the best option. Importantly, residual stumps or insufficient ligation may result in even higher stroke risk than without intervention. Percutaneous left atrial appendage occlusion, although requiring minimally invasive access, failed to demonstrate reduced ischemic stroke events compared to warfarin. In this review article, we summarize current treatment options and discuss the strengths and major limitations of the therapies for stroke risk reduction in patients with AF.&#10;~&#10;PMID: 28956288&#10;Journal: Advances in therapy" target="_blank">
<polygon fill="transparent" stroke="black" points="1096.75,-1412 978.75,-1412 978.75,-1344 1102.75,-1344 1102.75,-1406 1096.75,-1412"/>
<polyline fill="none" stroke="black" points="1096.75,-1412 1096.75,-1406 "/>
<polyline fill="none" stroke="black" points="1102.75,-1406 1096.75,-1406 "/>
<text text-anchor="middle" x="1040.75" y="-1396.8" font-family="Times New Roman,serif" font-size="14.00">Ueberham, Dagres,</text>
<text text-anchor="middle" x="1040.75" y="-1381.8" font-family="Times New Roman,serif" font-size="14.00">Potpara, Bollmann,</text>
<text text-anchor="middle" x="1040.75" y="-1366.8" font-family="Times New Roman,serif" font-size="14.00">Hindricks</text>
<text text-anchor="middle" x="1040.75" y="-1351.8" font-family="Times New Roman,serif" font-size="14.00">(2017 10)</text>
</a>
</g>
</g>
<!-- 29171208 -->
<g id="node37" class="node">
<title>29171208</title>
<g id="a_node37"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/29171208/" xlink:title="Date: 2017 Nov&#10;Title: Real&#45;world Data and Recommended Dosage of Non&#45;vitamin K Oral Anticoagulants for Korean Patients.&#10;By: Joung&#10;~&#10;Abstract: Regulatory approvals of non&#45;vitamin K antagonist oral anticoagulants (NOACs) have been based on large randomized phase III trials evaluating dabigatran, rivaroxaban, apixaban, or edoxaban relative to warfarin for atrial fibrillation (AF). The results of the trials showed that all NOACs were at least non&#45;inferior to warfarin in the prevention of stroke/thromboembolism and showed lower rates of intracranial bleeding than those associated with warfarin. However, the trials were designed differently, varied in the inclusion/exclusion criteria, and used either one dose or a low/high dose of the NOAC drug. Some of these differences have challenged the ability to directly compare various NOACs, and comparative data on effectiveness and intracranial bleeding are sparse in &#39;real&#45;world&#39; patients. Real&#45;world data complement data from large randomized phase III trials by providing new aspects of the &#39;real&#45;world&#39; absolute risks of ischemic and hemorrhagic stroke associated with NOACs vs. warfarin. Moreover, &#39;real&#45;world&#39; fragile patients might have been included (e.g., patients with increased risk of bleeding, liver disease, and chronic kidney disease), although these patients would be less represented in trials. This paper introduces recently published real&#45;world data of NOACs and further suggests the recommended dosage of NOACs for Korean patients.&#10;~&#10;PMID: 29171208&#10;Journal: Korean circulation journal" target="_blank">
<polygon fill="transparent" stroke="black" points="2331.75,-1397 2257.75,-1397 2257.75,-1359 2337.75,-1359 2337.75,-1391 2331.75,-1397"/>
<polyline fill="none" stroke="black" points="2331.75,-1397 2331.75,-1391 "/>
<polyline fill="none" stroke="black" points="2337.75,-1391 2331.75,-1391 "/>
<text text-anchor="middle" x="2297.75" y="-1381.8" font-family="Times New Roman,serif" font-size="14.00">Joung</text>
<text text-anchor="middle" x="2297.75" y="-1366.8" font-family="Times New Roman,serif" font-size="14.00">(2017 Nov)</text>
</a>
</g>
</g>
<!-- 29360144 -->
<g id="node38" class="node">
<title>29360144</title>
<g id="a_node38"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/29360144/" xlink:title="Date: 2018 Jan&#10;Title: Agreement between coding schemas used to identify bleeding&#45;related hospitalizations in claims analyses of nonvalvular atrial fibrillation patients.&#10;By: Coleman, Vaitsiakhovich, Nguyen, Weeda, Sood, Bunz, Schaefer, Meinecke, Eriksson&#10;~&#10;Abstract: Schemas to identify bleeding&#45;related hospitalizations in claims data differ in billing codes used and coding positions allowed. We assessed agreement across bleeding&#45;related hospitalization coding schemas for claims analyses of nonvalvular atrial fibrillation (NVAF) patients on oral anticoagulation (OAC).&#10;~&#10;PMID: 29360144&#10;Journal: Clinical cardiology" target="_blank">
<polygon fill="transparent" stroke="black" points="1539.75,-1412 1401.75,-1412 1401.75,-1344 1545.75,-1344 1545.75,-1406 1539.75,-1412"/>
<polyline fill="none" stroke="black" points="1539.75,-1412 1539.75,-1406 "/>
<polyline fill="none" stroke="black" points="1545.75,-1406 1539.75,-1406 "/>
<text text-anchor="middle" x="1473.75" y="-1396.8" font-family="Times New Roman,serif" font-size="14.00">Coleman,</text>
<text text-anchor="middle" x="1473.75" y="-1381.8" font-family="Times New Roman,serif" font-size="14.00">Vaitsiakhovich,</text>
<text text-anchor="middle" x="1473.75" y="-1366.8" font-family="Times New Roman,serif" font-size="14.00">Nguyen, Weeda, Sood</text>
<text text-anchor="middle" x="1473.75" y="-1351.8" font-family="Times New Roman,serif" font-size="14.00">(2018 Jan)</text>
</a>
</g>
</g>
<!-- 29371284 -->
<g id="node39" class="node">
<title>29371284</title>
<g id="a_node39"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/29371284/" xlink:title="Date: 2018 01 24&#10;Title: Comparative effectiveness of novel oral anticoagulants in UK patients with non&#45;valvular atrial fibrillation and chronic kidney disease: a matched cohort study.&#10;By: Loo, Coulombe, Dell&#39;Aniello, Brophy, Suissa, Renoux&#10;~&#10;Abstract: To evaluate the effectiveness and safety of novel oral anticoagulants (NOACs) compared with vitamin K antagonists (VKAs) among patients with non&#45;valvular atrial fibrillation (NVAF), particularly those with chronic kidney disease (CKD).&#10;~&#10;PMID: 29371284&#10;Journal: BMJ open" target="_blank">
<polygon fill="transparent" stroke="black" points="1844.75,-1412 1740.75,-1412 1740.75,-1344 1850.75,-1344 1850.75,-1406 1844.75,-1412"/>
<polyline fill="none" stroke="black" points="1844.75,-1412 1844.75,-1406 "/>
<polyline fill="none" stroke="black" points="1850.75,-1406 1844.75,-1406 "/>
<text text-anchor="middle" x="1795.75" y="-1396.8" font-family="Times New Roman,serif" font-size="14.00">Loo, Coulombe,</text>
<text text-anchor="middle" x="1795.75" y="-1381.8" font-family="Times New Roman,serif" font-size="14.00">Dell&#39;Aniello,</text>
<text text-anchor="middle" x="1795.75" y="-1366.8" font-family="Times New Roman,serif" font-size="14.00">Brophy, Suissa</text>
<text text-anchor="middle" x="1795.75" y="-1351.8" font-family="Times New Roman,serif" font-size="14.00">(2018 01 24)</text>
</a>
</g>
</g>
<!-- 29373602 -->
<g id="node40" class="node">
<title>29373602</title>
<g id="a_node40"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/29373602/" xlink:title="Date: 2018&#10;Title: Apixaban 5 and 2.5 mg twice&#45;daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity&#45;score&#45;matched approach.&#10;By: Li, Keshishian, Hamilton, Horblyuk, Gupta, Luo, Mardekian, Friend, Nadkarni, Pan, Lip, Deitelzweig&#10;~&#10;Abstract: Prior real&#45;world studies have shown that apixaban is associated with a reduced risk of stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few studies evaluated the effectiveness and safety of apixaban according to its dosage, and most studies contained limited numbers of patients prescribed 2.5 mg twice&#45;daily (BID) apixaban. Using pooled data from 4 American claims database sources, baseline characteristics and outcomes for patients prescribed 5 mg BID and 2.5 mg BID apixaban versus warfarin were compared. After 1:1 propensity&#45;score matching, 31,827 5 mg BID apixaban&#45;matched warfarin patients and 6600 2.5 mg BID apixaban&#45;matched warfarin patients were identified. Patients prescribed 2.5 mg BID apixaban were older, had clinically more severe comorbidities, and were more likely to have a history of stroke and bleeding compared with 5 mg BID apixaban patients. Compared with warfarin, 5 mg BID apixaban was associated with a lower risk of stroke/SE (hazard ratio [HR]: 0.70, 95% confidence interval [CI]: 0.60&#45;0.81) and major bleeding (HR: 0.59, 95% CI: 0.53&#45;0.66). Compared with warfarin, 2.5 mg BID apixaban was also associated with a lower risk of stroke/SE (HR: 0.63, 95% CI: 0.49&#45;0.81) and major bleeding (HR: 0.59, 95% CI: 0.49&#45;0.71). In this real&#45;world study, both apixaban doses were assessed in 2 patient groups differing in age and clinical characteristics. Each apixaban dose was associated with a lower risk of stroke/SE and major bleeding compared with warfarin in the distinct population for which it is being prescribed in United States clinical practice.&#10;~&#10;PMID: 29373602&#10;Journal: PloS one" target="_blank">
<polygon fill="transparent" stroke="black" points="2709.25,-1412 2584.25,-1412 2584.25,-1344 2715.25,-1344 2715.25,-1406 2709.25,-1412"/>
<polyline fill="none" stroke="black" points="2709.25,-1412 2709.25,-1406 "/>
<polyline fill="none" stroke="black" points="2715.25,-1406 2709.25,-1406 "/>
<text text-anchor="middle" x="2649.75" y="-1396.8" font-family="Times New Roman,serif" font-size="14.00">Li, Keshishian,</text>
<text text-anchor="middle" x="2649.75" y="-1381.8" font-family="Times New Roman,serif" font-size="14.00">Hamilton, Horblyuk,</text>
<text text-anchor="middle" x="2649.75" y="-1366.8" font-family="Times New Roman,serif" font-size="14.00">Gupta</text>
<text text-anchor="middle" x="2649.75" y="-1351.8" font-family="Times New Roman,serif" font-size="14.00">(2018)</text>
</a>
</g>
</g>
<!-- 29525786 -->
<g id="node41" class="node">
<title>29525786</title>
<g id="a_node41"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/29525786/" xlink:title="Date: 2018 03 10&#10;Title: Safety and Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists: Pilot Implementation of a Near&#45;Real&#45;Time Monitoring Program in Italy.&#10;By: Mayer, Kirchmayer, Coletta, Agabiti, Belleudi, Cappai, Di Martino, Schneeweiss, Davoli, Patorno&#10;~&#10;Abstract: Real&#45;time monitoring is used to the ends of postmarketing observational research on newly marketed drugs. We implemented a pilot near&#45;real&#45;time monitoring program on the test case of oral anticoagulants. Specifically, we evaluated the safety and effectiveness of direct oral anticoagulants compared to vitamin K antagonists in nonvalvular atrial fibrillation secondary prevention during 2013&#45;2015 in the Lazio Region, Italy.&#10;~&#10;PMID: 29525786&#10;Journal: Journal of the American Heart Association" target="_blank">
<polygon fill="transparent" stroke="black" points="852.75,-1185.5 730.75,-1185.5 730.75,-1117.5 858.75,-1117.5 858.75,-1179.5 852.75,-1185.5"/>
<polyline fill="none" stroke="black" points="852.75,-1185.5 852.75,-1179.5 "/>
<polyline fill="none" stroke="black" points="858.75,-1179.5 852.75,-1179.5 "/>
<text text-anchor="middle" x="794.75" y="-1170.3" font-family="Times New Roman,serif" font-size="14.00">Mayer, Kirchmayer,</text>
<text text-anchor="middle" x="794.75" y="-1155.3" font-family="Times New Roman,serif" font-size="14.00">Coletta, Agabiti,</text>
<text text-anchor="middle" x="794.75" y="-1140.3" font-family="Times New Roman,serif" font-size="14.00">Belleudi</text>
<text text-anchor="middle" x="794.75" y="-1125.3" font-family="Times New Roman,serif" font-size="14.00">(2018 03 10)</text>
</a>
</g>
</g>
<!-- 29622587 -->
<g id="node42" class="node">
<title>29622587</title>
<g id="a_node42"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/29622587/" xlink:title="Date: 2018 04 05&#10;Title: Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.&#10;By: Chan, See, Tu, Yeh, Chang, Wu, Lee, Wang, Kuo, Kuo&#10;~&#10;Abstract: Whether non&#45;vitamin K antagonist oral anticoagulants (NOACs) are superior to warfarin among Asians with nonvalvular atrial fibrillation remains unclear.&#10;~&#10;PMID: 29622587&#10;Journal: Journal of the American Heart Association" target="_blank">
<polygon fill="transparent" stroke="black" points="2859.25,-1178 2734.25,-1178 2734.25,-1125 2865.25,-1125 2865.25,-1172 2859.25,-1178"/>
<polyline fill="none" stroke="black" points="2859.25,-1178 2859.25,-1172 "/>
<polyline fill="none" stroke="black" points="2865.25,-1172 2859.25,-1172 "/>
<text text-anchor="middle" x="2799.75" y="-1162.8" font-family="Times New Roman,serif" font-size="14.00">Chan, See, Tu, Yeh,</text>
<text text-anchor="middle" x="2799.75" y="-1147.8" font-family="Times New Roman,serif" font-size="14.00">Chang</text>
<text text-anchor="middle" x="2799.75" y="-1132.8" font-family="Times New Roman,serif" font-size="14.00">(2018 04 05)</text>
</a>
</g>
</g>
<!-- 29654196 -->
<g id="node43" class="node">
<title>29654196</title>
<g id="a_node43"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/29654196/" xlink:title="Date: 2018 04 13&#10;Title: Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.&#10;By: Martinez, Sood, Bunz, Coleman&#10;~&#10;Abstract: Frailty predicts poorer outcomes and decreased anticoagulation use in patients with nonvalvular atrial fibrillation. We sought to assess the effectiveness and safety of apixaban, dabigatran and rivaroxaban versus warfarin in frail nonvalvular atrial fibrillation patients.&#10;~&#10;PMID: 29654196&#10;Journal: Journal of the American Heart Association" target="_blank">
<polygon fill="transparent" stroke="black" points="1717.25,-1404.5 1616.25,-1404.5 1616.25,-1351.5 1723.25,-1351.5 1723.25,-1398.5 1717.25,-1404.5"/>
<polyline fill="none" stroke="black" points="1717.25,-1404.5 1717.25,-1398.5 "/>
<polyline fill="none" stroke="black" points="1723.25,-1398.5 1717.25,-1398.5 "/>
<text text-anchor="middle" x="1669.75" y="-1389.3" font-family="Times New Roman,serif" font-size="14.00">Martinez, Sood,</text>
<text text-anchor="middle" x="1669.75" y="-1374.3" font-family="Times New Roman,serif" font-size="14.00">Bunz, Coleman</text>
<text text-anchor="middle" x="1669.75" y="-1359.3" font-family="Times New Roman,serif" font-size="14.00">(2018 04 13)</text>
</a>
</g>
</g>
<!-- 29663521 -->
<g id="node44" class="node">
<title>29663521</title>
<g id="a_node44"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/29663521/" xlink:title="Date: 2018 08&#10;Title: Effectiveness and safety of rivaroxaban vs warfarin in people with non&#45;valvular atrial fibrillation and diabetes: an administrative claims database analysis.&#10;By: Coleman, Bunz, Eriksson, Meinecke, Sood&#10;~&#10;Abstract: To assess the effectiveness and safety of rivaroxaban vs warfarin in people with non&#45;valvular atrial fibrillation and diabetes treated in routine practice.&#10;~&#10;PMID: 29663521&#10;Journal: Diabetic medicine : a journal of the British Diabetic Association" target="_blank">
<polygon fill="transparent" stroke="black" points="622.75,-1412 498.75,-1412 498.75,-1344 628.75,-1344 628.75,-1406 622.75,-1412"/>
<polyline fill="none" stroke="black" points="622.75,-1412 622.75,-1406 "/>
<polyline fill="none" stroke="black" points="628.75,-1406 622.75,-1406 "/>
<text text-anchor="middle" x="563.75" y="-1396.8" font-family="Times New Roman,serif" font-size="14.00">Coleman, Bunz,</text>
<text text-anchor="middle" x="563.75" y="-1381.8" font-family="Times New Roman,serif" font-size="14.00">Eriksson, Meinecke,</text>
<text text-anchor="middle" x="563.75" y="-1366.8" font-family="Times New Roman,serif" font-size="14.00">Sood</text>
<text text-anchor="middle" x="563.75" y="-1351.8" font-family="Times New Roman,serif" font-size="14.00">(2018 08)</text>
</a>
</g>
</g>
<!-- 29909576 -->
<g id="node45" class="node">
<title>29909576</title>
<g id="a_node45"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/29909576/" xlink:title="Date: 2018 Oct&#10;Title: Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation.&#10;By: Ujeyl, Kster, Wille, Stammschulte, Hein, Harder, Gundert&#45;Remy, Bleek, Ihle, Schrder, Schillinger, Zawinell, Schubert&#10;~&#10;Abstract: The pivotal trials for stroke prevention in non&#45;valvular atrial fibrillation (NVAF) compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims&#45;based studies. Comparisons with phenprocoumon, the most frequently used vitamin K antagonist (VKA) in Germany, are scarce.&#10;~&#10;PMID: 29909576&#10;Journal: European journal of clinical pharmacology" target="_blank">
<polygon fill="transparent" stroke="black" points="2560.75,-1412 2438.75,-1412 2438.75,-1344 2566.75,-1344 2566.75,-1406 2560.75,-1412"/>
<polyline fill="none" stroke="black" points="2560.75,-1412 2560.75,-1406 "/>
<polyline fill="none" stroke="black" points="2566.75,-1406 2560.75,-1406 "/>
<text text-anchor="middle" x="2502.75" y="-1396.8" font-family="Times New Roman,serif" font-size="14.00">Ujeyl, Kster,</text>
<text text-anchor="middle" x="2502.75" y="-1381.8" font-family="Times New Roman,serif" font-size="14.00">Wille,</text>
<text text-anchor="middle" x="2502.75" y="-1366.8" font-family="Times New Roman,serif" font-size="14.00">Stammschulte, Hein</text>
<text text-anchor="middle" x="2502.75" y="-1351.8" font-family="Times New Roman,serif" font-size="14.00">(2018 Oct)</text>
</a>
</g>
</g>
<!-- 29973392 -->
<g id="node46" class="node">
<title>29973392</title>
<g id="a_node46"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/29973392/" xlink:title="Date: 2018 07 04&#10;Title: Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.&#10;By: Vinogradova, Coupland, Hill, Hippisley&#45;Cox&#10;~&#10;Abstract: To investigate the associations between direct oral anticoagulants (DOACs) and risks of bleeding, ischaemic stroke, venous thromboembolism, and all cause mortality compared with warfarin.&#10;~&#10;PMID: 29973392&#10;Journal: BMJ (Clinical research ed.)" target="_blank">
<polygon fill="transparent" stroke="black" points="1392.25,-1412 1297.25,-1412 1297.25,-1344 1398.25,-1344 1398.25,-1406 1392.25,-1412"/>
<polyline fill="none" stroke="black" points="1392.25,-1412 1392.25,-1406 "/>
<polyline fill="none" stroke="black" points="1398.25,-1406 1392.25,-1406 "/>
<text text-anchor="middle" x="1347.75" y="-1396.8" font-family="Times New Roman,serif" font-size="14.00">Vinogradova,</text>
<text text-anchor="middle" x="1347.75" y="-1381.8" font-family="Times New Roman,serif" font-size="14.00">Coupland, Hill,</text>
<text text-anchor="middle" x="1347.75" y="-1366.8" font-family="Times New Roman,serif" font-size="14.00">Hippisley&#45;Cox</text>
<text text-anchor="middle" x="1347.75" y="-1351.8" font-family="Times New Roman,serif" font-size="14.00">(2018 07 04)</text>
</a>
</g>
</g>
<!-- 30020424 -->
<g id="node47" class="node">
<title>30020424</title>
<g id="a_node47"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/30020424/" xlink:title="Date: 2019 04 01&#10;Title: Effectiveness and safety of rivaroxaban vs. warfarin in non&#45;valvular atrial fibrillation patients with a non&#45;sex&#45;related CHA2DS2&#45;VASc score of 1.&#10;By: Coleman, Turpie, Bunz, Eriksson, Sood, Baker&#10;~&#10;Abstract: To compare the effectiveness and safety of standard&#45;dose rivaroxaban (20mg o.d.) and warfarin in non&#45;valvular atrial fibrillation (NVAF) patients with a non&#45;sex&#45;related CHA2DS2&#45;VASc score of 1.&#10;~&#10;PMID: 30020424&#10;Journal: European heart journal. Cardiovascular pharmacotherapy" target="_blank">
<polygon fill="transparent" stroke="black" points="739.75,-1412 631.75,-1412 631.75,-1344 745.75,-1344 745.75,-1406 739.75,-1412"/>
<polyline fill="none" stroke="black" points="739.75,-1412 739.75,-1406 "/>
<polyline fill="none" stroke="black" points="745.75,-1406 739.75,-1406 "/>
<text text-anchor="middle" x="688.75" y="-1396.8" font-family="Times New Roman,serif" font-size="14.00">Coleman, Turpie,</text>
<text text-anchor="middle" x="688.75" y="-1381.8" font-family="Times New Roman,serif" font-size="14.00">Bunz, Eriksson,</text>
<text text-anchor="middle" x="688.75" y="-1366.8" font-family="Times New Roman,serif" font-size="14.00">Sood</text>
<text text-anchor="middle" x="688.75" y="-1351.8" font-family="Times New Roman,serif" font-size="14.00">(2019 04 01)</text>
</a>
</g>
</g>
<!-- 30299591 -->
<g id="node48" class="node">
<title>30299591</title>
<g id="a_node48"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/30299591/" xlink:title="Date: 2019 02&#10;Title: Effectiveness and safety of rivaroxaban vs. warfarin in patients with non&#45;valvular atrial fibrillation and heart failure.&#10;By: Martinez, Bunz, Eriksson, Meinecke, Sood, Coleman&#10;~&#10;Abstract: Heart failure (HF) is a common co&#45;morbidity in non&#45;valvular atrial fibrillation (NVAF) patients and a potent risk factor for stroke, bleeding, and a decreased time&#45;in&#45;therapeutic range with warfarin. We assessed the real&#45;world effectiveness and safety of rivaroxaban and warfarin in NVAF patients with co&#45;morbid HF.&#10;~&#10;PMID: 30299591&#10;Journal: ESC heart failure" target="_blank">
<polygon fill="transparent" stroke="black" points="3242.75,-1412 3118.75,-1412 3118.75,-1344 3248.75,-1344 3248.75,-1406 3242.75,-1412"/>
<polyline fill="none" stroke="black" points="3242.75,-1412 3242.75,-1406 "/>
<polyline fill="none" stroke="black" points="3248.75,-1406 3242.75,-1406 "/>
<text text-anchor="middle" x="3183.75" y="-1396.8" font-family="Times New Roman,serif" font-size="14.00">Martinez, Bunz,</text>
<text text-anchor="middle" x="3183.75" y="-1381.8" font-family="Times New Roman,serif" font-size="14.00">Eriksson, Meinecke,</text>
<text text-anchor="middle" x="3183.75" y="-1366.8" font-family="Times New Roman,serif" font-size="14.00">Sood</text>
<text text-anchor="middle" x="3183.75" y="-1351.8" font-family="Times New Roman,serif" font-size="14.00">(2019 02)</text>
</a>
</g>
</g>
<!-- 30383768 -->
<g id="node49" class="node">
<title>30383768</title>
<g id="a_node49"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/30383768/" xlink:title="Date: 2018&#10;Title: Real&#45;world comparison of bleeding risks among non&#45;valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.&#10;By: Tepper, Mardekian, Masseria, Phatak, Kamble, Abdulsattar, Petkun, Lip&#10;~&#10;Abstract: Limited real&#45;world data are available regarding the comparative safety of non&#45;vitamin K antagonist oral anticoagulants (NOACs). The objective of this retrospective claims observational cohort study was to compare the risk of bleeding among non&#45;valvular atrial fibrillation (NVAF) patients prescribed apixaban, dabigatran, or rivaroxaban. NVAF patients aged 18 years with a 1&#45;year baseline period were included if they were new initiators of NOACs or switched from warfarin to a NOAC. Cox proportional hazards modelling was used to estimate the adjusted hazard ratios of any bleeding, clinically relevant non&#45;major (CRNM) bleeding, and major inpatient bleeding within 6 months of treatment initiation for rivaroxaban and dabigatran compared to apixaban. Among 60,227 eligible patients, 8,785 were prescribed apixaban, 20,963 dabigatran, and 30,529 rivaroxaban. Compared to dabigatran or rivaroxaban patients, apixaban patients were more likely to have greater proportions of baseline comorbidities and higher CHA2DS2&#45;VASc and HAS&#45;BLED scores. After adjusting for baseline clinical and demographic characteristics, patients prescribed rivaroxaban were more likely to experience any bleeding (HR: 1.35, 95% confidence interval [CI]: 1.26&#45;1.45), CRNM bleeding (HR: 1.38, 95% CI: 1.27&#45;1.49), and major inpatient bleeding (HR: 1.43, 95% CI: 1.17&#45;1.74), compared to patients prescribed apixaban. Dabigatran patients had similar bleeding risks as apixaban patients. In conclusion, NVAF patients treated with rivaroxaban appeared to have an increased risk of any bleeding, CRNM bleeding, and major inpatient bleeding, compared to apixaban patients. There was no significant difference in any bleeding, CRNM bleeding, or inpatient major bleeding risks between patients treated with dabigatran and apixaban.&#10;~&#10;PMID: 30383768&#10;Journal: PloS one" target="_blank">
<polygon fill="transparent" stroke="black" points="1628.25,-1185.5 1507.25,-1185.5 1507.25,-1117.5 1634.25,-1117.5 1634.25,-1179.5 1628.25,-1185.5"/>
<polyline fill="none" stroke="black" points="1628.25,-1185.5 1628.25,-1179.5 "/>
<polyline fill="none" stroke="black" points="1634.25,-1179.5 1628.25,-1179.5 "/>
<text text-anchor="middle" x="1570.75" y="-1170.3" font-family="Times New Roman,serif" font-size="14.00">Tepper, Mardekian,</text>
<text text-anchor="middle" x="1570.75" y="-1155.3" font-family="Times New Roman,serif" font-size="14.00">Masseria, Phatak,</text>
<text text-anchor="middle" x="1570.75" y="-1140.3" font-family="Times New Roman,serif" font-size="14.00">Kamble</text>
<text text-anchor="middle" x="1570.75" y="-1125.3" font-family="Times New Roman,serif" font-size="14.00">(2018)</text>
</a>
</g>
</g>
<!-- 30423205 -->
<g id="node50" class="node">
<title>30423205</title>
<g id="a_node50"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/30423205/" xlink:title="Date: 2019 02&#10;Title: Effectiveness and safety of 110 or 150mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation.&#10;By: Blin, Dureau&#45;Pournin, Cottin, Bnichou, Mismetti, Abouelfath, Lassalle, Droz, Moore&#10;~&#10;Abstract: We compared the 1&#45;year safety and effectiveness of dabigatran 110mg (D110) or 150mg (D150) twice daily to vitamin K antagonists (VKA) in patients with nonvalvular atrial fibrillation.&#10;~&#10;PMID: 30423205&#10;Journal: British journal of clinical pharmacology" target="_blank">
<polygon fill="transparent" stroke="black" points="338.25,-1631 219.25,-1631 219.25,-1563 344.25,-1563 344.25,-1625 338.25,-1631"/>
<polyline fill="none" stroke="black" points="338.25,-1631 338.25,-1625 "/>
<polyline fill="none" stroke="black" points="344.25,-1625 338.25,-1625 "/>
<text text-anchor="middle" x="281.75" y="-1615.8" font-family="Times New Roman,serif" font-size="14.00">Blin, Dureau&#45;</text>
<text text-anchor="middle" x="281.75" y="-1600.8" font-family="Times New Roman,serif" font-size="14.00">Pournin, Cottin,</text>
<text text-anchor="middle" x="281.75" y="-1585.8" font-family="Times New Roman,serif" font-size="14.00">Bnichou, Mismetti</text>
<text text-anchor="middle" x="281.75" y="-1570.8" font-family="Times New Roman,serif" font-size="14.00">(2019 02)</text>
</a>
</g>
</g>
<!-- 30571400 -->
<g id="node51" class="node">
<title>30571400</title>
<g id="a_node51"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/30571400/" xlink:title="Date: 2018 12&#10;Title: Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.&#10;By: Lip, Keshishian, Li, Hamilton, Masseria, Gupta, Luo, Mardekian, Friend, Nadkarni, Pan, Baser, Deitelzweig&#10;~&#10;Abstract: Background and Purpose&#45; This ARISTOPHANES study (Anticoagulants for Reduction in Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) used multiple data sources to compare stroke/systemic embolism (SE) and major bleeding (MB) among a large number of nonvalvular atrial fibrillation patients on non&#45;vitamin K antagonist oral anticoagulants (NOACs) or warfarin. Methods&#45; A retrospective observational study of nonvalvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin from January 1, 2013, to September 30, 2015, was conducted pooling Centers for Medicare and Medicaid Services Medicare data and 4 US commercial claims databases. After 1:1 NOAC&#45;warfarin and NOAC&#45;NOAC propensity score matching in each database, the resulting patient records were pooled. Cox models were used to evaluate the risk of stroke/SE and MB across matched cohorts. Results&#45; A total of 285292 patients were included in the 6 matched cohorts: 57929 apixaban&#45;warfarin, 26838 dabigatran&#45;warfarin, 83007 rivaroxaban&#45;warfarin, 27096 apixaban&#45;dabigatran, 62619 apixaban&#45;rivaroxaban, and 27538 dabigatran&#45;rivaroxaban patient pairs. Apixaban (hazard ratio [HR], 0.61; 95% CI, 0.54&#45;0.69), dabigatran (HR, 0.80; 95% CI, 0.68&#45;0.94), and rivaroxaban (HR, 0.75; 95% CI, 0.69&#45;0.82) were associated with lower rates of stroke/SE compared with warfarin. Apixaban (HR, 0.58; 95% CI, 0.54&#45;0.62) and dabigatran (HR, 0.73; 95% CI, 0.66&#45;0.81) had lower rates of MB, and rivaroxaban (HR, 1.07; 95% CI, 1.02&#45;1.13) had a higher rate of MB compared with warfarin. Differences exist in rates of stroke/SE and MB across NOACs. Conclusions&#45; In this largest observational study to date on NOACs and warfarin, the NOACs had lower rates of stroke/SE and variable comparative rates of MB versus warfarin. The findings from this study may help inform the discussion on benefit and risk in the shared decision&#45;making process for stroke prevention between healthcare providers and nonvalvular atrial fibrillation patients. Clinical Trial Registration&#45; URL: https://www.clinicaltrials.gov/ . Unique identifier: NCT03087487.&#10;~&#10;PMID: 30571400&#10;Journal: Stroke" target="_blank">
<polygon fill="transparent" stroke="black" points="3102.25,-1412 3001.25,-1412 3001.25,-1344 3108.25,-1344 3108.25,-1406 3102.25,-1412"/>
<polyline fill="none" stroke="black" points="3102.25,-1412 3102.25,-1406 "/>
<polyline fill="none" stroke="black" points="3108.25,-1406 3102.25,-1406 "/>
<text text-anchor="middle" x="3054.75" y="-1396.8" font-family="Times New Roman,serif" font-size="14.00">Lip, Keshishian,</text>
<text text-anchor="middle" x="3054.75" y="-1381.8" font-family="Times New Roman,serif" font-size="14.00">Li, Hamilton,</text>
<text text-anchor="middle" x="3054.75" y="-1366.8" font-family="Times New Roman,serif" font-size="14.00">Masseria</text>
<text text-anchor="middle" x="3054.75" y="-1351.8" font-family="Times New Roman,serif" font-size="14.00">(2018 12)</text>
</a>
</g>
</g>
<!-- 30597611 -->
<g id="node52" class="node">
<title>30597611</title>
<g id="a_node52"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/30597611/" xlink:title="Date: 2019 02&#10;Title: Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.&#10;By: Martinez, Baker, Sood, Bunz, Meinecke, Eriksson, Coleman&#10;~&#10;Abstract: Patients with nonvalvular atrial fibrillation (NVAF) often have multiple comorbidities requiring concomitant medications in addition to their oral anticoagulant (OAC). The objective of this study was to evaluate the impact of polypharmacy on the effectiveness and safety of rivaroxaban versus warfarin in patients with NVAF managed in routine clinical practice.&#10;~&#10;PMID: 30597611&#10;Journal: Pharmacotherapy" target="_blank">
<polygon fill="transparent" stroke="black" points="850.75,-1412 748.75,-1412 748.75,-1344 856.75,-1344 856.75,-1406 850.75,-1412"/>
<polyline fill="none" stroke="black" points="850.75,-1412 850.75,-1406 "/>
<polyline fill="none" stroke="black" points="856.75,-1406 850.75,-1406 "/>
<text text-anchor="middle" x="802.75" y="-1396.8" font-family="Times New Roman,serif" font-size="14.00">Martinez, Baker,</text>
<text text-anchor="middle" x="802.75" y="-1381.8" font-family="Times New Roman,serif" font-size="14.00">Sood, Bunz,</text>
<text text-anchor="middle" x="802.75" y="-1366.8" font-family="Times New Roman,serif" font-size="14.00">Meinecke</text>
<text text-anchor="middle" x="802.75" y="-1351.8" font-family="Times New Roman,serif" font-size="14.00">(2019 02)</text>
</a>
</g>
</g>
<!-- 30924051 -->
<g id="node53" class="node">
<title>30924051</title>
<g id="a_node53"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/30924051/" xlink:title="Date: 2019 Aug&#10;Title: Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non&#45;valvular atrial fibrillation in the CMS medicare population.&#10;By: Amin, Keshishian, Dina, Dhamane, Nadkarni, Carda, Russ, Rosenblatt, Mardekian, Yuce, Baker&#10;~&#10;Abstract: Atrial fibrillation (AF) prevalence increases with age; &gt;80% of US adults with AF are aged 65years. Compare the risk of stroke/systemic embolism (SE), major bleeding (MB), net clinical outcome (NCO), and major adverse cardiac events (MACE) among elderly non&#45;valvular AF (NVAF) Medicare patients prescribed direct oral anticoagulants (DOACs) VS warfarin. NVAF patients aged 65years who initiated DOACs (apixaban, dabigatran, and rivaroxaban) or warfarin were selected from 01JAN2013&#45;31DEC2015 in CMS Medicare data. Propensity score matching was used to balance DOAC and warfarin cohorts. Cox proportional hazards models estimated the risk of stroke/SE, MB, NCO, and MACE. 37,525 apixaban&#45;warfarin, 18,131 dabigatran&#45;warfarin, and 55,359 rivaroxaban&#45;warfarin pairs were included. Compared to warfarin, apixaban (HR: 0.69; 95% CI 0.59&#45;0.81) and rivaroxaban (HR: 0.82; 95% CI 0.73&#45;0.91) had lower risk of stroke/SE, and dabigatran (HR: 0.88; 95% CI 0.72&#45;1.07) had similar risk of stroke/SE. Apixaban (MB: HR: 0.61; 95% CI 0.57&#45;0.67; NCO: HR: 0.64; 95% CI 0.60&#45;0.69) and dabigatran (MB: HR: 0.79; 95% CI 0.71&#45;0.89; NCO: HR: 0.84; 95% CI 0.76&#45;0.93) had lower risk of MB and NCO, and rivaroxaban had higher risk of MB (HR: 1.08; 95% CI 1.02&#45;1.14) and similar risk of NCO (HR: 1.04; 95% CI 0.99&#45;1.09). Compared to warfarin, apixaban had a lower risk for stroke/SE, MB, and NCO; dabigatran had a lower risk of MB and NCO; and rivaroxaban had a lower risk of stroke/SE but higher risk of MB. All DOACs had lower risk of MACE compared to warfarin.&#10;~&#10;PMID: 30924051&#10;Journal: Journal of thrombosis and thrombolysis" target="_blank">
<polygon fill="transparent" stroke="black" points="2991.75,-1412 2879.75,-1412 2879.75,-1344 2997.75,-1344 2997.75,-1406 2991.75,-1412"/>
<polyline fill="none" stroke="black" points="2991.75,-1412 2991.75,-1406 "/>
<polyline fill="none" stroke="black" points="2997.75,-1406 2991.75,-1406 "/>
<text text-anchor="middle" x="2938.75" y="-1396.8" font-family="Times New Roman,serif" font-size="14.00">Amin, Keshishian,</text>
<text text-anchor="middle" x="2938.75" y="-1381.8" font-family="Times New Roman,serif" font-size="14.00">Dina, Dhamane,</text>
<text text-anchor="middle" x="2938.75" y="-1366.8" font-family="Times New Roman,serif" font-size="14.00">Nadkarni</text>
<text text-anchor="middle" x="2938.75" y="-1351.8" font-family="Times New Roman,serif" font-size="14.00">(2019 Aug)</text>
</a>
</g>
</g>
<!-- 31022899 -->
<g id="node54" class="node">
<title>31022899</title>
<g id="a_node54"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/31022899/" xlink:title="Date: 2019 Apr 24&#10;Title: Effectiveness and Safety of Direct Oral Anticoagulants versus Vitamin K Antagonists for People Aged 75 Years and over with Atrial Fibrillation: A Systematic Review and Meta&#45;Analyses of Observational Studies.&#10;By: Mitchell, Watson, Welsh, McGrogan&#10;~&#10;Abstract: Older people, are underrepresented in randomised controlled trials of direct oral anticoagulants (DOACs) for stroke prevention in atrial fibrillation (AF). The aim of this study was to combine data from observational studies to provide evidence for the treatment of people aged 75 years. Medline, Embase, Scopus and Web of Science were searched. The primary effectiveness outcome was ischaemic stroke. Safety outcomes were major bleeding, intracranial haemorrhage, gastrointestinal bleeding, myocardial infarction, and mortality. Twenty&#45;two studies were eligible for inclusion. Two studies related specifically to people 75 years but were excluded from meta&#45;analysis due to low quality; all data in the meta&#45;analyses were from subgroups. The pooled risk estimate of ischaemic stroke was slightly lower for DOACs. There was no significant difference in major bleeding, mortality, or myocardial infarction. Risk of intracranial haemorrhage was 44% lower with DOACs, but risk of GI bleeding was 46% higher. Our results suggest that DOACs may be preferable for the majority of older patients with AF, provided they are not at significant risk of a GI bleed. However, these results are based entirely on data from subgroup analyses so should be interpreted cautiously. There is a need for adequately powered research in this patient group.&#10;~&#10;PMID: 31022899&#10;Journal: Journal of clinical medicine" target="_blank">
<polygon fill="transparent" stroke="black" points="2227.75,-1404.5 2113.75,-1404.5 2113.75,-1351.5 2233.75,-1351.5 2233.75,-1398.5 2227.75,-1404.5"/>
<polyline fill="none" stroke="black" points="2227.75,-1404.5 2227.75,-1398.5 "/>
<polyline fill="none" stroke="black" points="2233.75,-1398.5 2227.75,-1398.5 "/>
<text text-anchor="middle" x="2173.75" y="-1389.3" font-family="Times New Roman,serif" font-size="14.00">Mitchell, Watson,</text>
<text text-anchor="middle" x="2173.75" y="-1374.3" font-family="Times New Roman,serif" font-size="14.00">Welsh, McGrogan</text>
<text text-anchor="middle" x="2173.75" y="-1359.3" font-family="Times New Roman,serif" font-size="14.00">(2019 Apr 24)</text>
</a>
</g>
</g>
<!-- 31112292 -->
<g id="node55" class="node">
<title>31112292</title>
<g id="a_node55"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/31112292/" xlink:title="Date: 2019 08&#10;Title: Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.&#10;By: Deitelzweig, Keshishian, Li, Kang, Dhamane, Luo, Balachander, Rosenblatt, Mardekian, Pan, Nadkarni, Di Fusco, Garcia Reeves, Yuce, Lip&#10;~&#10;Abstract: Older adult patients are underrepresented in clinical trials comparing non&#45;vitamin K antagonist oral anticoagulants (NOACs) and warfarin. This subgroup analysis of the ARISTOPHANES study used multiple data sources to compare the risk of stroke/systemic embolism (SE) and major bleeding (MB) among very old patients with nonvalvular atrial fibrillation (NVAF) prescribed NOACs or warfarin.&#10;~&#10;PMID: 31112292&#10;Journal: Journal of the American Geriatrics Society" target="_blank">
<polygon fill="transparent" stroke="black" points="2923.25,-1631 2824.25,-1631 2824.25,-1563 2929.25,-1563 2929.25,-1625 2923.25,-1631"/>
<polyline fill="none" stroke="black" points="2923.25,-1631 2923.25,-1625 "/>
<polyline fill="none" stroke="black" points="2929.25,-1625 2923.25,-1625 "/>
<text text-anchor="middle" x="2876.75" y="-1615.8" font-family="Times New Roman,serif" font-size="14.00">Deitelzweig,</text>
<text text-anchor="middle" x="2876.75" y="-1600.8" font-family="Times New Roman,serif" font-size="14.00">Keshishian, Li,</text>
<text text-anchor="middle" x="2876.75" y="-1585.8" font-family="Times New Roman,serif" font-size="14.00">Kang, Dhamane</text>
<text text-anchor="middle" x="2876.75" y="-1570.8" font-family="Times New Roman,serif" font-size="14.00">(2019 08)</text>
</a>
</g>
</g>
<!-- 31195999 -->
<g id="node56" class="node">
<title>31195999</title>
<g id="a_node56"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/31195999/" xlink:title="Date: 2019 06 13&#10;Title: Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment nave non&#45;valvular atrial fibrillation patients in the US Department of defense population.&#10;By: Gupta, Trocio, Keshishian, Zhang, Dina, Mardekian, Nadkarni, Shank&#10;~&#10;Abstract: Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are at least non&#45;inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among patients with non&#45;valvular atrial fibrillation (NVAF), but the comparative risk of major bleeding varies between DOACs and warfarin. Using US Department of Defense (DOD) data, this study compared the risk of stroke/SE and major bleeding for DOACs relative to warfarin.&#10;~&#10;PMID: 31195999&#10;Journal: BMC cardiovascular disorders" target="_blank">
<polygon fill="transparent" stroke="black" points="3637.75,-1412 3521.75,-1412 3521.75,-1344 3643.75,-1344 3643.75,-1406 3637.75,-1412"/>
<polyline fill="none" stroke="black" points="3637.75,-1412 3637.75,-1406 "/>
<polyline fill="none" stroke="black" points="3643.75,-1406 3637.75,-1406 "/>
<text text-anchor="middle" x="3582.75" y="-1396.8" font-family="Times New Roman,serif" font-size="14.00">Gupta, Trocio,</text>
<text text-anchor="middle" x="3582.75" y="-1381.8" font-family="Times New Roman,serif" font-size="14.00">Keshishian, Zhang,</text>
<text text-anchor="middle" x="3582.75" y="-1366.8" font-family="Times New Roman,serif" font-size="14.00">Dina</text>
<text text-anchor="middle" x="3582.75" y="-1351.8" font-family="Times New Roman,serif" font-size="14.00">(2019 06 13)</text>
</a>
</g>
</g>
<!-- 31390972 -->
<g id="node57" class="node">
<title>31390972</title>
<g id="a_node57"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/31390972/" xlink:title="Date: 2019 09&#10;Title: Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation.&#10;By: Blin, Fauchier, Dureau&#45;Pournin, Sacher, Dallongeville, Bernard, Lassalle, Droz&#45;Perroteau, Moore&#10;~&#10;Abstract: Background and Purpose&#45; We compared the 1&#45;year safety and effectiveness of rivaroxaban 15 mg (R15) or rivaroxaban 20 mg (R20) to vitamin K antagonists (VKAs) in patients with nonvalvular atrial fibrillation. Methods&#45; New user cohort study of patients dispensed R15 or R20 versus VKA in 2013 or 2014 for nonvalvular atrial fibrillation, followed 1 year in the French Systme National des Donnes de Sant (66 million people). R15 and R20 users were matched 1:1 with VKA users on sex, age, date of first drug dispensing, and high&#45;dimensional propensity score. Hazard ratios (95% CIs) for stroke and systemic embolism, major bleeding, and death were computed using Cox proportional hazards or models by Fine and Gray during exposure. Results&#45; In 31171 matched R20 and VKA, mean age, 71; 62% men; 76% with CHA2DS2&#45;VASc 2; 5% HAS&#45;BLED &gt;3 (hypertension, abnormal renal and liver function, stroke, bleeding, labile INR, elderly, drugs or alcohol); incidence rates for stroke and systemic embolism were 1.5% and 1.9% (hazard ratio, 0.79 [0.69&#45;0.90]); major bleeding, 1.5% and 2.2% (0.67 [0.59&#45;0.77]); death, 3.9% and 5.8% (0.67 [0.61&#45;0.73]). In 23314 matched R15 and VKA patients, mean age, 80; 47% men; 93% with CHA2DS2&#45;VASc 2 and 9% with HAS&#45;BLED &gt;3; incidence rates of stroke and systemic embolism were 2.3% and 2.1% (1.05 [0.92&#45;1.21]); major bleeding, 2.4% and 2.9% (0.84 [0.74&#45;0.96]); death, 9.1% and 10.8% (0.85 [0.79&#45;0.90]). Numbers needed to treat to observe one fewer death (NNT) were 46 for R15 and 61 for R20. Conclusions&#45; In real life in France over 2013 to 2015, R15 and R20 were at least as effective and safer than VKA. Clinical Trial Registration&#45; URL: http://www.encepp.eu. Unique identifier: EUPAS14567.&#10;~&#10;PMID: 31390972&#10;Journal: Stroke" target="_blank">
<polygon fill="transparent" stroke="black" points="2793.75,-1865 2691.75,-1865 2691.75,-1782 2799.75,-1782 2799.75,-1859 2793.75,-1865"/>
<polyline fill="none" stroke="black" points="2793.75,-1865 2793.75,-1859 "/>
<polyline fill="none" stroke="black" points="2799.75,-1859 2793.75,-1859 "/>
<text text-anchor="middle" x="2745.75" y="-1849.8" font-family="Times New Roman,serif" font-size="14.00">Blin, Fauchier,</text>
<text text-anchor="middle" x="2745.75" y="-1834.8" font-family="Times New Roman,serif" font-size="14.00">Dureau&#45;Pournin,</text>
<text text-anchor="middle" x="2745.75" y="-1819.8" font-family="Times New Roman,serif" font-size="14.00">Sacher,</text>
<text text-anchor="middle" x="2745.75" y="-1804.8" font-family="Times New Roman,serif" font-size="14.00">Dallongeville</text>
<text text-anchor="middle" x="2745.75" y="-1789.8" font-family="Times New Roman,serif" font-size="14.00">(2019 09)</text>
</a>
</g>
</g>
<!-- 31549153 -->
<g id="node58" class="node">
<title>31549153</title>
<g id="a_node58"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/31549153/" xlink:title="Date: 2020 07 01&#10;Title: Effectiveness and safety of rivaroxaban vs. warfarin in patients with non&#45;valvular atrial fibrillation and coronary or peripheral artery disease.&#10;By: Coleman, Baker, Meinecke, Eriksson, Martinez, Bunz, Alberts&#10;~&#10;Abstract: There are scarce data evaluating the effectiveness and safety of rivaroxaban vs. warfarin in non&#45;valvular atrial fibrillation (NVAF) patients with concomitant coronary artery disease (CAD) and/or peripheral artery disease (PAD) treated in routine practice.&#10;~&#10;PMID: 31549153&#10;Journal: European heart journal. Cardiovascular pharmacotherapy" target="_blank">
<polygon fill="transparent" stroke="black" points="4083.75,-68 3959.75,-68 3959.75,0 4089.75,0 4089.75,-62 4083.75,-68"/>
<polyline fill="none" stroke="black" points="4083.75,-68 4083.75,-62 "/>
<polyline fill="none" stroke="black" points="4089.75,-62 4083.75,-62 "/>
<text text-anchor="middle" x="4024.75" y="-52.8" font-family="Times New Roman,serif" font-size="14.00">Coleman, Baker,</text>
<text text-anchor="middle" x="4024.75" y="-37.8" font-family="Times New Roman,serif" font-size="14.00">Meinecke, Eriksson,</text>
<text text-anchor="middle" x="4024.75" y="-22.8" font-family="Times New Roman,serif" font-size="14.00">Martinez</text>
<text text-anchor="middle" x="4024.75" y="-7.8" font-family="Times New Roman,serif" font-size="14.00">(2020 07 01)</text>
</a>
</g>
</g>
<!-- 32341789 -->
<g id="node59" class="node">
<title>32341789</title>
<g id="a_node59"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/32341789/" xlink:title="Date: 2020&#10;Title: Safety and effectiveness of non&#45;vitamin K oral anticoagulants versus warfarin in real&#45;world patients with non&#45;valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.&#10;By: Kohsaka, Katada, Saito, Jenkins, Li, Mardekian, Terayama&#10;~&#10;Abstract: To assess the safety (ie, risk of bleeding) and effectiveness (ie, risk of stroke/systemic embolism (SE)) separately for four non&#45;vitamin K oral anticoagulants (NOACs; apixaban, dabigatran, edoxaban and rivaroxaban) versus warfarin in Japanese patients with non&#45;valvular atrial fibrillation (NVAF), including those at high risk of bleeding and treated with reduced doses of NOACs.&#10;~&#10;PMID: 32341789&#10;Journal: Open heart" target="_blank">
<polygon fill="transparent" stroke="black" points="3512.75,-1404.5 3402.75,-1404.5 3402.75,-1351.5 3518.75,-1351.5 3518.75,-1398.5 3512.75,-1404.5"/>
<polyline fill="none" stroke="black" points="3512.75,-1404.5 3512.75,-1398.5 "/>
<polyline fill="none" stroke="black" points="3518.75,-1398.5 3512.75,-1398.5 "/>
<text text-anchor="middle" x="3460.75" y="-1389.3" font-family="Times New Roman,serif" font-size="14.00">Kohsaka, Katada,</text>
<text text-anchor="middle" x="3460.75" y="-1374.3" font-family="Times New Roman,serif" font-size="14.00">Saito, Jenkins, Li</text>
<text text-anchor="middle" x="3460.75" y="-1359.3" font-family="Times New Roman,serif" font-size="14.00">(2020)</text>
</a>
</g>
</g>
<!-- 32415705 -->
<g id="node60" class="node">
<title>32415705</title>
<g id="a_node60"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/32415705/" xlink:title="Date: 2020 12&#10;Title: Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3&#45;year period population&#45;based prospective cohort study.&#10;By: Bouget, Balusson, Maignan, Pavageau, Roy, Lacut, Scailteux, Nowak, Oger&#10;~&#10;Abstract: The objective was to compare major bleeding risk of direct oral anticoagulants (DOACs; per type and dose) with vitamin K antagonists (VKAs), irrespective of indication, using real&#45;world data.&#10;~&#10;PMID: 32415705&#10;Journal: British journal of clinical pharmacology" target="_blank">
<polygon fill="transparent" stroke="black" points="522.75,-1631 400.75,-1631 400.75,-1563 528.75,-1563 528.75,-1625 522.75,-1631"/>
<polyline fill="none" stroke="black" points="522.75,-1631 522.75,-1625 "/>
<polyline fill="none" stroke="black" points="528.75,-1625 522.75,-1625 "/>
<text text-anchor="middle" x="464.75" y="-1615.8" font-family="Times New Roman,serif" font-size="14.00">Bouget, Balusson,</text>
<text text-anchor="middle" x="464.75" y="-1600.8" font-family="Times New Roman,serif" font-size="14.00">Maignan, Pavageau,</text>
<text text-anchor="middle" x="464.75" y="-1585.8" font-family="Times New Roman,serif" font-size="14.00">Roy</text>
<text text-anchor="middle" x="464.75" y="-1570.8" font-family="Times New Roman,serif" font-size="14.00">(2020 12)</text>
</a>
</g>
</g>
<!-- 32453608 -->
<g id="node61" class="node">
<title>32453608</title>
<g id="a_node61"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/32453608/" xlink:title="Date: 2020 Jan&#45;Dec&#10;Title: Analysis of Effectiveness, Safety, and Bleeding Related to Rivaroxaban in Elderly Patients.&#10;By: Hou, Li, Zhang, Qin, Jiang, Zhao&#10;~&#10;Abstract: This study explored the efficacy and safety of rivaroxaban in elderly patients, at different doses and age of patients, and analyzed risk factors of bleeding. A retrospective analysis was conducted of 299 patients aged 60 years or older who were admitted to the First Hospital of Jilin University between January 2016 and August 2018. It was found that the rate of bleeding events (but not embolism) significantly increased as the dose of oral rivaroxaban increased (P &lt; .001), and with age, especially in patients aged 80 years (P = .001, both). The multivariate logistic regression analysis indicated that age (odds ratio [OR]: 2.963, 95% CI: 1.627&#45;5.396) and the daily dose of rivaroxaban (OR: 2.325, 95% CI: 1.483&#45;3.645) were independent risk factors for bleeding. The study determined that rivaroxaban anticoagulant therapy is effective in the elderly patients, but the risk of bleeding increases with age, and is a concern especially in the most old patients. The recommended daily dose of rivaroxaban is effective, but a lower dose is safer for the elderly patients.&#10;~&#10;PMID: 32453608&#10;Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis" target="_blank">
<polygon fill="transparent" stroke="black" points="4071.25,-279.5 3972.25,-279.5 3972.25,-226.5 4077.25,-226.5 4077.25,-273.5 4071.25,-279.5"/>
<polyline fill="none" stroke="black" points="4071.25,-279.5 4071.25,-273.5 "/>
<polyline fill="none" stroke="black" points="4077.25,-273.5 4071.25,-273.5 "/>
<text text-anchor="middle" x="4024.75" y="-264.3" font-family="Times New Roman,serif" font-size="14.00">Hou, Li, Zhang,</text>
<text text-anchor="middle" x="4024.75" y="-249.3" font-family="Times New Roman,serif" font-size="14.00">Qin, Jiang</text>
<text text-anchor="middle" x="4024.75" y="-234.3" font-family="Times New Roman,serif" font-size="14.00">(2020 Jan&#45;Dec)</text>
</a>
</g>
</g>
<!-- 32539675 -->
<g id="node62" class="node">
<title>32539675</title>
<g id="a_node62"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/32539675/" xlink:title="Date: 2020 07&#10;Title: Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.&#10;By: Van Ganse, Danchin, Mah, Hanon, Jacoud, Nolin, Dalon, Lefevre, Cott, Gollety, Falissard, Belhassen, Steg&#10;~&#10;Abstract: The effects of direct oral anticoagulants in nonvalvular atrial fibrillation should be assessed in actual conditions of use. France has near&#45;universal healthcare coverage with a unified healthcare information system, allowing large population&#45;based analyses. NAXOS (Evaluation of Apixaban in Stroke and Systemic Embolism Prevention in Patients With Nonvalvular Atrial Fibrillation) aimed to compare the safety, effectiveness, and mortality of apixaban with vitamin K antagonists (VKAs), rivaroxaban, and dabigatran, in oral anticoagulant&#45;naive patients with nonvalvular atrial fibrillation.&#10;~&#10;PMID: 32539675&#10;Journal: Stroke" target="_blank">
<polygon fill="transparent" stroke="black" points="2071.25,-1623.5 1938.25,-1623.5 1938.25,-1570.5 2077.25,-1570.5 2077.25,-1617.5 2071.25,-1623.5"/>
<polyline fill="none" stroke="black" points="2071.25,-1623.5 2071.25,-1617.5 "/>
<polyline fill="none" stroke="black" points="2077.25,-1617.5 2071.25,-1617.5 "/>
<text text-anchor="middle" x="2007.75" y="-1608.3" font-family="Times New Roman,serif" font-size="14.00">Van Ganse, Danchin,</text>
<text text-anchor="middle" x="2007.75" y="-1593.3" font-family="Times New Roman,serif" font-size="14.00">Mah, Hanon, Jacoud</text>
<text text-anchor="middle" x="2007.75" y="-1578.3" font-family="Times New Roman,serif" font-size="14.00">(2020 07)</text>
</a>
</g>
</g>
<!-- 32676543 -->
<g id="node63" class="node">
<title>32676543</title>
<g id="a_node63"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/32676543/" xlink:title="Date: 2020 Jul&#10;Title: Bleeding Risk in Nonvalvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta&#45;Analysis of Observational Studies.&#10;By: Wang, Kehar, Iansavitchene, Lazo&#45;Langner&#10;~&#10;Abstract: Introduction In randomized trials in atrial fibrillation (AF) patients on direct oral anticoagulants (DOACs) have a lower risk of bleeding compared with warfarin. However, data from randomized trials may not extrapolate to general population. We aimed to determine the risk of bleeding in patients on DOACs in observational studies. Materials and Methods Observational studies from 1990 to January 2019 were included. A pooled effect hazard ratio (HR) was calculated with a random effects model using the generic inverse variance method. Subgroup analyses according to previous anticoagulants exposure, study type, funding source, and DOAC type (direct thrombin inhibitors vs. factor Xa inhibitors) were conducted. Results A total of 35 studies comprising 2,356,201 patients were included. The average pooled HR for observational data was 0.78 (95% confidence interval [CI] 0.71, 0.85). There were no statistically significant differences in pooled HR by previous exposure to anticoagulants, DOAC type (direct thrombin vs. factor Xa inhibitors), study type, and funding source. Among patients receiving factor Xa inhibitors, patients on apixaban had a lower risk of bleeding compared with warfarin (HR 0.60, 95% CI 0.50, 0.71, p &lt;0.001) in contrast to those on rivaroxaban (HR 0.98, 95% CI 0.91, 1.06, p =0.60). Conclusion In observational studies, AF patients on DOACs experience less bleeding events compared with warfarin; however, apixaban and dabigatran, but not rivaroxaban, have a lower risk of bleeding than warfarin.&#10;~&#10;PMID: 32676543&#10;Journal: TH open : companion journal to thrombosis and haemostasis" target="_blank">
<polygon fill="transparent" stroke="black" points="1052.25,-1857.5 963.25,-1857.5 963.25,-1789.5 1058.25,-1789.5 1058.25,-1851.5 1052.25,-1857.5"/>
<polyline fill="none" stroke="black" points="1052.25,-1857.5 1052.25,-1851.5 "/>
<polyline fill="none" stroke="black" points="1058.25,-1851.5 1052.25,-1851.5 "/>
<text text-anchor="middle" x="1010.75" y="-1842.3" font-family="Times New Roman,serif" font-size="14.00">Wang, Kehar,</text>
<text text-anchor="middle" x="1010.75" y="-1827.3" font-family="Times New Roman,serif" font-size="14.00">Iansavitchene,</text>
<text text-anchor="middle" x="1010.75" y="-1812.3" font-family="Times New Roman,serif" font-size="14.00">Lazo&#45;Langner</text>
<text text-anchor="middle" x="1010.75" y="-1797.3" font-family="Times New Roman,serif" font-size="14.00">(2020 Jul)</text>
</a>
</g>
</g>
<!-- 33093817 -->
<g id="node64" class="node">
<title>33093817</title>
<g id="a_node64"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/33093817/" xlink:title="Date: 2020 Sep&#10;Title: Practice&#45;derived data on non&#45;vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials.&#10;By: Domek, Gumprecht, Ding, Lip, Lane&#10;~&#10;Abstract: Anticoagulation is fundamental in the management of patients with atrial fibrillation (AF). The study aims to provide a comparative review of the major phase III randomized clinical trials (RCTs) and real&#45;world data (RWD) from reliable, high&#45;grade Phase IV studies that assess the efficacy and safety of non&#45;vitamin K antagonist oral anticoagulants (NOACs) vs. vitamin K antagonists (VKAs). Observational studies based on nationwide or health insurance database records on the use of NOACs vs. VKAs in patients with AF were included. We performed a comparison of the efficacy and safety characteristics associated with NOACs vs. VKAs in RCTs and RWD. Although RCTs provide strong support for evidence&#45;based practice, RWD may be used to reflect the broader picture of various clinical settings, provide supplementary insight and fulfil knowledge gaps. Both study types confirmed the safety and efficacy of NOACs in preventing stroke and thromboembolism in patients with AF. In comparison to VKAs, NOACs were associated with reduced risk of ischaemic events and lower rates of adverse events such as major bleeding or intracranial haemorrhage. Administration of NOACs might be associated with increased risk of dose&#45;related gastrointestinal bleeding and myocardial ischaemic events, especially in the early treatment period after switching from VKAs. Special care should be taken in challenging clinical situations like severe renal or hepatic impairment when the treatment regimen needs to be considered individually. Randomized clinical trial and RWD studies are complementary and present comparable findings, affirming that NOACs are safe and effective for anticoagulation of patients with AF in daily clinical practice.&#10;~&#10;PMID: 33093817&#10;Journal: European heart journal supplements : journal of the European Society of Cardiology" target="_blank">
<polygon fill="transparent" stroke="black" points="1259.25,-1404.5 1134.25,-1404.5 1134.25,-1351.5 1265.25,-1351.5 1265.25,-1398.5 1259.25,-1404.5"/>
<polyline fill="none" stroke="black" points="1259.25,-1404.5 1259.25,-1398.5 "/>
<polyline fill="none" stroke="black" points="1265.25,-1398.5 1259.25,-1398.5 "/>
<text text-anchor="middle" x="1199.75" y="-1389.3" font-family="Times New Roman,serif" font-size="14.00">Domek, Gumprecht,</text>
<text text-anchor="middle" x="1199.75" y="-1374.3" font-family="Times New Roman,serif" font-size="14.00">Ding, Lip, Lane</text>
<text text-anchor="middle" x="1199.75" y="-1359.3" font-family="Times New Roman,serif" font-size="14.00">(2020 Sep)</text>
</a>
</g>
</g>
<!-- 33253294 -->
<g id="node65" class="node">
<title>33253294</title>
<g id="a_node65"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/33253294/" xlink:title="Date: 2020&#10;Title: The risk of stroke/systemic embolism and major bleeding in Asian patients with non&#45;valvular atrial fibrillation treated with non&#45;vitamin K oral anticoagulants compared to warfarin: Results from a real&#45;world data analysis.&#10;By: Bang, On, Lee, Jang, Han, Han, Won, Park, Lee, Choi, Kang, Suh, Kim&#10;~&#10;Abstract: Although randomized trials provide a high level of evidence regarding the efficacy of non&#45;vitamin K oral anticoagulants (NOACs), the results of such trials may differ from those observed in day&#45;to&#45;day clinical practice.&#10;~&#10;PMID: 33253294&#10;Journal: PloS one" target="_blank">
<polygon fill="transparent" stroke="black" points="3226.25,-1623.5 3131.25,-1623.5 3131.25,-1570.5 3232.25,-1570.5 3232.25,-1617.5 3226.25,-1623.5"/>
<polyline fill="none" stroke="black" points="3226.25,-1623.5 3226.25,-1617.5 "/>
<polyline fill="none" stroke="black" points="3232.25,-1617.5 3226.25,-1617.5 "/>
<text text-anchor="middle" x="3181.75" y="-1608.3" font-family="Times New Roman,serif" font-size="14.00">Bang, On, Lee,</text>
<text text-anchor="middle" x="3181.75" y="-1593.3" font-family="Times New Roman,serif" font-size="14.00">Jang, Han</text>
<text text-anchor="middle" x="3181.75" y="-1578.3" font-family="Times New Roman,serif" font-size="14.00">(2020)</text>
</a>
</g>
</g>
<!-- 33587284 -->
<g id="node66" class="node">
<title>33587284</title>
<g id="a_node66"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/33587284/" xlink:title="Date: 2021 Mar&#10;Title: Cost&#45;Effectiveness of Direct Non&#45;Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non&#45;Valvular Atrial Fibrillation Based on Available &#39;Real&#45;World&#39; Evidence: The Italian National Health System Perspective.&#10;By: Lorenzoni, Pirri, Turchetti&#10;~&#10;Abstract: The increasing availability of real&#45;world evidence (RWE) about safety and effectiveness of direct non&#45;vitamin K oral anticoagulants (DOACs) for the management of atrial fibrillation (AF) offers the opportunity to better understand the clinical and economic implications of DOACs versus vitamin K antagonists (VKAs). The objective of this study was to compare the economic implications of DOACs and VKAs using data from real&#45;world evidence in patients with AF.&#10;~&#10;PMID: 33587284&#10;Journal: Clinical drug investigation" target="_blank">
<polygon fill="transparent" stroke="black" points="1214.25,-1623.5 1113.25,-1623.5 1113.25,-1570.5 1220.25,-1570.5 1220.25,-1617.5 1214.25,-1623.5"/>
<polyline fill="none" stroke="black" points="1214.25,-1623.5 1214.25,-1617.5 "/>
<polyline fill="none" stroke="black" points="1220.25,-1617.5 1214.25,-1617.5 "/>
<text text-anchor="middle" x="1166.75" y="-1608.3" font-family="Times New Roman,serif" font-size="14.00">Lorenzoni, Pirri,</text>
<text text-anchor="middle" x="1166.75" y="-1593.3" font-family="Times New Roman,serif" font-size="14.00">Turchetti</text>
<text text-anchor="middle" x="1166.75" y="-1578.3" font-family="Times New Roman,serif" font-size="14.00">(2021 Mar)</text>
</a>
</g>
</g>
<!-- 33657116 -->
<g id="node67" class="node">
<title>33657116</title>
<g id="a_node67"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/33657116/" xlink:title="Date: 2021&#10;Title: Predicting major bleeding among hospitalized patients using oral anticoagulants for atrial fibrillation after discharge.&#10;By: Qazi, Schnitzer, Ct, Martel, Dorais, Perreault&#10;~&#10;Abstract: Real&#45;world predictors of major bleeding (MB) have been well&#45;studied among warfarin users, but not among all direct oral anticoagulant (DOAC) users diagnosed with atrial fibrillation (AF). Thus, our goal was to build a predictive model of MB for new users of all oral anticoagulants (OAC) with AF.&#10;~&#10;PMID: 33657116&#10;Journal: PloS one" target="_blank">
<polygon fill="transparent" stroke="black" points="2326.25,-1631 2227.25,-1631 2227.25,-1563 2332.25,-1563 2332.25,-1625 2326.25,-1631"/>
<polyline fill="none" stroke="black" points="2326.25,-1631 2326.25,-1625 "/>
<polyline fill="none" stroke="black" points="2332.25,-1625 2326.25,-1625 "/>
<text text-anchor="middle" x="2279.75" y="-1615.8" font-family="Times New Roman,serif" font-size="14.00">Qazi, Schnitzer,</text>
<text text-anchor="middle" x="2279.75" y="-1600.8" font-family="Times New Roman,serif" font-size="14.00">Ct, Martel,</text>
<text text-anchor="middle" x="2279.75" y="-1585.8" font-family="Times New Roman,serif" font-size="14.00">Dorais</text>
<text text-anchor="middle" x="2279.75" y="-1570.8" font-family="Times New Roman,serif" font-size="14.00">(2021)</text>
</a>
</g>
</g>
<!-- 33950207 -->
<g id="node68" class="node">
<title>33950207</title>
<g id="a_node68"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/33950207/" xlink:title="Date: 2021 May 03&#10;Title: Trends in Incidence of Intracerebral Hemorrhage and Association With Antithrombotic Drug Use in Denmark, 2005&#45;2018.&#10;By: Hald, Mller, Garca Rodrguez, Al&#45;Shahi Salman, Sharma, Christensen, Hellfritzsch, Pottegrd, Hallas, Gaist&#10;~&#10;Abstract: Spontaneous (nontraumatic) intracerebral hemorrhage (ICH) is the most severe complication of antithrombotic drug use.&#10;~&#10;PMID: 33950207&#10;Journal: JAMA network open" target="_blank">
<polygon fill="transparent" stroke="black" points="2547.75,-1865 2431.75,-1865 2431.75,-1782 2553.75,-1782 2553.75,-1859 2547.75,-1865"/>
<polyline fill="none" stroke="black" points="2547.75,-1865 2547.75,-1859 "/>
<polyline fill="none" stroke="black" points="2553.75,-1859 2547.75,-1859 "/>
<text text-anchor="middle" x="2492.75" y="-1849.8" font-family="Times New Roman,serif" font-size="14.00">Hald, Mller,</text>
<text text-anchor="middle" x="2492.75" y="-1834.8" font-family="Times New Roman,serif" font-size="14.00">Garca Rodrguez,</text>
<text text-anchor="middle" x="2492.75" y="-1819.8" font-family="Times New Roman,serif" font-size="14.00">Al&#45;Shahi Salman,</text>
<text text-anchor="middle" x="2492.75" y="-1804.8" font-family="Times New Roman,serif" font-size="14.00">Sharma</text>
<text text-anchor="middle" x="2492.75" y="-1789.8" font-family="Times New Roman,serif" font-size="14.00">(2021 May 03)</text>
</a>
</g>
</g>
<!-- 34173286 -->
<g id="node69" class="node">
<title>34173286</title>
<g id="a_node69"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/34173286/" xlink:title="Date: 2021 Oct&#10;Title: Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population&#45;based cohort studies.&#10;By: van den Ham, Souverein, Klungel, Platt, Ernst, Dell&#39;Aniello, Schmiedl, Grave, Rottenkolber, Huerta, Martn Merino, Len&#45;Muoz, Montero, Andersen, Aakjaer, De Bruin, Gardarsdottir&#10;~&#10;Abstract: To establish the risk of major bleeding in direct oral anticoagulant (DOAC) users (overall and by class) versus vitamin K antagonist (VKA) users, using health care databases from four European countries and six provinces in Canada.&#10;~&#10;PMID: 34173286&#10;Journal: Pharmacoepidemiology and drug safety" target="_blank">
<polygon fill="transparent" stroke="black" points="645.25,-1857.5 526.25,-1857.5 526.25,-1789.5 651.25,-1789.5 651.25,-1851.5 645.25,-1857.5"/>
<polyline fill="none" stroke="black" points="645.25,-1857.5 645.25,-1851.5 "/>
<polyline fill="none" stroke="black" points="651.25,-1851.5 645.25,-1851.5 "/>
<text text-anchor="middle" x="588.75" y="-1842.3" font-family="Times New Roman,serif" font-size="14.00">van den Ham,</text>
<text text-anchor="middle" x="588.75" y="-1827.3" font-family="Times New Roman,serif" font-size="14.00">Souverein, Klungel,</text>
<text text-anchor="middle" x="588.75" y="-1812.3" font-family="Times New Roman,serif" font-size="14.00">Platt, Ernst</text>
<text text-anchor="middle" x="588.75" y="-1797.3" font-family="Times New Roman,serif" font-size="14.00">(2021 Oct)</text>
</a>
</g>
</g>
<!-- 34280330 -->
<g id="node70" class="node">
<title>34280330</title>
<g id="a_node70"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/34280330/" xlink:title="Date: 2021 09&#10;Title: Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation : A Cohort Study.&#10;By: Kim, Pawar, Gagne, Bessette, Lee, Glynn, Schneeweiss&#10;~&#10;Abstract: The role of differing levels of frailty in the choice of oral anticoagulants for older adults with atrial fibrillation (AF) is unclear.&#10;~&#10;PMID: 34280330&#10;Journal: Annals of internal medicine" target="_blank">
<polygon fill="transparent" stroke="black" points="2218.25,-1623.5 2095.25,-1623.5 2095.25,-1570.5 2224.25,-1570.5 2224.25,-1617.5 2218.25,-1623.5"/>
<polyline fill="none" stroke="black" points="2218.25,-1623.5 2218.25,-1617.5 "/>
<polyline fill="none" stroke="black" points="2224.25,-1617.5 2218.25,-1617.5 "/>
<text text-anchor="middle" x="2159.75" y="-1608.3" font-family="Times New Roman,serif" font-size="14.00">Kim, Pawar, Gagne,</text>
<text text-anchor="middle" x="2159.75" y="-1593.3" font-family="Times New Roman,serif" font-size="14.00">Bessette, Lee</text>
<text text-anchor="middle" x="2159.75" y="-1578.3" font-family="Times New Roman,serif" font-size="14.00">(2021 09)</text>
</a>
</g>
</g>
<!-- 34379219 -->
<g id="node71" class="node">
<title>34379219</title>
<g id="a_node71"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/34379219/" xlink:title="Date: 2021 Aug 11&#10;Title: Direct comparison of non&#45;vitamin K antagonist oral anticoagulant versus warfarin for stroke prevention in non&#45;valvular atrial fibrillation: a systematic review and meta&#45;analysis of real&#45;world evidences.&#10;By: Waranugraha, Rizal, Syaban, Faratisha, Erwan, Yunita&#10;~&#10;Abstract: To overcome the several drawbacks of warfarin, non&#45;vitamin K antagonist oral anticoagulants (NOACs) were developed. Even though randomized controlled trials (RCTs) provided high&#45;quality evidence, the real&#45;world evidence is still needed. This systematic review and meta&#45;analysis proposed to measure the safety and efficacy profile between warfarin and NOACs in non&#45;valvular atrial fibrillation (NVAF) patients in preventing stroke.&#10;~&#10;PMID: 34379219&#10;Journal: The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology" target="_blank">
<polygon fill="transparent" stroke="black" points="2551.25,-2084 2428.25,-2084 2428.25,-2016 2557.25,-2016 2557.25,-2078 2551.25,-2084"/>
<polyline fill="none" stroke="black" points="2551.25,-2084 2551.25,-2078 "/>
<polyline fill="none" stroke="black" points="2557.25,-2078 2551.25,-2078 "/>
<text text-anchor="middle" x="2492.75" y="-2068.8" font-family="Times New Roman,serif" font-size="14.00">Waranugraha, Rizal,</text>
<text text-anchor="middle" x="2492.75" y="-2053.8" font-family="Times New Roman,serif" font-size="14.00">Syaban, Faratisha,</text>
<text text-anchor="middle" x="2492.75" y="-2038.8" font-family="Times New Roman,serif" font-size="14.00">Erwan</text>
<text text-anchor="middle" x="2492.75" y="-2023.8" font-family="Times New Roman,serif" font-size="14.00">(2021 Aug 11)</text>
</a>
</g>
</g>
<!-- 34398204 -->
<g id="node72" class="node">
<title>34398204</title>
<g id="a_node72"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/34398204/" xlink:title="Date: 2021 08 02&#10;Title: Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding.&#10;By: Lip, Keshishian, Zhang, Kang, Dhamane, Luo, Klem, Ferri, Jiang, Yuce, Deitelzweig&#10;~&#10;Abstract: Many patients with nonvalvular atrial fibrillation (NVAF) are at a high risk of gastrointestinal (GI) bleeding due to conditions including older age; stage III to V chronic kidney disease (CKD); HAS&#45;BLED (hypertension, kidney or liver disease, stroke history, prior bleeding, unstable international normalized ratio, age &gt;65, drug or alcohol use) score of 3 or greater; corticosteroid, antiplatelet or nonsteroidal anti&#45;inflammatory drug (NSAID) use; or GI conditions.&#10;~&#10;PMID: 34398204&#10;Journal: JAMA network open" target="_blank">
<polygon fill="transparent" stroke="black" points="3351.25,-1631 3250.25,-1631 3250.25,-1563 3357.25,-1563 3357.25,-1625 3351.25,-1631"/>
<polyline fill="none" stroke="black" points="3351.25,-1631 3351.25,-1625 "/>
<polyline fill="none" stroke="black" points="3357.25,-1625 3351.25,-1625 "/>
<text text-anchor="middle" x="3303.75" y="-1615.8" font-family="Times New Roman,serif" font-size="14.00">Lip, Keshishian,</text>
<text text-anchor="middle" x="3303.75" y="-1600.8" font-family="Times New Roman,serif" font-size="14.00">Zhang, Kang,</text>
<text text-anchor="middle" x="3303.75" y="-1585.8" font-family="Times New Roman,serif" font-size="14.00">Dhamane</text>
<text text-anchor="middle" x="3303.75" y="-1570.8" font-family="Times New Roman,serif" font-size="14.00">(2021 08 02)</text>
</a>
</g>
</g>
<!-- 34643934 -->
<g id="node73" class="node">
<title>34643934</title>
<g id="a_node73"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/34643934/" xlink:title="Date: 2021 Nov&#10;Title: Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non&#45;Asian Patients with Atrial Fibrillation: A Systematic Review and Meta&#45;Analysis.&#10;By: Escobar, Barrios, Lip, Amin, Auladell&#45;Rispau, Santero, Salazar, Requeijo&#10;~&#10;Abstract: Real&#45;life data about the use of dabigatran in patients with non&#45;valvular atrial fibrillation are warranted. The objective of this systematic review and meta&#45;analysis was to assess the effectiveness and safety of dabigatran, globally and stratified by dose (110/150 mg twice daily), vs vitamin K antagonists in non&#45;Asian patients with non&#45;valvular atrial fibrillation from &#39;real&#45;world&#39; studies.&#10;~&#10;PMID: 34643934&#10;Journal: Clinical drug investigation" target="_blank">
<polygon fill="transparent" stroke="black" points="2220.25,-1857.5 2111.25,-1857.5 2111.25,-1789.5 2226.25,-1789.5 2226.25,-1851.5 2220.25,-1857.5"/>
<polyline fill="none" stroke="black" points="2220.25,-1857.5 2220.25,-1851.5 "/>
<polyline fill="none" stroke="black" points="2226.25,-1851.5 2220.25,-1851.5 "/>
<text text-anchor="middle" x="2168.75" y="-1842.3" font-family="Times New Roman,serif" font-size="14.00">Escobar, Barrios,</text>
<text text-anchor="middle" x="2168.75" y="-1827.3" font-family="Times New Roman,serif" font-size="14.00">Lip, Amin,</text>
<text text-anchor="middle" x="2168.75" y="-1812.3" font-family="Times New Roman,serif" font-size="14.00">Auladell&#45;Rispau</text>
<text text-anchor="middle" x="2168.75" y="-1797.3" font-family="Times New Roman,serif" font-size="14.00">(2021 Nov)</text>
</a>
</g>
</g>
<!-- 34722686 -->
<g id="node74" class="node">
<title>34722686</title>
<g id="a_node74"><a xlink:href="https://pubmed.ncbi.nlm.nih.gov/34722686/" xlink:title="Date: 2021&#10;Title: Reappraisal of Non&#45;vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Systematic Review and Meta&#45;Analysis.&#10;By: Liu, Yang, Cheng, Ma, Zhu&#10;~&#10;Abstract: Background: Recent observational studies have compared effectiveness and safety profiles between non&#45;vitamin K antagonist oral anticoagulants (NOACs) and warfarin in patients with atrial fibrillation (AF). Nevertheless, the confounders may exist due to the nature of clinical practice&#45;based data, thus potentially influencing the reliability of results. This systematic review and meta&#45;analysis were conducted to compare the effect of NOACs with warfarin based on the propensity score&#45;based observational studies vs. randomized clinical trials (RCTs). Methods: Articles included were systematically searched from the PubMed and EMBASE databases until March 2021 to obtain relevant studies. The primary outcomes were stroke or systemic embolism (SSE) and major bleeding. Hazard ratios (HRs) and 95% confidence intervals (CIs) of the outcomes were extracted and then pooled by the random&#45;effects model. Results: A total of 20 propensity score&#45;based observational studies and 4 RCTs were included. Compared with warfarin, dabigatran (HR, 0.82 [95% CI, 0.71&#45;0.96]), rivaroxaban (HR, 0.80 [95% CI, 0.75&#45;0.85]), apixaban (HR, 0.75 [95% CI, 0.65&#45;0.86]), and edoxaban (HR, 0.71 [95% CI, 0.60&#45;0.83]) were associated with a reduced risk of stroke or systemic embolism, whereas dabigatran (HR, 0.76 [95% CI, 0.65&#45;0.87]), apixaban (HR, 0.61 [95% CI, 0.56&#45;0.67]), and edoxaban (HR, 0.58 [95% CI, 0.45&#45;0.74]) but not rivaroxaban (HR, 0.92 [95% CI, 0.84&#45;1.00]) were significantly associated with a decreased risk of major bleeding based on the observational studies. Furthermore, the risk of major bleeding with dabigatran 150 mg was significantly lower in observational studies than that in the RE&#45;LY trial, whereas the pooled results of observational studies were similar to the data from the corresponding RCTs in other comparisons. Conclusion: Data from propensity score&#45;based observational studies and NOAC trials consistently suggest that the use of four individual NOACs is non&#45;inferior to warfarin for stroke prevention in AF patients.&#10;~&#10;PMID: 34722686&#10;Journal: Frontiers in cardiovascular medicine" target="_blank">
<polygon fill="transparent" stroke="black" points="3461.25,-1850 3348.25,-1850 3348.25,-1797 3467.25,-1797 3467.25,-1844 3461.25,-1850"/>
<polyline fill="none" stroke="black" points="3461.25,-1850 3461.25,-1844 "/>
<polyline fill="none" stroke="black" points="3467.25,-1844 3461.25,-1844 "/>
<text text-anchor="middle" x="3407.75" y="-1834.8" font-family="Times New Roman,serif" font-size="14.00">Liu, Yang, Cheng,</text>
<text text-anchor="middle" x="3407.75" y="-1819.8" font-family="Times New Roman,serif" font-size="14.00">Ma, Zhu</text>
<text text-anchor="middle" x="3407.75" y="-1804.8" font-family="Times New Roman,serif" font-size="14.00">(2021)</text>
</a>
</g>
</g>
</g>
</svg>
